ANALYTICAL METHOD DEVELOPMENT FOR THE DETECTION AND ANALYSIS OF PROTEIN CARBONYLS by Coffey, Chelsea M
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2015
ANALYTICAL METHOD DEVELOPMENT
FOR THE DETECTION AND ANALYSIS OF
PROTEIN CARBONYLS
Chelsea M. Coffey
Virginia Commonwealth University, coffeycm@vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Analytical Chemistry Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/3737
 
 
 
 
 
 
COPYRIGHT PAGE 
 
 
 
 
 
©Chelsea Coffey             2015 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANALYTICAL METHOD DEVELOPMENT FOR THE 
DETECTION AND ANALYSIS OF PROTEIN CARBONYLS 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of  
Doctor of Philosophy at Virginia Commonwealth University 
 
 
 
By: 
Chelsea Coffey 
 
 
Advisor: Dr. Scott Gronert 
Department of Chemistry 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May 2015 
ii 
 
 
 
Acknowledgement 
First and foremost, I would like to express my gratitude to my advisor, Dr. Scott Gronert, for his 
constant support over these last five years.  I have the utmost respect for him as a professor, 
mentor, scientist, and person. His relentless guidance and support helped make this research 
possible. I will be forever grateful for the scientist he has helped me to become and will always 
treasure the experiences gained in his research group.  
I would also like to thank my committee members, Dr. Maryanne Collinson, Dr. Matthew 
Hartman, and Dr. Andrew Ottens. I am honored to name you as members of my committee and 
am grateful for all of the advice provided over the years.  
To my fellow group members: a big thank-you goes out to our research scientist, Dr. David 
Simpson, who was always willing and able to offer guidance and assistance. I would also like to 
thank Dr. Mark Davis, Keyanna Conner, and Malissa Grose for their constant support. Lastly, I 
owe my deepest gratitude to Dr. Suresh Narayanasamy, who will always have a special place in 
my heart. Thank you for being my lab mate, mentor, and best friend.  
I would also like to thank Dr. Michael Hunnicutt, whose passion and enthusiasm for science 
inspire me. I’m grateful for all I have learned from this amazing instructor, despite his allegiance 
to dUKe.   
Last, but not least, words cannot express the gratitude and love I have for my family. To my 
mom, dad, brother, and better half, thank you for continuously loving and supporting me. I 
would not be where I am or who I am today without your influence. I love you with all of my 
heart.   
iii 
 
 
 
Table of Contents 
List of Tables .............................................................................................................................. viii 
List of Figures ............................................................................................................................... ix 
List of Schemes ............................................................................................................................ xii 
List of Abbreviations ................................................................................................................. xiii 
Abstract .........................................................................................................................................xv 
Chapter 1 – Introduction ..............................................................................................................1 
 1.1 Introduction ..................................................................................................................2                   
 1.2 Pro-oxidants and Antioxidants ...................................................................................3 
 1.3 Protein Oxidation .........................................................................................................6 
 1.4 Protein Carbonylation ...............................................................................................11 
  1.4.1 Protein Carbonylation Mechanisms ..............................................................12 
  1.4.2 Carbonylation and Aging ..............................................................................15 
  1.4.3 Carbonylation and Disease ...........................................................................16 
  1.4.4 Detecting Carbonylation ...............................................................................16 
 1.5 Mass Spectrometry ....................................................................................................18 
  1.5.1 Ionization ......................................................................................................19 
  1.5.2 Mass Analyzer ..............................................................................................20 
  1.5.3 Detector .........................................................................................................22 
  1.5.4 Data Analysis ................................................................................................23 
  1.5.5 Quantitative Proteomics ................................................................................24 
Chapter 2 – Developing Analytical Methods Using Carbonylated Human Serum  
Albumin (HSA) as a Model Protein ...........................................................................................25 
 2.1 Abstract .......................................................................................................................26 
 2.2 Introduction ................................................................................................................27 
 2.3 Experimental Design ..................................................................................................31 
  2.3.1 Materials .......................................................................................................31 
iv 
 
 
 
  2.3.2 HSA Modification .........................................................................................32 
  2.3.3 Labeling of Modified HSA ...........................................................................32 
  2.3.4 Biotin Quantitation Assay .............................................................................33 
  2.3.5 Western Blotting ...........................................................................................33 
  2.3.6 Protein Digestion ..........................................................................................34 
  2.3.7 Monomeric Avidin Column Enrichment ......................................................34 
2.3.7.1 Enrichment at Peptide Level ..........................................................35 
2.3.7.2 Enrichment at Protein Level ..........................................................35  
2.3.8 Mass Spectrometry........................................................................................36 
2.3.9 Database Searches and Analysis ...................................................................36 
2.3.10 FTC Assay ..................................................................................................37 
2.3.10.1 Preparation of Standards ..............................................................37 
2.3.10.2 Fluorometry..................................................................................38 
2.3.10.3 Fluorescence Anisotropy .............................................................38 
2.4 Results .........................................................................................................................39 
2.4.1 Labeling Efficiency .......................................................................................39 
2.4.2 Enrichment at the Peptide Level ...................................................................45 
2.4.3 Enrichment at the Protein Level ...................................................................47 
2.4.4 FTC Assay ....................................................................................................48 
2.5 Discussion....................................................................................................................53 
2.5.1 Labeling ........................................................................................................53 
2.5.2 Spectral Counting..........................................................................................60 
2.5.3 Monomeric Avidin Column Enrichment ......................................................61 
2.5.4 FTC Assay ....................................................................................................62 
2.6 Conclusion ..................................................................................................................64 
Chapter 3 - A Cleavable Biotin Tag Enabling Enrichment and Identification of  
Protein Carbonylation Modification Sites .................................................................................65 
v 
 
 
 
3.1 Abstract .......................................................................................................................66 
3.2 Introduction ................................................................................................................67 
3.3 Experimental Design ..................................................................................................71 
3.3.1 Materials .......................................................................................................71 
3.3.2 Carbonylating HSA .......................................................................................71 
3.3.3 Protein Biotinylation and Enrichment ..........................................................72 
3.3.4 Biotin Quantitation Assay .............................................................................72 
3.3.5 Trypsin Digestion..........................................................................................73 
3.3.6 LC-MS/MS ...................................................................................................73 
3.3.7 Data Analysis ................................................................................................74 
3.4 Results .........................................................................................................................75 
3.4.1 Labeling Efficiency .......................................................................................75 
3.4.2 Identification of Modification Sites ..............................................................76 
3.5 Discussion....................................................................................................................81 
3.5.1 Labeling Efficiency .......................................................................................81 
3.5.2 Spectral Counting..........................................................................................81 
3.5.3 Identification of Modification Sites ..............................................................82 
3.5.4 Limitations ....................................................................................................89 
3.5.5 SpectraST ......................................................................................................91 
3.6 Conclusion ..................................................................................................................96 
Chapter 4 – Application: Investigation of Protein Carbonylation in Human Plasma  
Collected From Chronic Kidney Disease (CKD) Patients on Dialysis ....................................97 
4.1 Abstract .......................................................................................................................98 
4.2 Introduction ................................................................................................................99 
4.3 Experimental Design ................................................................................................103 
4.3.1 Materials .....................................................................................................103 
4.3.2 Plasma Preparation......................................................................................103 
vi 
 
 
 
4.3.3 Protein Labeling ..........................................................................................104 
4.3.4 Protein Digestion ........................................................................................104 
4.3.5 Mass Spectrometry......................................................................................105 
4.3.6 Database Searches and Analysis .................................................................105 
4.3.7 Western Blotting .........................................................................................106 
4.3.8 Biotin Quantitation Assay ...........................................................................107 
4.3.9 FTC Assay ..................................................................................................108 
4.4 Results .......................................................................................................................109 
4.4.1 Western Blotting .........................................................................................109 
4.4.2 Biotin Quantitation Assay ...........................................................................113 
4.4.3 FTC Assay ..................................................................................................114  
4.4.4 Mass Spectrometry......................................................................................118 
4.5 Discussion..................................................................................................................120 
4.5.1 Analytical Assays........................................................................................120 
4.5.2 Other Factors to Consider ...........................................................................125 
4.6 Conclusion ................................................................................................................127 
Chapter 5 – Application: Investigation of Protein Carbonylation in Human  
Plasma/Serum Collected From Trauma Patients ...................................................................128  
5.1 Abstract .....................................................................................................................129 
5.2 Introduction ..............................................................................................................130 
5.3 Experimental Design ................................................................................................134 
5.3.1 Materials .....................................................................................................134 
5.3.2 Preparation of Plasma/Serum ......................................................................134 
5.3.3 Protein Biotinylation ...................................................................................135 
5.3.4 ProteoMiner Depletion................................................................................136 
5.3.5 Western Blotting .........................................................................................136 
5.3.6 Affinity Enrichment and Tryptic Digestion ................................................137 
vii 
 
 
 
5.3.7 iTRAQ Labeling .........................................................................................137 
5.3.8 Mass Spectrometry......................................................................................138 
5.3.9 Database Searches and Analysis .................................................................139 
5.3.10 FTC Assay ................................................................................................139 
5.4 Results .......................................................................................................................141 
5.4.1 Western Blotting: Patients W, X, Y, and Z .................................................141 
5.4.2 FTC Assay: Patient X .................................................................................144 
5.4.3 iTRAQ Quantitation: Patients W and X .....................................................146 
5.4.4 ProteoMiner Depletion and iTRAQ Quantitation: Patients Y and Z ..........150 
5.5 Discussion..................................................................................................................154 
5.5.1 Western Blotting .........................................................................................154 
5.5.2 FTC Assay: Patient X .................................................................................154 
5.5.3 iTRAQ: Patients W and X ..........................................................................155 
5.5.4 ProteoMiner and iTRAQ: Patients Y and Z ................................................156 
5.6 Conclusion ................................................................................................................158 
References ...................................................................................................................................159 
Appendices ..................................................................................................................................178  
 
 
 
 
 
 
 
 
viii 
 
 
 
List of Tables 
Table 1-1  Factors related to various types of protein oxidation ...............................................7 
Table 2-1  Fractions of biotinylated peptides detected with mass spectrometry  
before and after monomeric avidin column enrichment ........................................41 
 
Table 2-2  Fractions of biotinylated peptides detected with mass spectrometry  
before and after monomeric avidin column enrichment ........................................45 
  
Table 2-3  Fractions of carbonylated HSA spiked into plasma, labeled, and then  
detected with mass spectrometry before and after monomeric avidin  
column enrichment.................................................................................................47 
 
Table 2-4 Enrichment results at the protein level – mass spectrometry spectral 
counting results for Labels 1, 2, and 4 ...................................................................48  
 
Table 2-5 Average anisotropy (r) values along with standard deviations for three  
replicate instrumental analyses for both Standard Sets..........................................52 
 
Table 3-1 Peptide Prophet Analysis: List of modified HSA peptides with mass shifts for 
modified cysteine (C), histidine (H), and lysine (K) .............................................93 
 
Table 3-2 SpectraST Analysis: List of modified HSA peptides with mass shifts for 
  modified cysteine (C), histidine (H), and lysine (K) .............................................93  
 
Table 4-1 The CKD stages according to the National Kidney Foundation (KDOQI) ...........99 
 
Table 4-2 Calculated biotin to protein ratios for two subsets of CKD patient samples .......113 
 
 
 
 
 
 
 
 
 
ix 
 
 
 
List of Figures 
Figure 1-1 Protein oxidation is dependent on the actions of pro-oxidants, 
antioxidants, and proteases ......................................................................................5 
 
Figure 1-2 Formation, detoxification, and reaction of α,β-unsaturated  
aldehydes during LPO............................................................................................14 
 
Figure 1-3 A general diagram for an LTQ equipped with ESI ................................................21 
 
Figure 2-1 Structure of acrolein ...............................................................................................29 
 
Figure 2-2 Biotin quantitation assay results ............................................................................43 
 
Figure 2-3 Labeling efficiencies visualized via Western blotting ...........................................44 
 
Figure 2-4 Principle of fluorescence anisotropy ......................................................................49 
 
Figure 2-5 HSA Standard Set 1 includes (A) Emission spectrum and  
(B) Corresponding calibration curve. HSA Standard Set 2  
includes (C) Emission spectrum and (D) Corresponding  
calibration curve.....................................................................................................50  
 
Figure 2-6 HSA Standard Set 1 includes (A) Emission spectrum and  
(B) Corresponding calibration curve. HSA Standard Set 2  
includes (C) Emission spectrum and (D) Corresponding  
calibration curve.....................................................................................................51  
 
Figure 2-7 Structures and molecular weights for Labels 1-4 ..................................................55 
 
Figure 2-8 Peptide level: Plot depicting number of MS/MS spectra identified  
before and after enrichment of HSA derivatized with three  
different biotin labels .............................................................................................57 
 
Figure 2-9 Plot depicting number of MS/MS spectra identified following  
protein enrichment for Label 4-derivatized HSA ..................................................59 
 
Figure 3-1 Biotin quantitation assay results ............................................................................76 
 
Figure 3-2 Percent of modified peptides for 0, 10, 25, 50, and 75 %  
carbonylated HSA spikes .......................................................................................78 
 
 
Figure 3-3 HSA amino acid sequence .....................................................................................79 
 
 
x 
 
 
 
Figure 3-4 MS/MS spectrum of the peptide RH528.24PYFYAPELLFFAK  
in the +2 charge state, m/z 1145.84, with the oxidative  
modification on the histidine (H) residue ..............................................................80 
 
Figure 3-5 Spectral counting results for triplicate injections of 0, 10, 25,  
50, and 75 % carbonylated HSA spikes .................................................................83 
 
Figure 3-6 Comparison of modification sites identified between the alkoxyamine  
 label versus the biotin hydrazide labels .................................................................85 
 
Figure 3-7 Number of spectra for shared modification sites between the  
biotin hydrazide labels and the alkoxyamine label ................................................86 
 
Figure 3-8 Comparison of modified peptide spectra to unmodified peptide  
spectra for certain peptides ....................................................................................88 
 
Figure 3-9 SpectraST spectrum for RH528.24PYFYAPELLFFAK  
in the +2 charge state .............................................................................................95  
 
Figure 4-1 SAMPLE SET #1: Duplicate Western blot analyses of  
patient samples 907, 935, and 967 .......................................................................111 
 
Figure 4-2 SAMPLE SET #2: Duplicate Western blot analyses of  
patient samples 910, 930, and 952 .......................................................................112 
 
Figure 4-3 CKD Sample Set 1: emission spectra from three interday FTC  
assay analyses of patient samples 909, 922, and 951 ..........................................115 
 
Figure 4-4 CKD Sample Set 2 emission spectra from: A. First sample  
preparation on Day 1. B. Second sample preparation on Day 2.  
C. First sample preparation reanalyzed on Day 3. D. Second  
sample preparation reanalyzed on Day 3. ............................................................116  
 
Figure 4-5 Average anisotropy (r) values and standard deviations for triplicate  
analyses of patient samples control 909, HD 922, and PD 951 ...........................117 
 
Figure 4-6 Average percentage of methionine/histidine oxidation for three LC-MS/MS 
 analyses of sample numbers 907, 924, 935, 962, and 967 ...................................119 
 
Figure 5-1 Illustration depicting the acute phase response ....................................................132 
 
Figure 5-2 Western blot analyses of trauma patient samples W and X .................................142 
 
Figure 5-3 Western blot analyses of trauma patient samples Y and Z ..................................143 
 
Figure 5-4 Emission spectra from triplicate FTC assay analyses of Patient X .....................145 
xi 
 
 
 
 
Figure 5-5 A. Components of an iTRAQ label. B. Product following reaction  
between iTRAQ label and a peptide (indicated by amide bond) .........................146 
 
 
Figure 5-6 Carbonylated protein levels for ten proteins that exhibited  
the most change over the course of eight days for Patient W ..............................148 
 
Figure 5-7 Carbonylated protein levels for ten proteins that exhibited  
the most change over the course of six days for Patient X ..................................149 
 
Figure 5-8 ProteoMiner concept depicting equalization of proteins .....................................151 
 
Figure 5-9 Carbonylated protein levels for ten proteins that exhibited  
the most change over the course of four days for Patient Y ................................152 
 
Figure 5-10 Carbonylated protein levels for ten proteins that exhibited  
the most change over the course of four days for Patient Z .................................153 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
 
 
List of Schemes 
Scheme 1-1 Initiation (1), propagation (2-3), and termination (4) steps  
of the lipid peroxidation process ..............................................................................9 
 
Scheme 1-2 Carbonylation of arginine, lysine, and proline to form  
glutamic and aminoadipic semialdehydes .............................................................13 
 
Scheme 2-1 Acrolein-based Michael addition forms adducts on cysteine,  
histidine, and lysine ...............................................................................................39 
 
Scheme 2-2 Reaction between a hydrazide and an aldehyde to form a  
 hydrazone ...............................................................................................................40 
 
Scheme 2-3 Tautomerization of HABA upon addition of avidin with a  
subsequent red shift................................................................................................42 
 
Scheme 2-4 The labeling of carbonylated proteins with FTC ...................................................48 
 
Scheme 3-1 Products resulting from reaction of the alkoxyamine label with a protein  
carbonyl and subsequent enrichment, reduction, and alkylation ...........................70 
 
Scheme 4-1 Reaction between a protein carbonyl and DNPH to form the  
derivatized product...............................................................................................109 
 
Scheme 4-2 Chemiluminescence reaction ...............................................................................110 
 
Scheme 4-3 Redox processes of methionine (Met) .................................................................124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
 
 
List of Abbreviations 
4-HNE   4-hydroxynonenal 
4-ONE   4-oxo-2-nonenal 
ACN    Acetonitrile 
ACR    Acrolein 
AGEs    Advanced glycation end products 
APPs    Acute Phase Proteins 
APR    Acute Phase Response 
ARP    Aldehyde reactive probe  
BSA    Bovine Serum Albumin 
CaCl2    Calcium chloride dehydrate 
CAPD    Continuous Ambulatory Peritoneal Dialysis 
CDC    Centers for Disease Control and Prevention 
CEMs    Channel electron multipliers 
CHAPS   3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CID    Collision-induced dissociation 
CKD    Chronic Kidney Disease 
CVD    Cardiovascular Disease 
DMSO   Dimethyl Sulfoxide 
DNPH    2,4-dinitrophenylhydrazine 
DTT    Dithiothreitol 
ECD    Electron capture dissociation 
ECL    Enhanced Chemiluminescence 
ESI    Electrospray ionization 
ESRD    End Stage Renal Disease 
ETD    Electron transfer dissociation 
FDA    Food and Drug Administration  
FP    False Positive Rates 
FTC    Fluorescein-5-thiosemicarbazide 
GFR    Glomerular Filtration Rate 
GPx    Glutathione peroxidase 
GST    Glutathione-S-transferase 
GuHCl   Guanidine Hydrochloride 
H2O2    Hydrogen peroxide 
HABA    4'-hydroxyazobenzene-2-carboxylic acid 
HACA   6-hydroxycaproic acid 
HAVA   5-hydroxy-2-aminovaleric acid 
HD    Hemodialysis 
HOCl    Hypochlorous acid 
HPLC    High Pressure Liquid Chromatography 
HRP    Horseradish Peroxidase 
HSA    Human serum albumin 
IAA    Iodoacetamide  
ICAT    Isotope coded affinity tags 
ICR    Ion cyclotron resonance 
xiv 
 
 
 
iTRAQ   Isobaric tags for relative and absolute quantification 
kDa    Kilodaltons 
KDOQI   Kidney Disease Outcomes Quality Initiative 
LC    Long Chain 
LC-MS/MS   Liquid chromatography tandem mass spectrometry 
LD50    Lethal dose, 50% 
LOOH   Lipid hydroperoxides 
LPO    Lipid peroxidation 
LTQ    Linear quadrupole ion trap 
mA    Milliamps 
MALDI   Matrix-assisted laser desorption ionization 
MCO    Metal catalyzed oxidation 
MCX    Mixed-Mode Cation Exchange 
MDA    Malondialdehyde 
MDRD   Modification of Diet in Renal Disease study 
MES    2-(N-morpholino)ethanesulfonic acid 
MeSH    Medical Subject Headings 
MetSO   Methionine sulfoxide 
MSR    Methionine sulfoxide reductase 
NaBH3CN   Sodium Cyanoborohydride 
NCBI    National Center for Biotechnology Information 
PBS    Phosphate-Buffered Saline 
PD    Peritoneal Dialysis 
PEG    Polyethylene glycol 
PSMs    Peptide-Spectrum Matches 
PTMs    Post-translational modifications 
PUFAs   Polyunsaturated fatty acids 
PVDF    Polyvinylidene fluoride 
RNS    Reactive Nitrogen Species 
ROS    Reactive Oxygen Species 
SC    Spectral counting 
SDS    Sodium dodecyl sulfate 
SDS-PAGE   Sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
SILAC   Stable isotope labeling by amino acids 
SOD    Superoxide dismutase 
SPE    Solid phase extraction 
TBS    Tris-Buffered Saline 
TBS-T    Tris-Buffered Saline with Tween-20 
TCA    Trichloroacetic acid 
TFA    Trifluoroacetic acid 
TG    Tris/glycine buffer 
TGS    Tris/glycine/SDS buffer 
TMB    3,3’,5,5’-tetramethylbenzidine 
TMT    Tandem mass tags 
TOF    Time-of-flight 
TPP    Trans-Proteomic Pipeline 
 
 
 
 
Abstract 
 
 
ANALYTICAL METHOD DEVELOPMENT FOR THE DETECTION AND ANALYSIS OF 
PROTEIN CARBONYLS 
 
By Chelsea Coffey, Ph.D. 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2015. 
Director: Prof. Scott Gronert 
Department of Chemistry 
 
Oxidative stress can result in changes to many biomolecules and also affect their 
activities. We are interested in protein carbonylation, a type of unnatural oxidation which has 
been associated with numerous degenerative disease states and is also a consequence of the 
natural aging process. Protein carbonyls are stable species, but countless analytical barriers exist 
in terms of their identification. Thus, the main goal of this work was to develop and optimize 
analytical methods that could be used to help us better understand which, where, and how 
proteins are being carbonylated.  
 Initial studies involved method validation for carbonylating, tagging, and enriching the 
model protein human serum albumin (HSA). We have developed a reproducible method of 
 
 
 
 
producing carbonylated protein in vitro in which HSA is treated with acrolein to carbonylate 
cysteines, histidines, and lysines. Protein carbonyls are compatible with various affinity labels 
and enrichment techniques. We strived to learn more about the efficiencies of various biotin 
affinity labels and avidin enrichment techniques using quantitative assays and mass 
spectrometry. Results showed a preference for different affinity labels based on their chemical 
properties and suggested that monomeric columns are selective for particular peptides. Most 
recently, method development and validation work was done involving a cleavable biotin tag that 
enables both enrichment and identification of protein carbonylation modification sites. This 
affinity tag offered the highest labeling efficiency of all tags tested in the past and greater 
coverage of modification sites than biotin hydrazide reagents. 
 We applied our analytical methods to two sets of human blood samples. The first sample 
set was plasma taken from chronic kidney disease (CKD) patients. No carbonylation patterns 
were elucidated, but this project marked the beginning of blood analyses in which existing 
protocols were adapted to blood samples. The second sample set was serum/plasma taken from 
patients with traumatic injuries. We effectively applied our analytical methods to these sample 
sets and were able to visualize and quantitate temporal protein carbonylation patterns via 
Western blotting and iTRAQ-based mass spectrometry experiments. ProteoMiner experiments 
proved successful in that we were able to identify a larger and more diverse amount of 
carbonylated proteins via mass spectrometry.  
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Chapter 1 - INTRODUCTION 
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1.1 INTRODUCTION 
 “Drink green tea; it has antioxidants!” is a phrase commonly heard today, but most likely 
not fully comprehended. Antioxidants are necessary to help combat the pro-oxidants in a 
person’s body and maintain a balance between the two species. If this balance is not maintained, 
for instance the amount of pro-oxidants exceeds the amount of antioxidants, then oxidative stress 
occurs. This negatively affects protein structure and function and has been linked to the aging 
process and progression of various degenerative diseases.
1
 Four years ago, Madian et al. 
demonstrated a decrease in protein carbonylation, detected by selected reaction monitoring 
(SRM) analysis with a nanoUPLC-QSTAR mass spectrometer, in diabetic rats living on a green 
tea-based diet.
2
 Thus, scientific proof exists to support the claim that green tea is indeed a useful 
therapy for increased oxidation levels, particularly in relation to disease-associated oxidative 
stress. 
The human body is one of the most fascinating machines, but, just like any other piece of 
equipment, fades over time due to daily wear and tear. Aging is inevitable; thus, protein 
oxidative damage is inevitable. We cannot stop the aging process, but it is possible to develop 
therapies to treat oxidation. Not only could this potentially minimize and/or delay the effects of 
aging, but might also serve as treatment for various age-related diseases. Much is still unknown 
about the causal-effect relationship concerning protein oxidation and how to treat it. Regardless, 
with ever improving methods and technology, researchers continue to investigate where, how, 
and why proteins are being oxidatively modified as they work to prevent and/or treat oxidative 
stress-related aging and diseases.  
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1.2 PRO-OXIDANTS AND ANTIOXIDANTS 
 Oxidative stress hinges on the balance (redox potential) between the amount of pro-
oxidants and antioxidants in a biological system. While oxygen is essential in metabolic and 
energy-based processes in most biological species, it can also be very damaging. In the simplest 
of terms, pro-oxidants are electron acceptors and antioxidants are electron donors. In a biological 
system antioxidants generally donate a hydrogen or abstract an oxygen; pro-oxidants generally 
donate an oxygen.
3
 Pro-oxidants, also known as reactive oxygen species (ROS) or reactive 
nitrogen species (RNS), are capable of oxidizing and impairing proteins, lipids, carbohydrates, 
and DNA.
1,3–5
 These pro-oxidants can be radical species, which possess one or more unpaired 
electrons, or nonradical species. The radical species include: superoxide anion (O2
•−), hydroxyl 
(HO
•
), peroxyl (ROO
•
), alkoxyl (RO
•
), and nitric oxide (NO
•
)
3,6,7
 and are extremely reactive due 
to their ability to donate or abstract an electron. Nonradical species are equally damaging and 
include: hydrogen peroxide (H2O2), hypochlorous acid (HOCl), peroxides (ROOH), aldehydes 
(HCOR), ozone (O3), and peroxynitrite (ONOOH).
3,7
 Many pro-oxidant species are produced 
during daily metabolism.
1,3,4
 For instance, about 5% of molecular oxygen (O2) is repeatedly 
reduced to form H2O2, OH
•
, and hydroxide anion (OH
-
) in the electron transport chain. 
Conversely, antioxidants inhibit oxidation in many different ways, depending on the type of pro-
oxidant and antioxidant.
3
 Some antioxidants include: proteins like ceruloplasmin, transferrin, and 
ferritin; enzymes like superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione-S-
transferase (GST), methionine sulfoxide reductase (MSR), and glutathione reductase; vitamins 
A, C, and E; and metal ions like Zn
2+
, Mg
2+
, and Mn
2+
.
4
  
 
 
4 
 
 Both the environment and our bodies contribute to the production of ROS. Externally, 
different types of radiation and pollutants generate ROS, while internally, ROS are generated via 
daily metabolic activities. The diagram depicted in Figure 1-1, redrawn from Stadtman and 
Levine, shows the various pro-oxidants and anti-oxidants and the events that can occur due to 
imbalance.
4
 ROS are generally very reactive with brief half-lives ranging anywhere from 
nanoseconds to hs. Both reactivity and half-life length are affected by biological conditions, for 
instance pH and interfering species. Half-life does not necessarily constitute reactivity; ROS with 
longer half-lives can travel to produce oxidative damage at distant sites. On the other hand, ROS 
with extremely short half-lives cause oxidative damage near ROS production sites. The fast 
reactivity of ROS not only make them difficult to study, but also demonstrates the difficulty in 
preventing oxidative damage.
3
 Thus, in this dissertation, we focused on oxidative damage to 
proteins, which provide more robust markers of oxidative stress.   
 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1. Protein oxidation is dependent on the actions of pro-oxidants, antioxidants, 
and proteases. 
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1.3 PROTEIN OXIDATION 
As depicted in Figure 1-1, if proteases are unable to degrade oxidized proteins to 
peptides or individual amino acids, then these oxidized proteins remain in the system. By 
definition, protein oxidation is the covalent modification of the protein resulting directly from 
ROS or indirectly from interaction with secondary oxidative stress-related products. Each protein 
has a distinct biological function
1
 and its modified counterpart is stable for up to weeks at a 
time.
8
 This, along with the fact that native proteins are readily available via blood,
9
 makes 
modified proteins ideal species to study rather than the short lived ROS. Oftentimes, a loss of 
function is also observed with protein oxidation. For instance, metal catalyzed oxidation of 
fibrinogen leads to its inability to form clots
10
 and HOCl based-oxidation of the protease 
inhibitor α-1 antitrypsin leads to lung tissue degradation in emphysema patients.11  However, 
since there are a variety of oxidation mechanisms and a majority of amino acids can be 
oxidatively modified, many types of modified proteins can be formed. A compilation of these 
modifications can be found in Table 1-1, reproduced from Shacter.
1
 Various types of modified 
proteins have also been linked to aging
7,12–14
 and disease (an extensive list of biomarkers can be 
found in a review by Dalle-Donne et al.).
15
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Table 1-1. Factors related to various types of protein oxidation. 
MODIFICATION TYPE AMINO ACID(S) OXIDIZED PRO-OXIDANT(S)* 
Disulfides, glutathiolation Cys All, ONOO
-
 
Methionine sulfoxide Met All, ONOO
-
 
Carbonyls (aldehydes & ketones) Lys, Arg, Pro, Thr, etc. All 
Oxo-histidine His γ-Ray, MCO, 1O2 
Dityrosine Tyr γ-Ray, MCO, 1O2 
Chlorotyrosine Tyr HOCl 
Nitrotyrosine Tyr ONOO
-
 
Tryptophanyl modifications Trp γ-Ray 
Hydro(pero)xy derivatives Val, Leu, Tyr, Trp γ-Ray 
Chloramines, deamination Lys HOCl 
Lipid peroxidation adducts (MDA, HNE, etc.) Lys, Cys, His γ-Ray, MCO 
Amino acid oxidation adducts Lys, cys, His HOCl 
Glycoxidation adducts Lys Glucose 
Cross-links, aggregates, fragments Numerous All 
*All = γ-Ray, MCO, HOCl, ozone, 1O2; ONOO
-
 = peroxynitrite; MCO = metal catalyzed oxidation; HOCl = 
hypochlorous acid 
 
 
Only two of these mechanisms are involved extensively in this work and will be 
discussed in further detail: metal catalyzed oxidation (MCO) and lipid peroxidation (LPO). Since 
the early 1980s, Stadtman & Levine have studied MCO and determined it to be one of the most 
prevalent biological oxidation mechanisms.
4
 The most abundantly produced ROS are hydrogen 
peroxide and alkylperoxides, both of which are fairly harmless. Upon reaction with the transition 
metal iron (Fe (II)), hydroxyl radicals or alkoxyl radicals can be formed as shown in Equations 1 
and 2, respectively.
4,16
 These radicals generally modify proteins in a site specific manner, 
oxidizing approximately 1-3 amino acids at the locations of metal binding on the protein. This 
chemistry is commonly known as the Fenton reaction.
4,17,18
 MCO is often accomplished in model 
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systems using a combination of oxygen (O2), ascorbate, and iron (III) chloride (FeCl3) as 
pioneered by Levine.
10,19
   
 
H2O2 + Fe(II)          HO
•
 + OH
-
 + Fe(III)                              Eq (1) 
ROOH + Fe(II)          RO
•
 + OH
-
 + Fe(III)                              Eq (2) 
 
Unlike the direct oxidation induced by MCO, the reaction of lipid peroxidation products 
with protein amino acids is an indirect form of oxidative modification.
1,20,21
 Most cell 
membranes are composed of lipids, which also play a role in managing cell functions.
22
 In LPO, 
ROS react with lipids, which undergo hydrogen abstraction and oxygen insertion to produce 
compounds such as lipid peroxyl radicals, lipid hydroperoxides (LOOH), and/or secondary 
oxidation products.
20,21
 These secondary oxidation products react with amino acids to form 
oxidatively modified proteins. Polyunsaturated fatty acids (PUFAs) are the lipids most suitable 
for LPO because they contain bis-allylic methylene groups, from which the hydrogens are more 
easily removed.
20
 However, cholesterol, glycolipids, and phospholipids are also candidates for 
LPO modification.  
LPO progresses through three different steps: initiation, propagation, and termination. An 
overview of the process was recreated from Ayala et al. and is depicted below in Scheme 1-1.
21
  
In the initiation step, a pro-oxidant (R
•) captures an allylic hydrogen from the lipid, which leaves 
a carbon-centered lipid radical. In the propagation step, an oxygen molecule (O2) reacts with the 
lipid radical to create a lipid peroxy radical (LOO
•
). The lipid hydroperoxide (LOOH) is formed 
when LOO
•
 captures an allylic hydrogen from a second lipid, at which point this second lipid 
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now contains a radical and the process can continue in a repetitious fashion. In the termination 
step, LOO
• 
captures a hydrogen from an antioxidant to form a nonradical product.
20–23
  
 
 
 
 
 
 
 
 
 
Scheme 1-1. Initiation (1), propagation (2-3), and termination (4) steps of the lipid peroxidation 
process. 
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Of most interest in our work is the formation of the aldehyde-containing secondary 
oxidation products, which most commonly include: malondialdehyde (MDA),
24–26
 4-
hydroxynonenal (4-HNE),
24,27–29
 4-oxo-2-nonenal (4-ONE),
30–32 acrolein (ACR),24,33–35 propanal, 
and hexanal.
36
 These aldehydes result from fragmentation of an ester-containing LOOH
22
  and 
are particularly dangerous because they have longer life spans and thus can travel to create 
oxidative damage in distant locations.
24
 The electrophilic properties of the α,β-unsaturated 
aldehydes (4-HNE, 4-ONE, and ACR) make them extremely reactive toward nuclueophiles, such 
as sulfhydryl groups in cysteines and amino groups in lysines/histidines.
30,37
   
The majority of oxidative modifications regardless of the source are irreversible, with the 
exception of oxidation of sulfur-containing amino acids. Modification of the sulfur in both 
methionine and cysteine are reversible. Upon reaction with ROS, methionine is oxidized to form 
S- and R-stereoisomers of methionine sulfoxide (MetSO), commonly referred to as MetA and 
MetB, respectively. Two types of MetSO reductases, MsrA and MsrB, serve to return the 
oxidized amino acid back to its native form of methionine.
14,38
 Oxidation of cysteine can result in 
three products: sulfenic, sulfinic, and sulfonic acids, each of which contains one, two, or three 
additional oxygens, respectively. Sulfenic acid serves as an intermediate to form sulfinic or 
sulfonic acid and is reactive toward other thiols, resulting in disulfide bridges. Native cysteine 
can be reformed through reduction of disulfides by glutathione or thioredoxin or reduction of 
sulfinic acid by sulfiredoxin.
39
 This phenomenon is discussed further in Chapter 4 of this 
dissertation.   
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1.4 Protein Carbonylation 
Only eight years ago, the term ‘protein carbonylation’ was added to the PubMed Medical 
Subject Headings (MeSH) used to refine searches, and deemed a “standard marker for oxidative 
stress”.40 However, well before then, oxidative carbonylation had been studied as a valuable 
marker for various conditions and diseases
1,4,41–43
 and as a consequence of the natural aging 
process.
1,4,12,41,44
 Since aging accompanies the onset of numerous degenerative diseases, 
differentiating unique oxidative carbonylation patterns can be very challenging.
15
 Following 
methionine and cysteine oxidation, carbonylation is the third most prevalent post-translational 
modification
45
 and is a major concern due to the association of increased levels of oxidative 
carbonylation with aging and disease.
4 
Carbonylation, which involves the incorporation of an aldehyde or ketone onto an amino 
acid, is often used as a measure of oxidative stress. This type of modification is irreversible, 
meaning the chemical change is unaffected by antioxidant actions. Conversely, examples of 
reversible modifications include cysteine and methionine, both sulfur-containing residues and 
both subject to modification reversal by specific enzymes.
4,38,39,46
 The irreversibility of 
carbonylation is both a positive and negative. In terms of disease and aging, the irreversible 
nature causes an excess of unrepairable and dysfunctional proteins leading to further 
complications. On the other hand, the reactivity of the modification allows for a variety of 
labeling, enrichment, and detection techniques to be used. Following derivatization of the 
carbonyl, the stability of the moiety permits extended storage under proper conditions (-80°C). 
For these reasons, carbonylation is one of the most commonly studied types of markers for 
oxidative stress.
46
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1.4.1 Protein Carbonylation Mechanisms 
 Revolutionary work by Swallow,
47
 Garrison,
48
 and Scheussler & Schilling
49
 
demonstrated that HO
• 
was responsible for the formation of different types of oxidized products, 
which implied that protein carbonylation can occur via a variety of mechanisms. Direct 
carbonylation occurs when hydroxyl radicals oxidize amino acid side chains, generally those of 
arginine, lysine, proline, and threonine, to form aldehydes or ketones. Indirect carbonylation 
occurs when cysteines, histidines, or lysines react with secondary products from the lipid 
peroxidation process (4-HNE, ACR, MDA) to form aldehyde-containing oxidation products. 
Through the alpha-amidation pathway, hydroxyl radicals can also attack the protein backbone by 
capturing a hydrogen atom, leaving a carbon-centered radical that can react with oxygen or other 
carbon-centered radicals to form single or crosslinked carbonylation products. Lastly, the 
reaction between reducing sugars and lysine amino groups can produce carbonylated species 
known as advanced glycation end products (AGEs).
13,18,46
 The first two mechanisms concerning 
direct and indirect carbonylation were explored in this dissertation. 
  The hydroxyl radicals involved in direct oxidation are often derived from either ionizing 
radiation or MCO. The most prominent carbonylation products observed from direct oxidation 
are glutamic semialdehyde, derived from arginine or proline, and aminoadipic semialdehyde, 
derived from lysine.
46,50,51
 These products have been observed in model proteins such as 
glutamine synthetase, bovine serum albumin, ribonuclease A, and lysozyme as well as in 
biological samples such as rat liver. Reactions for the carbonylation of arginine, lysine, and 
proline to form glutamic and aminoadipic semialdehydes were recreated from Requena et al. and 
are depicted in Scheme 1-2.
50
 Although not pictured, the carbonylation derivative of threonine is 
known as 2-amino-3-ketobutyric acid.
15
  
 
 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
Scheme 1-2. Carbonylation of arginine, lysine, and proline to form glutamic and 
aminoadipic semialdehydes (figures in gold). Blue represents oxidation, red represents 
leaving groups, and green represents reduction. 
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Indirect carbonylation proceeds through Michael addition of secondary lipid peroxidation 
products (α,β-unsaturated aldehydes) to the sulfur of cysteine, or the amine of histidine and 
lysine. Visible in Figure 1-2, fragmentation of lipid hydroperoxides (LOOH) leads to the 
generation of reactive aldehyde-containing products. As illustrated by 4-HNE, these reactive 
species can either react with proteins to form carbonylation products or be detoxified by 
glutathionylation, oxidation via aldehyde dehydrogenase, or reduction via alcohol 
dehydrogenase.
52
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Formation, detoxification, and reaction of α,β-unsaturated aldehydes during LPO. 
PUFA = polyunsaturated fatty acids; ROS = reactive oxygen species; PRX, GRX = 
peroxiredoxin, glutathione peroxidase; PUFA-OOH = lipid hydroperoxides; 4-HNE = 4-
hydroxynonenal; GSTA4 = glutathione S-transferase alpha 4. (Redrawn from Grimsrud et al.) 
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1.4.2 Carbonylation and Aging 
 Recent research indicates that carbonylation affects nearly one-third of all proteins in a 
fully aged animal.
51
 That means one-third of proteins in matured species are potentially 
nonfunctional, which also play a role in the catalytic inactivation of enzymes.
4
 These conclusions 
originate from the “free radical theory of aging” proposed by Denham Harman in 1954, which 
postulates that the actions of free radicals promote aging and concomitant oxidation of 
biomolecules. Intuitively, Harman proposed that inhibiting free radicals would presumably 
increase an animal’s life span.53 Since then, correlations between aging and carbonylation have 
been identified by many researchers: Oliver & Levine (1987),
54
  Sohal, Sohal, & Orr (1995),
55
 
Bertlett & Stadtman (1997),
13
 and Stadtman (2006).
7
 One of the most popular representations of 
this trend was published by Stadtman and Levine in 2000.  The plot depicts a trend line 
correlating age and carbonyl content for human, fly, and rat samples, with the most prominent 
correlation in the last third of the animal’s lifetime.4   
  A comprehensive list of 179 carbonylated proteins identified during aging in an 
assortment of species can be found in the review by Cabiscol et al.
46
 The main purposes of 
compiling such a list were to classify the carbonylated proteins by physiological function and 
also cross reference these proteins across species. In doing so, it was determined that heat shock 
proteins and those associated with protein metabolism were most conducive to age-related 
carbonylation, and that various proteins, such as those involved in glucose metabolism, were 
carbonylated in a variety of species.
46
 This information indicates which physiological functions 
are most affected by the aging process and confirmed by identification in various organisms.  
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1.4.3 Carbonylation and Disease 
 Today, Harman’s “free radical theory of aging” could be changed to the Free Radical 
Theory of Aging and Disease, considering the overwhelming evidence correlating oxidation with 
disease progression. As with aging, an increase in ROS-derived oxidative carbonylation has been 
observed with the progression of countless diseases and conditions. An extensive, though not 
complete, list of diseases and conditions associated with carbonylation was published by Levine 
and Stadtman in 2006.
56
 Naturally, diseases and conditions associated with aging demonstrate 
compound carbonylation, yet the causal/effect relationship between carbonylation, aging, and 
disease has not been fully elucidated.
15,56,57
 The following are diseases/conditions that have been 
linked to oxidative carbonylation and published frequently and recently (within the last 15 
years): Alzheimer’s disease,58–62 caloric restriction/exercise,63–67 diabetes,2,68–71 ischemia-
reperfusion/stroke,
72–74
 sepsis,
75–80
 Parkinson’s disease,81–83 and kidney disease.5,8,84–86         
1.4.4 Detecting Carbonylation 
To this day, carbonyl detection and analysis remains a significant analytical challenge. 
However, much progress in analytical methodology has been made over the years as evidenced 
by pioneering contributions from Esterbauer et al.,
29
 Stadtman & Levine,
56
 Shacter,
10
 Dalle-
Donne et al.,
15
 Butterfield,
51
 and Regnier et al.,
87
 to name a few. Improvements in technology 
and instrumentation have also played a vital role in the advancement of methodologies.
46
  
In general, analytical analyses of carbonylated proteins can be divided into two 
categories: gel-based and gel-free. Sample preparation differs for these types of analyses, but 
both commonly utilize mass spectrometry as the final detection method. Gel-based methods 
often involve derivatizing carbonyl groups with an affinity tag, performing one-dimensional (1-
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D) or two-dimensional (2-D) Western blotting, and detecting with an antibody specific for the 
affinity tag. This technique allows for the visualization of an array of modified proteins, but 
complications including sensitivity and non-specific binding are often encountered.
46
 In-gel 
digestions of particular protein bands can be performed in preparation for identification by mass 
spectrometry.
88
 Gel-free methods involve a variety of assays and techniques for measuring 
protein carbonylation.
46
 Thanks to the early work by Green,
89
 affinity tags and enrichment 
systems utilizing the strong association between avidin and biotin are among the most popular 
sample preparation tools today. Regnier and coworkers popularized biotin hydrazide as an 
affinity label and monomeric avidin as an enrichment technique in the early 2000s.
2,87,90,91
 Since 
then, variations of these reagents have been used in an assortment of studies.
92–94
 One of the 
earliest and most popular assays was the DNPH assay developed by Levine et al. It involved 
derivatization of protein carbonyls with 2,4-dinitrophenylhydrazine (DNPH) and monitoring the 
molecule’s absorption around 370 nm using a spectrophotometer.95  
While each technique has its pros and cons, there still remains a universal struggle with 
many analytical factors such as: complex sample matrices, reproducibility, sensitivity, 
specificity, limit of detection, etc.
96
 More detailed information regarding these analytical 
challenges and particular proteomic techniques will be discussed throughout this dissertation. 
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1.5 MASS SPECTROMETRY 
 As mentioned previously, proteins are important to study because each possesses a 
unique function that correlates to metabolic activity and/or disease states. The term proteomics 
appeared in the 1990s as scientists took interest in identifying and quantifying various proteins
97
 
produced via the central dogma of biology: DNA>RNA>proteins.
98
 This was similar to 
genomics work at the time involving gene classification studies. With the production of 
100,000+ proteins from the human genome,
97
 one can imagine the immensity of classifying all 
human proteins in both natural and diseased states. Proteins are active in all living organisms, 
thus proteomics studies are not limited to human samples, further expanding the scope of these 
studies. A more refined field is redox proteomics, in which classification studies focus on the 
effects of oxidation of proteins.
46
 Throughout this dissertation, our interest is in redox proteomics 
due to our focus on protein carbonylation.  
 Within the last decade, mass spectrometry has become the foremost technique used in 
large, complex proteomics studies due to instrumentation improvements concerning mass 
accuracy, sensitivity, and resolution. The two most popular mass spectrometry-based proteomics 
methods are “top-down” analysis and “bottom-up” analysis. Top-down proteomics is used for 
the characterization of entire proteins, which are first fractionated, ionized in the gas phase, and 
then fragmented in the mass spectrometer.
97,99
 While this type of analysis is thought to offer a 
more comprehensive look at the entire protein and post-translational modifications (PTMs) it 
may carry,
99
 it also suffers from limited sensitivity and analysis of complex protein 
mixtures.
97,100
 Although improvements in resolution continue to fuel these types of 
analyses,
101,102
 bottom-up proteomics generally remains the analysis of choice. In this method, 
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large mixtures of proteins are digested to form peptides, which are then separated 
chromatographically and analyzed with liquid chromatography tandem mass spectrometry (LC-
MS/MS). Since smaller species are more easily fractionated, ionized, and fragmented, bottom-up 
methods, or shotgun proteomics as it is commonly known, can be applied to a larger variety of 
more complex protein samples.
97,99
 All of the work in this dissertation involved bottom-up 
proteomics methods. 
1.5.1 Ionization  
About 26 years ago, mass spectrometry broke into the world of biological compound 
analysis thanks to the   revolutionary work by Franz Hillenkamp, Koichi Tanaka, John Fenn, and 
their colleagues. Since then, mass spectrometry has climbed its way to the top of biological 
scientific techniques, where it remains to this day. In the simplest of terms, a mass spectrometer 
contains an ion source, a mass analyzer, and a detector. Combined, these components allow for 
selective determination of analyte concentration, elemental composition, and/or structural 
information; however, ions must be in the gas phase in order to be separated and detected. Since 
ions are charged species, the mass-to-charge (m/z) ratio is determined instead of the direct 
mass.
98
   
Biological sample analysis was limited due to the gas phase requirement until the mid-
1980s when two novel soft ionization techniques were proposed: matrix-assisted laser desorption 
ionization (MALDI) and electrospray ionization (ESI).
103–107
 The first practical experiments 
demonstrating the use of MALDI were published by Hillenkamp
106,107
 in 1985 and Tanaka
105
 in 
1988, roughly the same time as Fenn’s initial ESI reports between 1985-1989.103,104 Both 
achievements were honored with a Nobel Prize in 2002.
108,109
  As of today, ESI and matrix-
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assisted laser desorption ionization (MALDI) are the two most commonly used soft ionization 
techniques for biomolecules.
110
   
MALDI-MS analyses involve the addition of an organic-based matrix to a sample, which 
is then deposited on an analysis plate. The spot dries, forming a crystalline structure, which is 
next irradiated with a laser. The heating of the laser causes fast sublimation of the sample and 
matrix, and ultimately ionization.
109
 Despite MALDI’s ever growing success, we employed ESI 
ionization techniques for our analyses. The meaning of ESI implies exactly how it sounds; 
electrospray utilizes a needle carrying a charge of several kilovolts (1-6 kv) to disperse the liquid 
solution into small, charged droplets without causing fragmentation.  As the droplets travel from 
the needle to the mass spectrometer, the solvent evaporates, eventually leaving only a charged 
species in the gas phase. The nebulization and evaporation processes are both enhanced using 
nitrogen (N2) gas. The charged species pass through a heated capillary (100-300°C), which 
serves to finalize desolvation and transfer the ions into the mass spectrometer.
103,104,108
 Other 
benefits of ESI include the capacity to work at low sample concentrations (µM range) and low 
flow rates (1-20 µL/min), both of which can be reduced with the use of nanospray ionization 
(nano-ESI). Using a capillary instead of a needle, lower flow rates of 20-50 nL/min can be 
achieved, which is amenable to work at nM concentrations. Nano-ESI also decreases solvent and 
salt interferences.
108
 
1.5.2 Mass Analyzer 
 Following ionization, ions travel toward the mass analyzer, also known as the m/z 
analyzer. This device allows for spacial or temporal separation of the ions by their m/z using 
electric and/or magnetic fields, after which abundances can be determined by the detector.
98
  The 
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most common mass analyzers used in proteomics include: time-of-flight (TOF),
111
 quadrupole,
112
 
ion trap,
113
 and ion cyclotron resonance (ICR).
114
 While each offers various advantages and 
disadvantages, often times multiple analyzers will be connected in tandem to multiply the 
individual advantages.
110
 This was the case in our work, which involved a linear quadrupole ion 
trap (LTQ). The LTQ became commercially available in the early 2000s,
98
 but quadrupole ion 
traps (Q-traps) date back to the early 1950s. Paul first proposed the Q-trap in 1953,
115
 and it took 
about 40 years before their use with biological samples commenced.
116
 In typical LTQ 
instrumentation, the ESI-generated ions are focused into the ion traps using quadrupoles. Inside 
the ion trap, an electric potential is applied to a central ring electrode, drawing the ions toward 
the trap center. Upon application of an increasing Rf voltage, the ions are ejected from the trap 
based on their mass to charge; increasing mass to charge correlates with greater instability and 
thus ejection.
98,116
 Ion traps offer sensitivity and robustness, but low mass accuracy due to their 
limited trapping abilities.
110
 A diagram of a typical linear quadrupole ion trap adapted from the 
work by Schwartz and coworkers is pictured in Figure 1-3.
117
 The depiction also includes 
electrospray ionization and is representative of the instrumentation used in this dissertation.   
 
 
     
 
 
 
Figure 1-3. A general diagram for an LTQ equipped with ESI. Ideal vacuum pressures are 
presented at the top in torr. 
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 Peptide fragmentation is of particular importance in proteomics analyses and data 
interpretation. The three main fragmentation methods used in proteomics are electron capture 
dissociation (ECD), electron transfer dissociation (ETD), and collision-induced dissociation 
(CID). ECD was first proposed in 1998 by McLafferty et al.
118
 and involves exposing protonated 
proteins/peptides to thermal electrons. Protein/peptide capture of electrons is an exothermic 
process that results in fragmentation of the protein or peptide along the backbone.
98
 ECD has 
generally been confined to ICR analyzers,
118,119
 making the technique costly due to the expense 
of the instrumentation.
120
 Six years later, ECD was manipulated to create ETD by Syka et al.
119
 
In ETD, radical anions are used to transfer electrons to protonated peptides to induce 
fragmentation. ECD and ETD are typically employed when working with larger species and thus 
can be more conducive to PTM analyses.  However, they can also serve as complements to CID 
techniques. In CID, peptides are exposed to neutral gas (often helium) and those with three or 
less protons are usually fragmented upon collision, producing unique fragmentation patterns 
consisting of b- and y- ions. On the other hand, ECD and ETD produce fragmentation patterns 
consisting of c- and z- ions. These fragmentation patterns correlate to cleavages along the 
peptide backbone and assist with peptide identification. Unlike ECD, both ETD and CID are 
compatible with complex samples and a variety of instruments, including ion traps.
120
  
1.5.3 Detector 
 As can be seen in Figure 1-3, the detectors reside on opposite sides of the ion trap. The 
most important goal of a detector is signal amplification. Following mass to charge separation in 
the mass analyzer, ions enter the detector(s) and, upon interaction with a charged surface, 
produce secondary particles. The summation of these particles for each mass to charge represents 
an amplified signal, but remains proportional to the original ion count. Desired detector traits 
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include: fast, efficient amplification, sensitivity, accuracy, and long lifetime.
98,121
 Three of the 
most popular detectors that offer most if not all of these traits are faraday cups,
122,123
 electron 
multipliers,
124,125
 and channel electron multipliers.
126
 Our instrumentation utilized two channel 
electron multipliers (CEMs), also referred to as array detectors. The CEM consists of a 
conductive tube, closed on one end and open on the other. The closed end consists of an endcap 
containing hundreds of channels per square inch while the open end allows for ions and 
secondary particles to exit. A voltage is applied to the tube. As the ions strike the various 
channels, secondary electrons are produced. As these electrons progress down the channels, they 
continue to hit the walls, producing even more secondary electrons until they emerge from the 
tube. The amount of amplification is referred to as the gain, and in this case with CEM, is about 
10
7
-10
8
 electrons. The electrical signal can then be interpreted with data analysis software to 
produce a more useable and interpretable output.
98,121
   
1.5.4 Data Analysis 
 Most often in mass spectrometry-based proteomics, multiple scans/fragmentation events 
occur for each sample during a mass spectrometry analysis. This results in thousands of tandem 
mass spectra for each sample. Since this is too many spectra for manual confirmation, 
computational software has been developed to perform the task. Most software relates to one of 
two types of data analyses: de novo sequencing and database searching, both of which were 
developed in the late 1990s. De novo sequencing involves direct elucidation of peptide sequences 
from the tandem mass spectra. Database searching, which we used in our work, involves 
comparing experimental mass spectra to theoretical mass spectra from all peptides comprising a 
protein sequence.
127,128
 Various database searching software programs exist,  most notably 
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SEQUEST
129
 and MASCOT,
130
 both of which enable database comparisons, but differ in their 
scoring of peptide matches.
127
   
1.5.5 Quantitative Proteomics 
 Today, quantitation has become the hallmark of mass spectrometry-based proteomics 
experiments. Albeit difficult to accomplish, thanks to improvements in instrumental and sample 
preparation techniques, small differences in peptide and/or protein concentrations have been 
determined in relation to various states and stimuli. Up until the late-1990s, mass spectrometry 
exhibited widespread use for qualitative determination of a plethora of proteins in complex 
mixtures.
131
 In 1999, Gygi et al. introduced isotope coded affinity tags (ICAT)
132
 followed by 
various other quantitative techniques in the early-2000s. Quantitation in proteomics can be either 
relative or absolute. Relative quantitation consists of comparing protein amounts across analyses 
to create abundance ratios.
131
 Strictly relative techniques are often referred to as label-free 
quantitation methods with examples being spectral counting (SC)
133
 and peptide peak intensity 
measurements.
134
 These approaches assume that more material equals more peptide spectra or 
larger peaks, respectively. Absolute quantitation consists of determining precise amounts of 
protein present and these techniques can be used for relative quantitation as well. Since Gygi et 
al.’s work in 1999, stable isotope labeling has been produced in various formats: stable isotope 
labeling by amino acids (SILAC),
135
 ICAT,
132
 isobaric tags for relative and absolute quantitation 
(iTRAQ),
136
 and tandem mass tags (TMT).
137
 Quantitation techniques explored in this 
dissertation include SC used for simple model protein solutions and iTRAQ used for more 
complex biological samples.    
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Chapter 2 - DEVELOPING ANALYTICAL METHODS USING 
CARBONYLATED HUMAN SERUM ALBUMIN (HSA) AS A MODEL 
PROTEIN 
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2.1 ABSTRACT  
 There are countless analytical barriers that complicate proteomics experiments and this is 
apparent by the marked decline in protein biomarker elucidations over the past 25 years. In this 
chapter, our focus was on improving current analytical methods and implementing new 
procedures for the detection of protein carbonyls. Building upon previous studies in our lab, we 
worked on optimizing the biotin affinity tag used to label protein carbonyls and the enrichment 
techniques used to isolate biotin-labeled material. Experiments involved four different biotin tags 
and one enrichment product, which was incorporated at the protein and peptide level. We 
introduced and validated two new assays, the biotin quantitation assay and the FTC assay. The 
biotin quantitation assay, a UV-Vis spectroscopy-based assay, was used to assess labeling 
efficiency and the FTC assay, a fluorescence-based assay, was developed as a more sensitive 
alternative to the quantitation assay. Overall, we were able to determine the most efficient biotin 
label in terms of enrichment and mass spectrometry analyses and implement two new assays, 
which were later applied to biological sample sets.  
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2.2 INTRODUCTION 
A biomarker is defined as a measurable analyte that reflects the progression of a 
condition or disease. In terms of diseases, biomarkers generally reveal the initial onset and 
evolution of diseases along with responses to therapies.
138,140
 Most often, clinical-based assays 
are the byproducts of biomarker discovery – cheap, fast, and easy tests that can be used by a 
variety of technicians to identify biomarkers in patient samples. Blood is the optimum specimen 
for such tests.
138
 It is abundant, easily obtainable, and filled with proteins, offering a real-time 
depiction of the body’s state of health.9,138 Studies involving blood are addressed in Chapters 4 
and 5 of this dissertation, but those studies remained at the discovery phase. An initial discovery 
phase involves distinguishing differences in certain protein concentrations between control and 
treated samples or healthy and diseased subject samples from model systems or clinical studies, 
respectively.
138
 Identifying biomarkers is not necessarily difficult – it is not uncommon to 
elucidate a unique marker, in our case maybe a particular protein, specific to a certain condition. 
The difficulty resides in clinical validation, especially in regards to obtaining approval from the 
United States Food and Drug Administration (FDA). Over the past 20 years, rates for approving 
novel protein biomarkers have remained sluggish with approximately one biomarker approved 
per year according to regulations set forth by the FDA.
96,138,139
  
 In this study, we were not attempting to identify biomarkers, rather we were striving to 
develop methods that could potentially be used in biomarker discovery work. While this type of 
work is generally not as complicated as clinical validation work, which we encountered while 
applying our methods to human blood samples in Chapter 4, we still experienced many 
analytical barriers in our method development studies. Some common experimental obstacles 
 
 
28 
 
included: lack of availability of specific reagents and tools, cost of said reagents and tools, 
instrument variability between runs, sensitivity, reproducibility, and sample availability. In terms 
of conceptual issues, many researchers make poor biomarker predictions and thus waste effort 
and supplies investigating these assumptions.
96
 In relation to clinical validation, there is also a 
lack of knowledge pertaining to the pipeline, a term used to describe the steps between the 
discovery phase and diagnostic implementation phase. Many pipeline requirements are 
overlooked or ignored, making the proposed methods invalid and unpublishable.
96,141
    Relating 
to biological concerns, issues persist with inconsistent processing of biological samples in terms 
of collection, storage, handling, and improper experimental design, particularly in extensive 
studies with large numbers of samples.
96
 Another factor complicating experimental designs is the 
more recent requirement for multiple markers to confirm the presence and/or progression of a 
disease.
138
 This list outlines the barriers faced in analytical method development work and 
clinical validation studies, but is certainly not comprehensive.    
The following method development work involved the model protein human serum 
albumin (HSA). At ~66 kDa, HSA is made up of 585 amino acids in its secreted form. It is the 
most abundant protein in human plasma/serum, constituting roughly 60% of the protein mass.  
HSA serves to regulate colloid osmotic pressure, transport a variety of molecules, and combat 
oxidation as an antioxidant.
140,142,143
 Hence, not only is HSA readily available and cheap, it has 
been the focus of many investigations concerning carbonylation
144–146
 and antioxidant 
research.
140,147
 Of note, serum albumin is also the most prominently carbonylated protein in 
chronic kidney disease, end stage renal disease,
148
 and liver disease patients.
149
   
In our lab, we reproducibly created carbonylated serum albumin by conjugating it to one 
of the most reactive , -unsaturated aldehydes, 2-propenal, more commonly known as acrolein 
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(ACR).
150
 Its structure is depicted below in Figure 2-1. Because it is composed of an alkene 
linked to an electrophilic group, acrolein is considered to be a conjugated type-2 alkene.
37
 Its 
discovery dates back to the 19
th
 century. In the mid-1820s, a French lipid chemist coined the 
term glycerin, also known as glycerol, following the production of soap from fats and alkali. In 
1839, another chemist named Berzelius, classified a degradation product of glycerin as acrolein 
and, four years later, Redtenbacher was the first to prepare acrolein via distillation of glycerin. 
He made note of the molecule’s obnoxious smell and ability to instantly bring those exposed to 
tears.
34
 Over the years, scientists realized this small molecule was extremely toxic.
34,150
  
 
 
 
 
Acrolein is in the environment due to partial combustion of materials such as plastic, 
petrol, coal, and wood, excess heating of frying oil, for instance when cooking, and cigarette 
smoking. In biological systems, acrolein can be formed via oxidation of polyamine metabolites, 
during the lipid peroxidation process, or by organism-driven modification of certain allyl-
containing compounds or cyclophosphamide, an anticancer drug.
24
 Studies have correlated 
acrolein with cell apoptosis and acute toxicity.
24,35
 Acrolein-induced apoptosis has been observed 
at low micromolar concentrations in human alveolar macrophages,
151
 human bronchial epithelial 
cells,
152
 and human keratinocytes.
153
 Exposure to acrolein can cause extreme irritation of the 
eyes and mucosa and contact with acrolein can cause critical burns. According to Ullman’s 
Figure 2-1. Structure of acrolein. 
 
 
30 
 
Encyclopedia of Industrial Chemistry, the LD50 = 46 mg/kg  for oral ingestion by a rat and the 
LD50 = 562 mg/kg for dermal contact of a rabbit.
24
  
Despite its toxicity, acrolein is useful in our work because it is reactive toward 
nucleophilic sites of proteins, particularly thiol groups in cysteines and amino groups in 
histidines and lysines.
24,150
 Reaction with the thiol of cysteines rapidly forms the most stable 
protein adduct.
24
  Carbonylated products are formed by Michael addition, as illustrated in 
Scheme 2-1 in the results section. Serum albumin contains 59 lysines, 16 histidines, and 35 
cysteines (17 disulfide bridges), with the one free thiol at cysteine-34 being the most reactive 
towards acrolein modification.
24,142,146
 Creating carbonylated HSA in a reproducible fashion 
allowed us to use the modified protein to develop methods aimed at improving the detection and 
analysis of protein carbonyls.  
 
 
 
 
 
 
 
 
 
31 
 
2.3 EXPERIMENTAL DESIGN 
2.3.1 Materials 
Urea, 10x phosphate buffered saline (PBS), water (HPLC), methanol (HPLC), 
acetonitrile (ACN), dithiothreitol (DTT), dimethyl sulfoxide (DMSO), trifluoroacetic acid 
(TFA), Tween® 20, Brilliant blue, bovine serum albumin (BSA) (Fraction V), and Biotinylated 
BSA were purchased from Fisher Scientific (Pittsburgh, PA). Human serum albumin (HSA), (+)-
Biotin hydrazide, sodium cyanoborohydride (NaBH3CN), sodium dodecyl sulfate (SDS), 
iodoacetamide (IAA), and calcium chloride dehydrate (CaCl2) were purchased from Sigma-
Aldrich (St. Louis, MO). Trichloroacetic acid (TCA) and guanidine hydrochloride (GuHCl) were 
obtained from Acros Organics (Fair Lawn, NJ). Sequencing grade modified trypsin and 
3,3’,5,5’-Tetramethylbenzidine (TMB) substrate were obtained from Promega (Madison, WI). 
The BCA Protein Assay, Biotin Quantitation kits, Monomeric Avidin kits, EZ-Link Biotin-LC-
Hydrazide, and EZ-Link Biotin-PEG4-Hydrazide were purchased from Thermo Scientific 
(Rockford, IL). Aldehyde Reactive Probe (ARP) was purchased from Dojindo Laboratories 
(Rockville, MD). Oasis MCX extraction cartridges were purchased from Waters Corporation 
(Milford, MA). Mini PROTEAN® TGX
TM
 gels, 10x Tris/Glycine/SDS (TGS) Buffer, 10x tris-
buffered saline (TBS), 10x Tris/Glycine (TG) Buffer, Laemmli sample buffer, Mini Trans-Blot 
filter paper, Immun-Blot polyvinylidene fluoride (PVDF) Membranes for Protein Blotting, and 
Blotting Grade Blocker were obtained from Bio-Rad (Hercules, CA). Fluorescein-5-
thiosemicarbazide, HCl salt (FTC) was purchased from Marker Gene Technologies, Inc. 
(Eugene, OR).  
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2.3.2 HSA Modification 
 HSA was reacted with acrolein at a 10:1 acrolein:protein ratio and incubated at room 
temperature with gentle shaking for 1 h. Initial experiments proceeded directly to labeling. For 
spike experiments, excess acrolein was removed via precipitation of the protein with 20% TCA 
(aq). Solutions were incubated on ice for 30 min and supernatant removed following 
centrifugation. Pellets were washed three times with 50/50 ethanol/ethyl acetate or ice cold 
acetone, air dried 5 min, and resuspended in 2% SDS/PBS. Following dissolution, carbonylated 
HSA concentrations were determined with the BCA Assay.  
2.3.3 Labeling of Modified HSA  
Biotin hydrazide (Label 1), EZ-Link Biotin-LC-Hydrazide (Label 2), and EZ-Link 
Biotin-PEG4-Hydrazide (Label 3) were all prepared in DMSO at 50 mM. Aldehyde reactive 
probe (Label 4) was prepared in water at 50 mM. All labels were added to a final concentration 
of 5 mM and incubated at room temperature for 2 h using an Eppendorf ThermoMixer. To 
reduce and stabilize hydrazone bonds formed during labeling with Labels 1-3, NaBH3CN was 
prepared in PBS at 30 mM and added to a final concentration of 15 mM. The samples were 
incubated at room temperature for 1 h.  No reduction step was required when using Label 4. 
TCA precipitation was performed as detailed in Section 2.3.2. The supernatant was removed and 
the pellets resuspended in PBS, 5%SDS/PBS, or 8 M urea/PBS, depending on the experiment 
(biotin quantitation assay, Western blotting, or digestion, respectively). 
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2.3.4 Biotin Quantitation Assay 
The extent of biotinylation was assessed following the protocol provided by Thermo 
Scientific Pierce. Biotinylated protein was added to a solution containing 4'-hydroxyazobenzene-
2-carboxylic acid (HABA) conjugated to avidin. Biotin’s stronger affinity for avidin causes the 
displacement of HABA, invoking an absorbance change detectable with UV-Visible 
spectroscopy. Using the extinction coefficient of 34,000 M
-1
cm
-1
,
89
 the known protein 
concentrations, and the change in absorbance before and after biotinylated protein addition, the 
biotin to protein ratios were calculated and the extent of biotinylation determined. Commercially 
available biotinylated BSA was used as a standard; the manufacturer reports nine equivalents of 
biotin per BSA molecule. 
2.3.5 Western Blotting 
Equal amounts of biotinylated protein carrying Labels 1, 2, or 4 (5 µg) were incubated 
with 95% Laemmli buffer and 5% 2-mercaptoethanol for 5 min at 95°C. The samples, along with 
a protein standard ladder, were loaded onto a 4-20% gradient polyacrylamide SDS-PAGE gel 
and run in TGS buffer at 100 V and 90 mA for 1 h and 30 min. Proteins were then transferred to 
a PVDF membrane and run in TG buffer at 100 V and 300 mA for 1 h and 15 min. Following 
immunoblot, the membrane was blocked with 5% non-fat dry milk in 1X TBS-T (1xTBS buffer 
with 0.1% Tween® 20) for 1 h and then incubated with Streptavidin Poly-HRP at a 1:10,000 
dilution in 5% BSA and TBS-T overnight at 4°C. The membrane was washed with TBS-T and 
incubated with TMB substrate for 5 min to visualize protein bands.  
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2.3.6 Protein Digestion 
 Following labeling, 8 M urea was added to the protein solutions as a denaturant. To 
reduce disulfide bonds, DTT was added to a final concentration of 10 mM and samples were 
incubated on the ThermoMixer for 1 h at 37°C. To alkylate cysteines, IAA was added to a final 
concentration of 20 mM and samples were again incubated as described above and in the dark. 
During a third incubation, a second addition of DTT served to saturate unreacted IAA. Following 
dilution with PBS, CaCl2
 
was added to a final concentration of 1 mM, and overnight trypsin 
digestion was performed at 37°C and 300 rpm on the ThermoMixer. Formic acid was added to 
halt digestion and the acidified peptide samples were concentrated with individual Oasis MCX 
columns using the protocol supplied by Waters Corporation. Three 1-mL fractions were eluted 
from each column and then all fractions were dried with a Speed Vac concentrator. After 
evaporation, dried peptides were dissolved in 95/5 0.1% aqueous TFA/ACN, which helped to 
increase sensitivity and protonation during the electrospray ionization portion of the mass 
spectrometry analysis. The solution concentrations were established using a BCA assay kit 
following the protocol provided by Thermo Scientific Pierce.  
2.3.7 Monomeric Avidin Column Enrichment  
 Thermo Scientific Monomeric Avidin Kits were used for enrichment processes according 
to the procedure published by the manufacturers. In brief, columns were first washed with 4 
column volumes of PBS, followed by 3  column volumes of Biotin Blocking and Elution Buffer 
(2 mM D-biotin in PBS) and 6 column volumes of Regeneration Buffer (0.1M glycine, pH 2.8). 
The columns were again washed with PBS. Up to 2 mL of biotinylated protein was added to the 
columns and incubated for 1 h. Nonbound proteins were removed by washing columns with six 
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column volumes of PBS. Biotinylated material was eluted by addition of up to six column 
volumes of Biotin Blocking and Elution Buffer. (Validation experiments suggested the majority 
of biotinylated material eluted within 8 mL – see Table A1 in Appendix 1). Following elution, 
columns were washed with 2 column volumes of Regeneration Buffer and 3 column volumes of 
0.01% sodium azide in PBS, the same solution in which columns were stored in at 4°C. 
2.3.7.1 Enrichment at Peptide Level 
In order to imitate a more realistic, biological sample environment, biotinylated HSA 
(Labels 1-3) was spiked into a mixture of five proteins immediately prior to digestion at one 
tenth the concentration of the other proteins. The five proteins were: alcohol dehydrogenase, 
cytochrome C, lysozyme, ribonuclease A, and ubiquitin, and were chosen based on molecular 
weight, availability, and cost. Digestion proceeded as detailed in Section 2.3.6. Afterward, 
samples were divided into two aliquots: one portion was analyzed via mass spectrometry and the 
remaining fraction was enriched using monomeric avidin columns. Enriched samples were then 
purified via solid phase extraction (SPE), dried, and analyzed using mass spectrometry.  
2.3.7.2 Enrichment at Protein Level 
Once again, in order to create a more realistic, biological sample, carbonylated HSA was 
spiked into human serum at ranges between 5-20% (v/v), labeled with either Label 1, 2, or 4, and 
precipitated as detailed above. Biotinylated proteins were then enriched using monomeric avidin 
columns following the procedure published by the manufacturers. Proteins in the collected 
fractions were again precipitated with TCA, reconstituted in urea/PBS, and digested as detailed 
in Section 2.3.6.  
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2.3.8 Mass Spectrometry 
 Peptide solutions were analyzed using liquid chromatography – tandem mass 
spectrometry (LC-MS/MS) on a Thermo (San Jose, CA) LTQ XL linear ion trap mass 
spectrometer with a nanospray ionization source. Utilizing a Thermo (San Jose, CA) Finnigan 
Micro ASII autosampler and Surveyor Plus HPLC System, peptides were separated on a C-18 
reverse-phase column (150 µm × 10 cm, 5 µm particles, 300 Å pores) from Column Technology 
(Fremont, CA). Triplicate injections, each 20 µL, were made for each sample. Gradient elution 
from the column was accomplished using two mobile phases: A (0.1% formic acid in water) and 
B (0.1% formic acid in methanol) at a flow rate between 0.5-1 μL/min. For each 160 minute run, 
the gradient began with 5% B, rose to 25% B within 15 min, 90% B within 115 min, and then 
decreased back to 5% B within 145 min. Peptides were ionized using a nanospray source at 1.8 
kV. Precursor ions were obtained via a full scan in the range of 300-2000 m/z. A data-dependent 
scan procedure was used for the tandem mass spectrometry (MS/MS) analysis, in which resultant 
ions from the full scan were selected and subjected to further fragmentation using collision-
induced dissociation (CID). Analysis was completed in the positive ion mode with active 
dynamic exclusion, in which a precursor ion was excluded from the analysis for 180 seconds if it 
was selected for further fragmentation twice within 30 seconds.  
2.3.9 Database Searches and Analysis 
 The MS/MS spectra were analyzed using software distributed by Thermo, specifically 
Finnigan Xcalibur Bioworks 3.2 and the Sequest search engine used for peptide/protein 
identification. Searches were performed against an NCBI RefSeq database for Homo sapiens, 
which was obtained on March 11, 2012 and contained 67,440 entries.  Database sequences were 
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also reversed to enable decoy searches and false discovery rate approximations.
154
 No more than 
two missed cleavage sites were allowed. A fixed modification was set for carbamidomethylation 
(alkylated cysteines with mass shifts of +57. 021464 Da) and a differential modification was set 
for oxidation of methionine (+15.9949 Da).  Other differential modifications included: 
biotinylation at cysteine, histidine, and lysine for labels 1 (+298.4 Da), 2 (+411.5 Da), and 3 
(+545.3 Da) and histidine and lysine for label 4 (+369.147075 Da). Trans-Proteomic Pipeline 
(TPP) (Versions 4.4 and 4.6.3; Institute for Systems Biology in Seattle, Washington) was used to 
refine Sequest search results. In order to validate peptide-matched MS/MS spectra, 
PeptideProphet was used and only peptides with a minimum probability of 0.9 were accepted. 
Semi-quantitation was achieved using spectral counting (SC), in which identified tandem mass 
spectra were counted for each HSA peptide.
133
    
2.3.10 FTC Assay 
2.3.10.1 Preparation of Standards 
The following methods were adapted from the work of Mohanty et al.
155
 Fluorescein-5-
thiosemicarbazide (FTC) was initially dissolved in DMSO at 10 mM and stored at -20°C. 
Proteins from control plasma were isolated via TCA precipitation and reconstituted in 6 M 
GuHCl in 2-(N-morpholino)ethanesulfonic acid (MES) buffer. A solution of 5 µg/μL HSA in 
PBS was prepared and incubated with 0.015 M acrolein in DMSO (10:1 acrolein:protein) for 1 h 
on the ThermoMixer to carbonylate HSA. Excess acrolein was removed by TCA precipitation 
and proteins were reconstituted in 6 M GuHCl in MES. Both the plasma protein solution and 
oxidized HSA solution were diluted to10 μg/μL. A new solution of 10 µg/μL HSA in PBS was 
prepared. To create HSA Standard Set 1, the carbonylated HSA was spiked into the plain 10 
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µg/μL HSA solution at 0, 5, 10, and 20% (v/v) for total volumes of 100 µL each. To create HSA 
Standard Set 2, the oxidized HSA was spiked into the plasma protein solution at 0, 5, 10, and 
20% (v/v) for total volumes of 100 µL each. An equal volume of 304 µM FTC (10:1 FTC:HSA) 
was added and incubated overnight at room temperature, in the dark, and with gentle rotation. 
Proteins were isolated via TCA precipitation and reconstituted in 450 µL 3M GuHCl in PBS. 
2.3.10.2 Fluorometry 
 Fluorescence measurements were made using a Varian Cary Eclipse Fluorescence 
Spectrophotometer and analyzed with Scan Software Version 1.1 (132). The instrument was 
zeroed with PBS and sample measurements were made one at a time with an excitation 
wavelength of 492 nm and an emission wavelength of 550 nm. The excitation and emission slit 
widths were 5 nm and measurements were made at medium scan speed (600 nm/min).  
2.3.10.3 Fluorescence Anisotropy 
Anisotropy measurements were made to estimate the degree of binding between the 
fluorescent label and protein.  Measurements were made on the same instrument, but excitation 
and emitted light were polarized through the insertion of filters between the source and sample 
and the sample and detector. Sample solutions were excited with vertically polarized light and 
both vertically and horizontally polarized emissions were created via a filter oriented in both 
directions between the sample and detector. An instrumental correction factor known as the G-
factor, which is simply a ratio comparing horizontal and vertical emissions, was determined prior 
to each day’s experiments. G-factors typically ranged between 1.5-1.6. A total of three 
anisotropy measurements were always made for each sample and resulting anisotropy (r) values 
were averaged.   
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2.4 RESULTS 
2.4.1 Labeling Efficiency 
The essential purpose of the following study was to develop analytical methods for 
identifying the sites of protein oxidative carbonylation by mass spectrometry. In this study, we 
allowed HSA to react with acrolein, an α,β-unsaturated aldehyde. As a strong electrophile, 
acrolein reacts readily with nucleophiles, namely the side chains of cysteine, histidine, and 
lysine, as depicted in Scheme 2-1.
94
  This produced aldehyde-containing Michael addition 
products similar to those formed from lipid peroxidation processes,
1
 providing a convenient 
method for reproducibly preparing carbonylated protein samples. 
  
 
 
 
 
 
 
 
 
 
Scheme 2-1. Acrolein-based Michael addition forms adducts 
on cysteine, histidine, and lysine. (Redrawn from Ugur et al.) 
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In previous studies conducted by Dr. Ugur in our research lab, HSA was carbonylated, 
labeled, digested, and analyzed using a protocol similar to the one detailed above. Affinity tags, 
particularly biotin hydrazide reagents, were useful in our work in that they provided stability to 
the carbonyl and a means in which the samples could be enriched. A schematic showing the 
reaction between a hydrazide and aldehyde is pictured in Scheme 2-2. A total of five affinity 
tags were examined in terms of their labeling and ionization efficiency. For three of the tags, 
which were biotin hydrazide labels, monomeric avidin columns were utilized as a means of 
enrichment at the peptide level, affording an 8-9 fold enrichment factor when comparing the 
spectral counts for labeled peptides before and after enrichment (Table 2-1). There was little 
variation between the fraction of peptides detected after enrichment for the three labels, 
indicating none offered advantages during the enrichment process.
94
 Thus, enrichment was 
successful at the peptide level, but could labeled HSA be enriched at the protein level and in the 
presence of other proteins? 
  
 
 
 
 
 
 
Scheme 2-2. Reaction between a hydrazide and an aldehyde to form a hydrazone. R represents 
the hydrazide reagent chain and P represents the protein.  
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Table 2-1. Fractions of biotinylated peptides detected with mass                                                                                     
spectrometry before and after monomeric avidin column enrichment.                                                                                       
Labels 1, 2, and 3 refer to biotin hydrazide, EZ-link hydrazide-LC-biotin,                                                                                     
and EZ-link hydrazide-PEG4-biotin, respectively. (Recreated from Ugur et al.) 
LABEL BEFORE AFTER 
1 0.041 ± 17% 0.39 ± 8% 
2 0.044 ± 33% 0.34 ± 27% 
3 0.037 ± 14% 0.33 ± 33% 
 
Initial attempts to enrich biotin hydrazide-labeled HSA following TCA precipitation were 
unsuccessful. When eluted column fractions containing biotinylated HSA were analyzed using 
UV-Vis spectroscopy, no protein was detected at a wavelength of 280 nm. Upon stepwise 
alterations of the method, no improvements in enrichment were observed with this label. The 
biotin quantitation assay was adopted as a simpler and more direct means of assessing protein 
biotinylation prior to enrichment.  
The noncovalent interaction between biotin and avidin is one of the strongest in nature, 
even surpassing the strength of interactions between ligands and their respective antibodies. The 
dissociation constant for the biotin-avidin interaction is 10
-15
 M. Due to such great affinity and 
specificity, the complex is stable in solutions at various pH values and can also withstand 
repeated washes without dissociating.
156
 The biotin quantitation assay utilizes this strong 
interaction in conjunction with the weaker interaction between HABA and avidin. The 
dissociation constant for the HABA-avidin interaction is 10
-6
 M, about 2.5 times less than the 
affinity between biotin and avidin. When a biotinylated sample is incubated with HABA-avidin 
complex, the stronger affinity between biotin and avidin compromises the HABA-avidin bonds, 
 
 
42 
 
and the HABA is displaced. HABA alone absorbs light at 356 nm, but following binding with 
avidin, tautomerizes and shifts to an absorption around 500 nm. A depiction of this shift was 
redrawn from Hofstetter et al. and can be seen in Scheme 2-3.
157
 The replacement of HABA with 
biotinylated material is stoichiometric,
89
 and thus the decrease in absorbance observed as the 
freed HABA tautomerizes can be used to calculate a relative biotin to protein ratio.  
 
 
 
 
 
 
 
Test runs with the assay gave low biotin to protein ratios with Label 1, but higher ones 
with Labels 2 and 3. This indicated that either Label 1 was not the most efficient labeling reagent 
or was not as effective in the enrichment process.To gain more insight, collaboration with Dr. 
Ugur commenced. He prepared labeled HSA samples using the same three labeling reagents and 
then biotinylation was assessed using the quantitation assay. Inter- and intraday precision were 
considered: each labeled HSA sample was prepared once on three separate days and measured 
three times on each day. The nine measurements for each sample were averaged and the results 
are shown below in Figure 2-2.
94
  
Scheme 2-3. Tautomerization of HABA upon 
addition of avidin with a subsequent red shift. 
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These results suggested that Labels 2 and 3 were more efficient labeling reagents than 
Label 1. Interestingly, when these same samples were analyzed with mass spectrometry, this 
trend was not evident in terms of spectral counting (see Table 2-1). This implied that the label 
affected the ionization and detection of labeled peptides in the mass spectrometer, which 
apparently had a bias towards Label 1.
94
 The structures of all three labels are shown in Figure 2-
7.  
 The labeling efficiencies of Labels 1, 2, and 4 were also examined via Western blotting. 
The resulting blot is pictured below in Figure 2-3. Label 4 is depicted in Figure 2-7. Minimal 
background was observed in the controls. Looking at the intensity of the main HSA band around 
60,000 kDa, it appeared to be more intense for Label 2 (Lane 6 versus Lanes 3 and 9). However, 
no imaging software was used to calculate area intensities. 
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Figure 2-2. Biotin quantitation assay results. Label 1, 2, and 3 
refer to biotin hydrazide, EZ-link hydrazide-LC-biotin, and EZ-
link hydrazide-PEG4-biotin, respectively. BSA Standard refers 
to the commercially available biotinylated BSA, which has 
approximately nine biotin/protein. 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Labeling efficiencies visualized via Western blotting. The lane 
numbers correspond to: 1=Empty lane, 2=Label 1 no acrolein, 3=Label 1 + 
acrolein, 4=Empty lane, 5=Label 2 no acrolein, 6=Label 2 + acrolein, 
7=Empty lane, 8=Label 4 no acrolein, 9=Label 4 + acrolein, Std. Ladder 
has corresponding molecular weights in red. 
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2.4.2 Enrichment at the Peptide Level  
 Next, we ventured to see if the enrichment trends presented previously would persist in 
samples containing labeled HSA spiked into protein mixtures composed of: alcohol 
dehydrogenase, cytochrome C, lysozyme, ribonuclease A, and ubiquitin. Mass spectrometric 
spectral counting results from one sample preparation are shown in Table 2-2. Tryptic digests of 
HSA produce about 75 peptides. If we use Ugur’s estimate of 2.7 carbonyls per HSA protein 
determined with the DNPH assay, we would predict about 3.6% of the peptides would carry a 
carbonyl modification (2.7/75).
94
 However, since the carbonylated HSA spikes are at 10% the 
concentration of the five additional proteins, we would actually expect only about 0.3-0.4% of 
the peptides to carry a modification. We would expect ratios higher than this though due to our 
use of enrichment with ratios closer to one suggesting more efficient enrichment. Varying ratios 
between the three labels would suggest differing enrichment capabilities based on the labels’ 
properties. Mass spectra for modified and unmodified peptides for each label can be found in 
Appendix 4. 
 
 
 
 
 
 
These results differed from Dr. Ugur’s results presented in Table 2-1. Even though HSA 
was used in both studies, it is key to remember that the protocols varied and these samples 
Table 2-2. Fractions of biotinylated peptides 
detected with mass spectrometry before and after 
monomeric avidin column enrichment. Fractions 
were calculated by dividing the total number of 
spectra by the number of modified peptide spectra. 
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contained a small amount of labeled HSA mixed into a solution of five proteins.  These proteins 
competed for the spectral counts during the mass spectrometry analysis, which may explain the 
smaller fraction of labeled HSA detected prior to enrichment (Table 2-2). The variation in 
fractions of labeled peptides detected after enrichment also differed from Ugur’s study; this 
indicated that the labels offered varying enrichment efficiencies, possibly as a result of the more 
complex protein mixture. The ratios were much greater than the ratio predicted by the DNPH 
assay (0.036), showing that the enrichment was indeed successful. Theoretically, we would 
expect the ‘After’ ratio to equal one, but this was not the case due to incomplete release of 
biotinylated material from the columns. The small amount of material used in each MS run 
produced gaps in the analysis, ample time in which other non-biotinylated material could be 
identified and inadvertently incorporated into the enrichment ratio calculations.  
We also examined thresholds of the monomeric avidin columns at the peptide level. 
Carbonylated HSA was spiked into plasma at 0, 10, 20, and 30 % (v/v) and derivatized with 
Label 1, followed by reduction and TCA precipitation steps. The rest of the procedure was 
performed according to sections 2.3.6, 2.3.7.1, 2.3.8 and 2.3.9 and included two mass 
spectrometry analyses: the first prior to enrichment and the second after enrichment. Results 
from one preparation are presented in Table 2-3. Percent spikes at 5% or below resulted in no 
identifiable modified peptides in either mass spectrometry analysis, suggesting high column 
thresholds. Following this protocol, the lowest detection of modified material was at a 10% 
spike, resulting in only 5% enrichment. Based on the DNPH assay, we presumed that 3.6% of 
HSA peptides would carry a carbonyl modification if the entire HSA sample was allowed to 
react with acrolein. In actuality, for the 0, 10, 20, and 30% spike samples, we expected 0, 0.36, 
0.72, and 1.08% of HSA peptides to carry a carbonyl, respectively. Knowing this and comparing 
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the ‘Before’ and ‘After’ fractions, we observed about 50-60 fold improvement upon use of the 
columns, which was a significant enrichment. In terms of a biological sample though, 
carbonylated material would most often be below the column threshold and even enrichment 
would not provide enough modified material to elucidate carbonylation patterns.  
 
 
 
 
 
2.4.3 Enrichment at the Protein Level  
 Peptides were successfully enriched at the peptide level, but enriching at the protein level 
would allow us to isolate biotinylated proteins toward the beginning of the procedure, 
eliminating materials required to treat all samples and any procedural steps following the first 
mass spectrometry analysis. Regnier et al. have pioneered the incorporation of monomeric avidin 
columns at the protein level, successfully identifying carbonylated proteins in hydrogen 
peroxide-treated yeast,
91
 plasma from diabetic rats,
2
 human plasma from healthy patients,
158
 and 
human plasma from breast cancer patients.
43
 While they incorporated the columns into an HPLC 
format, we chose to use the columns provided with the commercially available kit. Initial 
experiments in which carbonylated HSA was spiked into serum and then derivatized with Label 
1 and enriched were unsuccessful. However, improvements in enrichment and subsequent 
detection were seen when we used Labels 2 and 4. Results from experiments with these three 
Table 2-3. Fractions of carbonylated HSA spiked 
into plasma, labeled, and then detected with mass 
spectrometry before and after monomeric avidin 
column enrichment. Fractions were calculated by 
dividing the total number of spectra by the number 
of modified peptide spectra. 
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labels are shown in Table 2-4. Mass spectra for modified and unmodified peptides for Labels 2 
and 4 can be found in Appendix 4. 
  
 
 
 
2.4.4 FTC Assay  
Being that FTC contains a hydrazide group, the molecule reacts with protein carbonyls in 
a similar fashion as biotin hydrazide, as illustrated below in Scheme 2-4.
157
  
 
 
 
 
 
 
 
 
 
 
 
Scheme 2-4. The labeling of carbonylated proteins 
with FTC. Blue represents an aldehyde and orange 
represents a reactive hydrazide. 
Table 2-4. Enrichment results at the protein level – mass spectrometry 
spectral counting results for Labels 1, 2, and 4. Fractions were calculated by 
dividing the total number of spectra by the number of modified peptide 
spectra. 
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FTC was first synthesized and used to detect and quantitate protein carbonyls about 30 
years ago. Like other colleagues in the same field, Stadtman et al. had worked with quantitative 
spectrophotometric methods for protein carbonyl detection, specifically the DNPH assay. 
However, more sensitivity was desired and thus, fluorescence techniques were explored. 
Labeling protein carbonyls with FTC provided the means for separation and visualization via 
SDS-PAGE and quantitation via fluorescence spectroscopy.
159
 Anisotropy (r) is a measure of the 
polarization of emitted light.
160
 Based on theories established by Perrin in the 1930s,
161
 
anisotropy measurements have been used to investigate protein size, shape, fluidity, and 
interactions. In the following experiments, anisotropy measurements were used to assess protein-
FTC interaction. Generally, polarized light is passed through a sample. If the fluorophores are 
bound to the proteins, there is minimal rotation and the emitted light remains polarized, giving 
higher anisotropy (r) values. If the fluorophores are not bound to the proteins, there is increased 
rotation and the emitted light is depolarized, giving lower r values. HSA bound to a fluorophore 
exhibits an anisotropy value around 0.2.
160
 In our experiments, free FTC (100 µM) exhibited an 
average r value of 0.026. The anisotropy principle is pictured below in Figure 2-4. 
 
 
 
 
 
Figure 2-4. Principle of fluorescence anisotropy.  
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The calibration curves depicted below in Figure 2-5 were constructed from the two types 
of carbonylated, FTC-labeled HSA standards. Samples in which carbonylated HSA was spiked 
into regular HSA are referred to as HSA Standard Set 1 and samples in which carbonylated HSA 
was spiked into control plasma are referred to as HSA Standard Set 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5. HSA Standard Set 1 includes (A) Emission spectrum and (B) Corresponding 
calibration curve with linear equation y=34.08x+74.731 and with a correlation coefficient (R
2
) 
of 0.9926. HSA Standard Set 2 includes (C) Emission spectrum and (D) Corresponding 
calibration curve with linear equation y=41.518x+4.7003 and with correlation coefficient (R
2
) 
of 0.9926. 
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Fluorescence intensity maxima at 518 nm were determined using the Scan Software and 
used to calculate the calibration curves. With R
2
 values close to one, both experiments 
demonstrated the assay’s ability to detect various concentrations of carbonylated protein. 
Standard calibrations such as those in Figure 2-5 could be used to determine FTC to protein 
ratios in samples with unknown amounts of protein carbonylation. Applications involving this 
assay can be found in Chapters 4 and 5. These same sets of standards were stored at -20°C for 
about two weeks and then reanalyzed with fluorescence spectroscopy to assess protein-FTC 
stability over time. Results are shown in Figure 2-6. Little change was observed in the 
fluorescence intensities and calibration curves for both HSA Standard Sets over the two weeks.  
 
 
 
 
 
 
 
 
 
 
Figure 2-6. HSA Standard Set 1 includes (A) Emission spectrum and (B) Corresponding 
calibration curve with linear equation y=33.559x+36.031and with a correlation coefficient (R
2
) 
of 0.9914. HSA Standard Set 2 includes (C) Emission spectrum and (D) Corresponding 
calibration curve with linear equation y=40.072x-4.5568 and with correlation coefficient (R
2
) 
of 0.9656. 
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As a means of assessing the stability of the interaction between FTC and HSA, 
fluorescence anisotropy measurements were made. We ultimately wanted to confirm that the 
label remained bound to HSA proteins. Measurements were made for samples in both HSA 
Sample Sets. Average anisotropy r values calculated from three replicates per sample are 
displayed below in Table 2-5.  Data corresponding to Figure 2-5 are in the column titled ‘First 
Analysis’ and data corresponding to Figure 2-6 are in the column titled ‘Second Analysis’ 
(measured 14 days after the First Analysis). Comparing r values for the first and second analyses, 
results indicated a decrease in value over time, which is consistent with release of the label and 
suggests that fluorescence measurements should be made immediately.  
 
 
Table 2-5. Average anisotropy (r) values along with standard deviations for three replicate 
instrumental analyses for both Standard Sets. The Second Analysis was performed about 14 days 
after the First Analysis. 
 
 
 
Sample Set % Carbonylated HSA First Analysis Second Analysis 
Standard Set 1 (HSA) 
0% 0.153 ± 0.004 0.129 ± 0.003 
5% 0.113 ± 0.006 0.080 ± 0.009 
10% 0.106 ± 0.000 0.040 ± 0.004 
20% 0.118 ± 0.002 0.068 ± 0.008 
Standard Set 2 (Plasma) 
0% 0.064 ± 0.009 0.119 ± 0.010 
5% 0.090 ± 0.011 0.055 ± 0.004 
10% 0.115 ± 0.001 0.060 ± 0.004 
20% 0.118 ± 0.003 0.063 ± 0.009 
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2.5 DISCUSSION 
2.5.1 Labeling 
 In this work, four different biotin affinity labels and their capabilities in tagging protein 
carbonyls were investigated:  Biotin hydrazide (Label 1), EZ-Link Biotin-LC-Hydrazide (Label 
2), EZ-Link Biotin-PEG4-Hydrazide (Label 3), and Aldehyde reactive probe (ARP) (Label 4). 
Detecting and quantifying carbonyls in vivo is problematic due to the variety of carbonyl 
modifications that exist. Thus, only a handful of broad studies, including our own,
94
 have been 
done to investigate labeling properties and efficiencies, while detailed and extensive studies are 
lacking in this area. A recent study published by Bollineni et al., one of the only of its kind, 
explored reactions between three different affinity labels (2,4-dinitrophenylhydrazdine, biotin 
hydrazide, and ARP) and three types of carbonyl species (aldehydes, ketones, and lactams). 
Using synthesized peptides, Bollineni et al. concluded that reagents were specific for reaction 
conditions and certain types of carbonyl modifications based on labeling efficiency analyses 
using HPLC, MALDI-TOF-MS, and ESI-LTQ-Orbitrap-MS. They also made the 
counterintuitive suggestion of labeling carbonyls at the peptide level,
92
 a finding in contradiction 
of Regnier et al. who proposed carbonyls should be labeled immediately.
158
   
 We only focused on one type of carbonyl species (LPO-based aldehyde mimicks) and we 
discovered labeling efficiency trends for Labels 1-4, with less extensive work done with Label 4. 
Although varying interday biotin/BSA and biotin/HSA ratio values indicated that biotin 
quantitation assay results had significant uncertainties, general ratio trends suggested that Labels 
2 and 3 were the most efficient, with corresponding ratios of about two and three biotin:protein, 
respectively. This was attributed to their varying spacer arm lengths, illustrated in Figure 2-7. 
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Longer chains could improve solubility and decrease steric hindrance and, in the case of Label 3, 
increase hydrophilicity. The concentrations of the affinity labels in solution were limited by their 
solubility. For instance, labels that failed to dissolve fully or crashed out of solution during use 
would affect the amount of label available to react with protein carbonyls. Longer chains 
decreased steric hindrance in two ways: 1. They allowed the hydrazide to react with protein 
carbonyls with less interference from the biotin moiety during labeling and 2. They allowed the 
biotin moiety to interact with avidin with less interference from the protein/peptide during 
enrichment. Lastly, hydrophilicity of the label determined at which sites on the protein it would 
react; hydrophilic labels are attracted to hydrophilic protein sites and vice versa.
162
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Figure 2-7. Structures and molecular weights for Labels 1-4. 
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 While longer chains may have contributed to monomeric avidin enrichment capabilities, 
mass spectrometry results indicated that this attribute hindered detection of the modification 
sites. Cumbersome tags can negatively affect ionization and fragmentation as demonstrated by 
Bollineni et al.
92
 Another contributing factor was the peptide structure, particularly the 
hydrophobicity/hydrophilicity of the amino acids comprising the peptides. An overview of the 
commonly modified residues detected with mass spectrometry before and after enrichment at the 
peptide level for Labels 1-3 is depicted in Figure 2-8. Interestingly, no modifications were 
observed at cysteine-34, the only free sulfur and most reactive site to acrolein modification.
24
 
Lysine-545 was the most detectable modification site for the longer chain labels, 2 and 3, 
especially following enrichment. The greatest number of spectra identified for a modification site 
was histidine-146, derivatized with Label 2. Histidine-146 was found within the peptide 
sequence HPYFYAPELLFFAK and is one of the most hydrophobic peptides identified. 
Shockingly, this modified peptide, with the highest spectral counts, was only detected prior to 
enrichment. In contrast, lysine-12, from a hydrophilic peptide with the sequence 
FKDLGEENFK, was only detected after enrichment. This revealed that the columns 
discriminated against certain peptides, an undesirable trait in this work. The number of spectra 
varied for each of the three labels in regards to these two peptides, with Label 2 prevailing in 
both cases. This indicated that peptide properties played a role in the enrichment process and that 
some labels were versatile enough to allow detection of both hydrophobic and hydrophilic 
peptides. Location of the amino acids within the HSA protein structure was not a factor for 
enrichment and MS/MS analyses, since samples were at the peptide level. Overall, this study 
confirmed that label choice impacted which modification sites were derivatized, enriched, and 
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subsequently detected at the peptide level. We chose not to perform experimental repeats due to 
the peptide discriminating quality of the columns.    
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Figure 2-8. Peptide level: Plot depicting number of MS/MS spectra identified before and after 
enrichment of HSA derivatized with three different biotin labels (more extensive data related to 
Table 2-2).   
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 Moving from the peptide to the protein level, we endeavored to apply enrichment to 
proteins reacted with Labels 1, 2, and 4. Upon obtaining poor results with Labels 1 and 2 as can 
be seen in Table 2-4 and Figure 2-9, we attempted to use Label 4, a biotin-containing 
alkoxyamine. Label 4, illustrated in Figure 2-7, was originally used to derivatize oxidation sites 
on DNA, but was utilized in the detection of protein carbonyls because of its oxime formation, 
which is more stable than the hydrazone formed with hydrazide reagents.
163,164
 Label 4 is 
relatively new, but an appealing option because it is water soluble, reactive at neutral pH and at 
room temperature, does not require reduction, and contains a biotin moiety for avidin 
enrichment. Several studies involving detection of Label 4-modified proteins in model 
systems
164–166
 and biological systems
145
 have been published. In our brief work with Label 4, we 
spiked carbonylated HSA into serum (20% v/v), derivatized with Label 4, and enriched with 
monomeric avidin columns, all at the protein level. While this approach saved time and 
materials, full-sized proteins could potentially cause steric hindrance during enrichment. Spectral 
counting results from one sample preparation are shown in Figure 2-9. Interestingly, similar and 
differing trends were distinguished between protein and peptide enrichment studies. It was 
expected that protein level enrichment would give patterns similar to those seen without 
enrichment. Again, the residue with the highest propensity for detection was the peptide 
containing histidine-146. This implied that since this peptide was not detected during peptide 
enrichment, protein enrichment was less discriminatory for this peptide. At protein level 
enrichment, Lysine-545 was hardly detected in contrast to peptide enrichment studies in which 
this residue was the most commonly detected site for Label 3. Histidine-367 was the second most 
commonly detected residue for Label 4 and, unlike the hydrophobic peptide containing histidine-
146, this peptide (CCAAADPHECYAK) was composed mostly of hydrophilic amino acids. 
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These varying results confirmed that experimental factors such as choice of affinity label, 
reaction conditions, and experimental design were crucial to detecting certain modifications 
regardless of enrichment occurring at the peptide or protein level. Again, we chose to not do 
experimental repeats in order to exert our efforts in finding a simpler and more effective means 
of enrichment. 
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Figure 2-9. Protein Level: Plot depicting number of MS/MS spectra identified following protein 
enrichment for Label 4-derviatized HSA (more extensive data related to Table 2-4).    
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2.5.2 Spectral Counting 
 We chose to use spectral counting (SC) as a semi-quantitative technique because it is 
quicker, cheaper, and more user-friendly than label-based quantitation methods, such as iTRAQ, 
ICAT, SILAC, etc. It is also commonly used in bottom-up proteomics experiments such as our 
own.
94,167–169
 Our LTQ analysis included ten MS/MS events, which generated a large number of 
fragmentation spectra. This increased the probability of identifying more peptides and further 
facilitated the use of SC. Unlike labeling-based quantitation methods, SC does not require a 
unique label for each sample and can be applied to a variety of samples. Nonetheless, SC suffers 
from high variability and a lack of sensitivity, which is problematic when investigating low 
abundance proteins since the corresponding identified peptides would be limited.
133,167
 Issues 
persist with saturation of high abundance proteins as a result of ion trapping limitations as well. 
This results in a diminished dynamic range. Despite these downfalls, theoretically we would 
expect a linear relationship between protein abundance and spectra counts, and Liu et al. 
confirmed this assumption for dynamic ranges on the order of 2 or greater.
170
 Decreased linearity 
would be expected for more complex samples.
133
 Being that the majority of our samples, aside 
from the serum/plasma, were simple solutions with six or fewer proteins, we resorted to spectral 
counting. Our intent was not to use spectral counting as a measure of protein abundance, but 
simply to use it as a measure of labeling efficiency and instrument detectability. This proved to 
be successful in that we were able to quantitatively distinguish efficiency differences between 
affinity labels based on a comparison of spectra counts for the various samples. 
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2.5.3 Monomeric Avidin Column Enrichment 
 The studies in this chapter were centered on one mode of affinity purification, the 
monomeric avidin columns. Numerous successful studies involving monomeric avidin column 
enrichment of carbonylated proteins have been published, including one from our own lab
94
 and 
most notably from Regnier et al.
90,146,158,171
 For this reason, we proceeded with using the columns 
while also investigating their enrichment capabilities more fully. Tetrameric avidin and biotin 
have the strongest specificity in nature with a dissociation constant of 10
-15
 M. Such a strong 
affinity complicates elution; therefore, avidin variations were created that exhibited decreased 
specificity. One of these variations is monomeric avidin which, along with biotin, has a 
dissociation constant of 10
-7
 M, more than half that between tetrameric avidin and biotin. Other 
variations include chemically and genetically modified avidin. Biotin products that show less 
affinity for avidin, such as desthiobiotin and 2-iminobiotin, have been developed as well.
171
 The 
relatively easy elution of biotinylated material from the monomeric avidin columns allows for 
identification of the modification site, a quality lacking in affinity-based bead products. 
Identifying sites of carbonylation is crucial in helping us to understand carbonylation 
mechanisms and also provides more solid confirmation of the identified affinity-labeled 
peptide.
90
   
Spike experiments indicated that we had to reach a concentration of 10% carbonylated 
HSA (v/v) to achieve detection of modifications. This implied that the columns required large 
amounts of protein, which is not always feasible, or required highly carbonylated protein 
samples, again which is not common in biological samples. Although we only worked with one 
type of carbonyl species (LPO-based aldehyde mimicks), blood contains a variety of carbonyl 
species at lower concentrations potentially undetectable with the columns. Thus, their use with 
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true biological samples would not be amenable. Their incorporation into the procedure at either 
the peptide or protein level introduced large sample volumes that required extra measures to 
reduce and purify. Hence, they were neither the most economical nor time efficient enrichment 
technique. Results in Table 2-2 indicated that Label 3 was the most efficient label in terms of 
enrichment, yet even upon using this label in enrichment experiments at the protein level, little to 
no improvements in detection were made. Poor results from enrichment experiments at the 
protein level could be explained by the use of SDS. Being that proteins were precipitated and not 
all serum proteins are directly soluble in PBS, a small amount of SDS was used to reconstitute 
proteins. Monomeric avidin lacks the structural strength that natural avidin possesses and thus, 
would be vulnerable to structural change in the presence of denaturants. This could result in 
decreased binding capacity and ultimately a loss of biotinylated material.
91
  
2.5.4 FTC Assay 
 HSA was carbonylated by allowing the protein to react with acrolein and then spiked into 
regular HSA or plasma at various spike amounts (v/v). FTC was added to label protein carbonyls 
and permit detection using fluorescence spectroscopy. Validation experiments were successful in 
that linear relationships (R
2
>0.99) were determined between the percent of carbonylated HSA 
and the fluorescence intensity. The sample stability was also investigated – HSA Standard Sets 1 
and 2 were stored at -20°C for two weeks and then reanalyzed. For both HSA Standard Sets, 
little change was observed in the fluorescence intensities and the calibration curves still offered a 
linear relationship between the percent of carbonylated HSA and the fluorescence intensity. 
Anisotropy experiments were performed to assess the stability of the interaction between FTC 
and HSA. For the first analysis, r values were roughly four to five times greater than that of free 
FTC, which indicated that the label was indeed bound to the HSA proteins.  However, a decrease 
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in the r value from the First to the Second Analysis (measured 14 days after the First Analysis) 
indicated release of the label over time. Thus, fluorescence measurements should be made 
immediately. The one sample that exhibited a reverse trend was the 0% carbonylated HSA 
sample in HSA Standard Set 2, which showed a greater r value for the second analysis. This 
could have resulted from inefficient removal of excess label, which then reacted with proteins 
over time or a measurement error. Based on the validation results though, this assay shows 
promise for use in more complex systems.  
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
2.6 CONCLUSION 
 Numerous analytical barriers still exist in proteomics experiments; however, our work 
has clarified some uncertainties concerning derivatization and enrichment techniques. Two new 
quantitative assays were also validated which can both be used as measures of labeling 
efficiency. Upon investigating labeling efficiency of various biotin labels, it was concluded that 
the labels affect enrichment and mass spectrometry analyses differently, depending on their 
chemical properties. In general, the longer chained, more hydrophilic labels offered better 
enrichment capabilities and were more readily detected via mass spectrometry. These results 
roughly correlated with research by Ugur et al. and Bollineni et al. Overall, it was confirmed that 
the choice of label influences the modification sites detected and extensive consideration should 
be given to this topic in future investigations of carbonyl modification sites. In terms of 
enrichment, the monomeric avidin columns discriminated against certain peptides at the peptide 
level and functioned poorly at the protein level, complicating experimental procedures and 
offering a high limit of detection. For these reasons, we began investigating the combination of a 
new label and a different form of enrichment. This new protocol allowed for detection of the 
protein carbonyl modification sites, like the monomeric avidin columns, but offered many 
advantages over the columns, as can be seen in the next chapter.  
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Chapter 3 – A CLEAVABLE BIOTIN TAG ENABLING ENRICHMENT 
AND IDENTIFICATION OF PROTEIN CARBONYLATION 
MODIFICATION SITES   
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3.1 ABSTRACT 
 Despite numerous variations in sample preparation, the use of monomeric avidin 
enrichment columns proved laborious and yielded unsatisfactory results in general. Thus, a 
different protocol was explored, one that still facilitated identification of modification sites just 
as the monomeric avidin columns had done, but was more user-friendly and time efficient. The 
combination of a cleavable biotin affinity tag and a streptavidin bead enrichment system allowed 
the best of both worlds: identification of modification sites and easy incorporation into existing 
protocols. General streptavidin bead enrichment protocols involve digestion off of the beads, 
resulting in various peptides assumed to have originated from the biotinylated protein, but 
without the modification sites still adhered to the beads. Our cleavable linker prevents this by 
allowing elution of the modification site from the beads. It contains a disulfide, which can be 
cleaved and alkylated with DTT and IAA, respectively, chemicals which are already 
incorporated into our procedure. We investigated the correlation between varying amounts of 
carbonylated protein and the percent of peptides carrying a modification site, along with various 
other procedural adjustments. The new cleavable biotin tag offered better labeling efficiency 
than previous labels, but also with preference for certain HSA sites, a trend alluded to in Chapter 
2.   
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3.2 INTRODUCTION 
A variety of derivatization methods for carbonyls have been used and include, but are not 
limited to: dinitrophenylhydrazine (DNPH),
172
 Girard P reagent (GRP),
173
 hydrazides,
94
 
fluorescent probes, 
155,174
 and alkoxyamines.
164
 DNPH-based techniques developed by Levine et 
al. hinge on UV-Vis Spectroscopy and Western blotting as detection methods and are primarily 
used for qualitative work. Two commonly used fluorescent probes are: fluorescein-5-
thiosemicarbazide and Alexa 488 fluorescence hydroxylamine. Quantitation methods involve the 
use of fluorescence spectroscopy or SDS-PAGE, with gel work being the most advantageous 
since removal of excess fluorescent probe is difficult in solution.
93
 Hydrazides, and 
alkoxyamines, particularly biotin hydrazide and aldehyde reactive probe (ARP), respectively, 
and GRP are all commonly used in quantitative mass spectrometry analyses, with hydrazides and 
alkoxyamines prevailing.
87,92
 Hydrazides require a reduction step to stabilize the resultant 
hydrazone bond, whereas, this is unnecessary when using alkoxyamines since an oxime is 
formed.
164
 Both contain the biotin moiety, which can be utilized in conjugation with avidin 
products for enrichment and prior to mass spectrometry.
93
  
The noncovalent interaction between biotin and avidin is one of the strongest in nature, 
even surpassing the strength of interactions between ligands and their respective antibodies. 
Avidin is a carbohydrate-containing tetramer with a basic isoelectric point (pI=10).
175
 The 
dissociation constant for the biotin-avidin interaction is 10
-15
 M. Due to such great affinity and 
specificity, the complex is stable in solutions at various pH values and can also withstand 
repeated washes without dissociating.
156
 Conversely, the abundance of carbohydrates and basic 
pI encourage nonspecific binding and such a strong dissociation constant hinders release of 
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biotinylated material.  Thus, avidin analogues with decreased affinity have been discovered. 
Popular products include monomeric avidin,
176,177
 neutrAvidin,
178
 and streptavidin,
179,180
 all of 
which have been used extensively as enrichment products for biotinylated carbonyls.
175
 One 
challenge when using streptavidin beads is the impossible feat of cleaving biotinylated material 
from the beads. This directs protocols to involve digestion on the beads, at the expense of leaving 
the modification site attached to the beads. Another challenge when working with biotin and 
avidin products is nonspecific binding, which can lead to peptides being falsely identified as part 
of a carbonylated protein.
87
 For this reason, our newly developed method is very useful because 
it allows for elution from the beads and identification of the modification site, providing 
steadfast confirmation of carbonylation. 
In this work, we have developed an analytical method utilizing an alkoxyamine biotin-
containing affinity tag and streptavidin beads. The EZ-Link Alkoxyamine-PEG4-SS-PEG4-biotin, 
pictured in Scheme 3-1, contains a carbonyl reactive site (alkoxyamine), a cleavable disulfide, 
and a biotin moiety permitting enrichment with avidin products and easy incorporation into 
existing protocols. Upon reaction between the protein carbonyl and alkoxyamine and subsequent 
enrichment, disulfide cleavage with DTT and alkylation with IAA can be achieved to yield two 
products, as depicted in Scheme 3-1. The most important product contains carbonylated protein 
conjugated to half of the alkylated label (alkoxyamine end), which provides a distinguishable 
mass when analyzing via mass spectrometry. The other product is the remainder of the label 
(biotin end) attached to the bead, which gets discarded. We’ve chosen to use human serum 
albumin (HSA) in our work because it is inexpensive and has been used previously in oxidative 
stress studies. 
181,182
 We have developed a reproducible method of producing carbonylated 
protein in vitro in which HSA is treated with acrolein to carbonylate cysteines, histidines, and 
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lysines. These reactions mimic the nucleophilic addition of aldehyde-containing lipid 
peroxidation products to proteins in an environment under oxidative stress.
94
 To the best of our 
knowledge, this will be the first report of using this label to investigate protein carobnylation 
sites. Our validation work involved quantifying the labeling efficiency and investigating our 
instrumental limits of detection. Percent of modification and identification efficiencies were 
investigated via mass spectrometry and determined by spectral counting (SC). The results 
suggest that the alkoxyamine is superior to Labels 1, 2, and 3 in terms of labeling efficiency and 
shows preference for particular sites difficult to detect with other labels.  
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Scheme 3-1. Products resulting from reaction of the alkoxyamine label with a protein 
carbonyl and subsequent enrichment, reduction, and alkylation. P=protein. 
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3.3 EXPERIMENTAL DESIGN 
3.3.1 Materials 
HSA, IAA, and CaCl2 were purchased from Sigma-Aldrich (St. Louis, MO). Formic Acid 
(LC/MS grade), urea, 10xPBS, water (HPLC), methanol (HPLC), ACN, DTT, DMSO, DTT, 
TFA, and biotinylated BSA were purchased from Fisher Scientific (Pittsburgh, PA). TCA was 
obtained from Acros Organics (Fair Lawn, NJ). The BCA Protein Assay, Biotin Quantitation kit, 
Streptavidin Ultralink Resin, and EZ-Link Alkoxyamine-PEG4-SS-PEG4-Biotin were purchased 
from Thermo Scientific (Rockford, IL). Oasis MCX extraction cartridges were purchased from 
Waters Corporation (Milford, MA). Sequencing grade modified trypsin was obtained from 
Promega (Madison, WI). 
3.3.2 Carbonylating HSA  
HSA (10 mg/mL) was reacted with acrolein at a 10:1 acrolein:protein ratio and incubated 
at room temperature with gentle shaking for 1 h. Initial experiments proceeded directly to 
labeling. For spike experiments, excess acrolein was removed via precipitation with 15% TCA 
(aq). Solutions were incubated on ice for 30 min and supernatant removed following 
centrifugation. Pellets were washed three times with ice cold acetone, air dried 5 min, and 
resuspended in 200 µL PBS. Following dissolution, carbonylated HSA concentrations were 
determined with the BCA Assay. A 10 mg/mL solution of carbonylated HSA was prepared and 
spiked into 10 mg/mL HSA in PBS at 0, 25, 50, and 75 % spikes (v/v). Other spikes prepared 
included: 5, 10, 12.5, 15, and 20%.  
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3.3.3 Protein Biotinylation and Enrichment 
EZ-Link Alkoxyamine-PEG4-SS-PEG4-Biotin was prepared in DMSO at 250 mM and 
stored at -80°C. Alkoxyamine label was added to carbonylated HSA at a final concentration of 5 
mM and incubated for 2 h at room temperature with gentle rotation. TCA precipitation was 
performed as detailed in the section above and pellets reconstituted in 500 µL PBS. Prior to 
enrichment, 500 µL aliquots of streptavidin bead slurry were washed four times with PBS. 
Labeled proteins (500 µg) were added and incubated overnight at room temperature with gentle 
rotation. 
3.3.4 Biotin Quantitation Assay 
The extent of biotinylation was assessed prior to enrichment by following the protocol 
provided by Thermo Scientific Pierce. Three experimental repetitions were performed. Each 
time, protein concentrations were measured using the BCA Assay prior to quantitating biotin. 
Briefly, 100 µL biotinylated HSA was added to a solution containing 100 µL HABA-avidin 
complex and 800 µL PBS. Biotin’s stronger affinity for avidin causes the displacement of 
HABA, invoking an absorbance change detectable with UV-visible spectroscopy at 500 nm. 
Using the extinction coefficient of 34,000 M
-1
cm
-1
,
89
 the known protein concentrations, and the 
change in absorbance before and after biotinylated protein addition, the biotin to protein ratios 
were calculated and the extent of biotinylation determined. Commercially available biotinylated 
BSA was used as a standard; the manufacturer reports nine equivalents of biotin per BSA 
molecule. 
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3.3.5 Trypsin Digestion 
Following enrichment, nonbound protein fractions were reserved while excess reagents 
were removed by washing the beads four times with PBS.  Both nonbound and bound proteins 
were denatured with 2 M urea and reduced with 10 mM DTT at 37°C, 300 rpm for 1 h. To 
alkylate cysteines, IAA was added to a final concentration of 15 mM and samples were again 
incubated as described above in the dark. A second 15 mM addition of DTT and 1 h incubation 
followed in order to quench excess IAA. Labeled proteins that were cleaved from the beads were 
transferred to new tubes and, along with nonbound samples, were diluted with PBS. CaCl2
 
was 
added to a final concentration of 1 mM and overnight trypsin digestion was performed at 37°C, 
300 rpm. Digestion was halted via acidification using 10% formic acid. The peptides were 
concentrated with Oasis MCX columns and dried with a Speed Vac concentrator. After 
evaporation, dried peptides were dissolved in 95/5 0.1% aqueous TFA/ACN and the solution 
concentrations were established using the BCA Assay. 
3.3.6 LC-MS/MS 
Peptide solutions were analyzed using liquid chromatography – tandem mass 
spectrometry (LC-MS/MS) on a Thermo (San Jose, CA) LTQ XL linear ion trap mass 
spectrometer with a nanospray ionization source. Utilizing a Perkin Elmer (Waltham, MA) 
Series 200 pump and an Agilent (Santa Clara, CA) 1100 series HPLC system equipped with an 
autosampler, peptides were separated on a C-18 reverse-phase column (150 µm × 10 cm, 5 µm 
particles, 300 Å pores) from Column Technology (Fremont, CA). Triplicate injections, each 20 
µL, were made for each sample. Gradient elution from the column was accomplished using two 
mobile phases: A (0.1% formic acid in water) and B (0.1% formic acid in methanol) at a flow 
 
 
74 
 
rate between 0.5-1 μL/min. For each 160 minute run, the gradient began with 5% B, rose to 25% 
B within 15 min, 90% B within 115 min, and then decreased back to 5% B within 145 min. 
Peptides were ionized using a nanospray source at 1.8 kV and analysis was completed in the 
positive ion mode. Precursor ions were obtained via a full scan (300-2000 m/z) with a data-
dependent scan procedure for MS/MS analyses. Active dynamic exclusion parameters excluded 
an ion from the analysis for 180 seconds if it was selected for further fragmentation twice within 
30 seconds.  
3.3.7 Data Analysis 
The MS/MS spectra were analyzed using software distributed by Thermo, specifically 
Finnigan Xcalibur Bioworks 3.3.1 and the Sequest search engine used for peptide/protein 
identification. Searches were performed against an NCBI RefSeq database for Homo sapiens, 
which was obtained on January 15, 2013 and contained 71,806 entries.  Database sequences were 
also randomized to enable decoy searches and false discovery rate approximations.
154
 No more 
than two missed cleavage sites were allowed. A fixed modification was set for 
carbamidomethylation (alkylated cysteines with mass shifts of +57.021464 Da). Differential 
modifications were set for three variations of cleaved alkoxyamine label products: reduced 
(+334.156 Da), alkylated (+391.177 Da), and full label (+882.38 Da), all at cysteine, histidine, 
and lysine. Identification of reduced or full label modified peptides would indicate inefficient 
alkylation or inefficient binding or washing, respectively. Trans-Proteomic Pipeline (TPP) 
(Version 4.6.3; Institute for Systems Biology in Seattle, Washington) was used to refine Sequest 
search results. In order to validate peptide-matched MS/MS spectra, PeptideProphet was used 
and only peptides with a minimum probability of 0.9 were accepted. Semi-quantitation was 
achieved using SC.
133
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3.4 RESULTS 
In this study, we reacted HSA with acrolein, an α,β-unsaturated aldehyde. As a strong 
electrophile, acrolein reacts readily with nucleophiles, namely side chains of cysteine, histidine, 
and lysine. This produces aldehyde-containing Michael addition products similar to those from 
lipid peroxidation processes
24
  and is a convenient method for reproducibly preparing 
carbonylated protein samples. Previous studies have indicated that a 10:1 acrolein:HSA ratio is 
optimum for this work and produces roughly 2.7 carbonyls per HSA molecule.
94
  
3.4.1 Labeling Efficiency 
Knowing that each acrolein-modified HSA protein carries about 3 active carbonyls, we 
needed to determine how efficiently those carbonyls react with our alkoxyamine affinity label. In 
order to do this, we utilized a commercial biotin quantitation assay. Both a control sample (no 
acrolein) and a treated sample (+ acrolein) were derivatized with the alkoxyamine and analyzed. 
Results are plotted in Figure 3-1, along with assay results for three other biotin labels taken from 
a previous study in our lab (see Figure 2-2).
94
 A commercial biotinylated BSA standard, which 
contained about 9 biotin/protein, served as a positive control; whereas, a sample treated with the 
alkoxyamine and no acrolein was a negative control. Although varying interday biotin/BSA and 
biotin/HSA ratio values indicated that biotin quantitation assay results have significant 
uncertainties, general ratio trends were elucidated. The assay revealed that the alkoxyamine label 
offered the best labeling efficiency out of all of the biotin affinity tags with an estimated four 
biotin per molecule.  
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3.4.2 Identification of Modification Sites 
Once labeling of the protein carbonyls was confirmed, samples were prepared containing 
varying amounts of acrolein-treated HSA (0, 25, 50, and 75 %) mixed with unmodified HSA 
(v/v). All samples were labeled, enriched, digested, and analyzed by LC-MS/MS. Nonbound 
protein fractions for each sample, which were collected following overnight incubation with the 
streptavidin beads and preceding PBS washes of the beads, were also digested, and analyzed by 
LC-MS/MS. Assuming all of the alkoxyamine-labeled HSA was captured by the beads, we 
would expect to find no modified material in the nonbound fractions. This protocol was repeated 
for a total of three separate sample preparations. The protocol was also repeated for other spiking 
levels, ranging from 5% to 20%. Little to no modifications were detected below 10% and the 
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Figure 3-1. Biotin quantitation assay results. BSA Standard refers to the commercially 
purchased biotinylated BSA which has approximately nine biotin/protein. Control 
Alkoxyamine was a sample of HSA prepared without acrolein and treated with the 
alkoxyamine. Error bars represent standard deviations. 
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most variation in the number of modified peptides detected was observed in quadruple repeat 
analyses of 10% carbonylated HSA. Thus, this was determined to be the point where our 
detection capabilities became less predictable. Spectral counting data for the 0, 10, 25, 50, and 
75% carbonylated HSA samples is summarized in Figure 3-2. The percent of modified peptides 
were determined for each sample preparation by dividing the number of modified peptide spectra 
by the total number of HSA spectra and then multiplying by 100. Error bars represent standard 
deviations for the percent of modified peptide spectra identified between the three trials. Only 
modifications that were detected in two or more trials were included in the data set for each 
sample. One modified peptide in the 3+ charge state, YKAAFTECCQAADK, was occasionally 
detected in the nonbound fractions (1-2 spectra) and in the 0% carbonylated HSA sample, which 
is visible in Figure 3-2. Upon manual inspection of the spectra for this peptide, the assignment 
was not accepted since the spectra contained few b
+
 and b
2+
 ions, poor runs of y
+
 and y
2+
 ions, 
and no coverage of the modified lysine.   
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Overall, a total of 12 modification sites were identified by mass spectrometry: five 
histidines, six lysines, and one cysteine. These sites are shown amidst the entire sequence for 
human serum albumin in Figure 3-3.
183
 There are 609 amino acids in the precursor form of HSA 
and 585 amino acids in its secreted form, sans the first 24 amino acids. Modification sites are 
labeled based on the secreted form of HSA; however, the first 24 amino acids are still visible in 
Figure 3-3 and are highlighted in yellow. Identified modification sites with a corresponding 
amino acid number are in red font. A value of 24 should be added to this number for the 
precursor form of HSA.
143
   The average sequence coverage in our mass spectrometry analyses 
was 87% based on the precursor form of HSA.  
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Figure 3-2. Percent of modified peptides for 0, 10, 25, 50, and 75 % carbonylated HSA 
spikes. Error bars represent standard deviation. The % carbonylated HSA represents the 
amount of carbonylated HSA spiked into regular HSA (v/v). Percent of modified 
peptides were determined by:  
#𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑠𝑝𝑒𝑐𝑡𝑟𝑎
#𝑡𝑜𝑡𝑎𝑙 𝑠𝑝𝑒𝑐𝑡𝑟𝑎
 𝑥 100. 
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585 
1 
MKWVTFISLL  FLFSSAYSRG  VFRRDAHKSE   VAHRFKDLGE   ENFKALVLIA 
FAQYLQQC34PF  EDHVKLVNEV  TEFAK51TCVAD   ESAENCDKSL   H67TLFGDKLCT 
VATLRETYGE  MADCCAKQEP   ERNECFLQHK   DDNPNLPRLV   RPEVDVMCTA 
FH128DNEETFLK  KYLYEIARRH146  PYFYAPELLF   FAKRYK162AAFT   ECCQAADKAA 
CLLPKLDELR  DEGKASSAKQ   RLKCASLQKF   GERAFKAWAV   ARLSQRFPKA 
EFAEVSKLVT  DLTKVHTECC   HGDLLECADD   RADLAK262YICE   NQDSISSKLK 
ECCEKPLLEK  SH288CIAEVEND   EMPADLPSLA   ADFVESKDVC  KNYAEAKDVF 
LGMFLYEYAR  RHPDYSVVLL   LRLAKTYETT   LEK359CCAAADP   H367ECYAKVFDE 
FK378PLVEEPQN  LIKQNCELFE   QLGEYKFQNA   LLVRYTKK4VP   QVSTPTLVEV 
SRNLGKVGSK  CCKHPEAKRM  PCAEDYLSVV   LNQLCVLHEK   TPVSDRVTKC 
CTESLVNRRP  CFSALEVDET   YVPKEFNAET   FTFHADICTL   SEKERQIKKQ 
TALVELVKHK  PKATKEQLK545A   VMDDFAAFVE   KCCKADDKET CFAEEGKKLV   
AASQAALGL 
 
Figure 3-3. HSA amino acid sequence. Amino acids only present in the precursor form are 
highlighted in yellow (first 24). Modification site numbers relate to the secreted form of HSA 
and are colored red.   
 
 
Modifications at H-146 were most often detected (see Figure 3-5) and an example of one 
such MS/MS spectrum, in the +2 charge state, can be seen in Figure 3-4. The MS/MS spectrum 
of the corresponding non-modified version of this peptide, also in the +2 charge state, can be 
found in Appendix 4. A more complete set of modified peptide mass spectra and their non-
modified counterparts can be viewed in the same appendix.    
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Figure 3-4. MS/MS spectrum of the peptide RH528.24PYFYAPELLFFAK in the +2 charge state, 
m/z 1145.84, with the oxidative modification on the histidine (H) residue. Blue peaks represent b 
ions and red peaks represent y ions. Peaks containing b#* or y#* represent a loss of water and 
peaks containing y#^ represent a loss of ammonia. Gray peaks represent unlabeled doubly 
charged b ions or those other than b or y ions. 
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3.5 DISCUSSION 
3.5.1 Labeling Efficiency 
 In the previous study with Labels 1, 2, and 3, increasing ratios were observed for labels 
with longer, more hydrophilic chains, which decreased steric hindrance and improved solubility, 
respectively. The alkoxyamine, which was the longest and most hydrophilic label we have 
studied, complied with this pattern and offered the greatest labeling capabilities we have seen 
thus far. Longer chains decreased steric hindrance in two ways: 1. They allowed the hydrazide to 
react with protein carbonyls with less interference from the biotin moiety during labeling and 2. 
They allowed the biotin moiety to interact with avidin with less interference from the 
protein/peptide during enrichment. One caveat was that the biotin:protein ratio for the 
alkoxyamine (~3.8) exceeded the amount of free carbonyls suggested by the DNPH assay (~2.7). 
However, the DNPH assay is known to give only approximate values. In addition, the control 
alkoxyamine sample, which gave about 1 biotin/protein, indicated that there was background 
reactivity in the samples. This has also been seen in work with other labels, including DNPH.
94
 
Finally, it is possible that the alkoxyamine is actually a more efficient label than DNPH.  
3.5.2 Spectral Counting 
Spectral counting (SC) was used as a means of quantitation because it aligns with our 
goal of assessing the label’s ability to allow us to identify modification sites. Our LTQ analysis 
included ten MS/MS events, which generated a large number of fragmentation spectra and 
increased the probability of identifying more peptides, further facilitating the use of SC.
133
 
Theoretically we would expect a linear relationship between protein abundance and spectral 
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counts, and Liu et al. confirmed this assumption for dynamic ranges on the order of 2 or greater 
170
. Decreased linearity would be expected for more complex samples.
133
 Being that all of our 
samples were simple solutions with only one protein (HSA), we decided to use spectral counting. 
Because we were focused on locating modification sites, our intent was not to use spectral 
counting as a measure of protein abundance, but simply to use it as a measure of detection 
efficiency of the labeled peptides. We were able to quantitatively distinguish differences in the 
amount of modified peptides between spike samples based on a comparison of spectral counts 
for each sample.  
3.5.3 Identification of Modification Sites 
As expected, very few modified peptides were detected in the 0% sample, which 
contained no acrolein-treated HSA. The few peptides that were identified could be attributed to 
false positive identifications or carry-over between instrumental runs. If complete separation was 
achieved using the streptavidin beads, we might expect the percent of modified peptide spectra 
(Figure 3-2) to be relatively constant across the samples. However, we observed increasing 
numbers of modified peptide spectra accompanying increasing amounts of carbonylated HSA in 
the spike, a phenomenon most likely caused by the high backgrounds in the samples. Each 
control sample produced several thousand spectra resulting from the cleavage, reduction, and 
digestion of non-biotinylated material stuck to the beads. The same should occur for the spike 
samples; thus, while the amount of carbonylated HSA varied across the spikes, the background 
remained roughly the same, causing the trend in Figure 3-2. In Appendix 2, Tables A2, A3, A4, 
and A5 display the number of modified peptide spectra detected for each site in the 0, 10, 25, 50, 
and 75 % spike samples. 
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An overview of the commonly modified residues detected by mass spectrometry in each 
sample is depicted in Figure 3-5. The same trend persists in this plot as the spike size increases. 
The scale was decreased in order to better visualize peptides with fewer counts. The number of 
spectra for H-146 in the 75% samples totaled 284. Only modifications that were detected in two 
or more trials were included in the data set for each sample. We see that the most commonly 
identified peptide contained H-146 and was the most hydrophobic amino acid sequence in this 
set: RHPYFYAPELLFFAK. As shown in Figure 2-8, this was also the most abundant peptide 
detected prior to enrichment using biotin hydrazide labels 1-3. The number of spectral counts for 
the alkoxyamine for this peptide (sum of three experiments) is considerably larger than the totals 
for Labels 1 and 3. It is similar to that of Label 2.  
 
 
 
 
 
 
 
 
 
 
Figure 3-5. Spectral counting results for triplicate injections of 0, 10, 25, 50, and 75 % 
carbonylated HSA spikes. Error bars represent the corresponding standard deviations. The 
number of spectra for H-146 in the 75% samples totaled 284. All spike samples were prepared 
three times, except for the 10% spike sample which was prepared four times. 
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Compared to the previous study in our lab,
94
 the alkoxyamine affinity tag presented some 
different labeling patterns, with certain sites being more prone to modification and/or detection 
than others. This comparison is displayed in Figures 3-6 and 3-7. Using the alkoxyamine, we 
were able to identify five unique modification sites otherwise undetected with the biotin 
hydrazide reagents; whereas, only two sites were unique to the biotin hydrazide reagents. Seven 
sites were common to all four labels (Figure 3-6). Surprisingly, K-525, which gave many spectra 
with the biotin hydrazide labels, gave none with the alkoxyamine. Spectral counts for peptides 
derivatized with Labels 1-3 or the alkoxyamine at the seven common sites are plotted in Figure 
3-7. A number of spectra were identified for carbonyl modification of C-34, the most reactive 
cysteine in HSA due to its nucleophilic sulfur atom and existence as the only free cysteine in 
HSA.
24
 This site has proven difficult to detect by mass spectrometry with some affinity tags, 
particularly Label 3.
94,184
 It has also been reported that some cysteinylation of C-34 occurs in 
commercial HSA samples, which would reduce the amount of free C-34 available for 
modification.
185
 The crystal structure of HSA reveals that C-34 is positioned in a crevice on the 
exterior of the protein and partially shielded by nearby amino acids.
186
 This justifies our findings; 
a longer-chained label would limit steric hindrance from the biotin moiety and promote reaction 
with the acrolein-modified cysteine. In our previous study, the longest-chained affinity tag, Label 
3, yielded the least amount of spectra at this site, potentially as a result of poor ionization of the 
labeled peptide. Figure 3-7 suggests that Labels 1-3 offer more modified peptide spectra for the 
shared lysines, but the alkoxyamine performs equal to or better than Labels 1-3 in terms of 
modification and detection of derivatized histidines. This is especially true for modifications at 
H-146, in which the alkoxyamine offered five times more spectra, and H-288, in which the 
alkoxyamine surpassed Labels 1 and 2 and Label 3 offered no spectra at all. Using Labels 1-3, 
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five separate lysine sites were modified versus only three histidine sites, with spectral counts for 
lysine modifications also exceeding those for histidine modifications.
94
 Similarly, more lysine 
sites were modified with the alkoxyamine, but histidine modifications at H-146, H-288, and H-
367 produced the highest number of modified peptide spectra by at least two fold. These same 
trends were also evident in Figure 2-8 (spectral counts before enrichment). Even though more 
lysine modification sites were identified, there were fewer overall spectra and larger 
uncertainties accompanying them. However, more rigorous quantitative experiments would be 
required to confirm the activities of these residues. 
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Figure 3-6. Comparison of modification sites identified between the 
alkoxyamine label versus the biotin hydrazide labels. 
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We decreased the percent spikes of carbonylated HSA in order to investigate regions of 
limited detection. Upon doing so, we found that the total number of modified peptide 
identifications fluctuated greatly once we reached 10% carbonylated HSA, with little to no 
material identified below that spike amount (i.e. 5% carbonylated HSA).  As can be seen in 
Figure 3-2, the data offered an average percent modification of 1.07 ± 1.02 % at the 10% spike. 
It appears that the operational limit of detection of any modification is between 5 and 10% spike. 
However, the percent modification value of 1.07 falls in line with expectations from the trend for 
the 0, 25, 50, and 75 percent modification values presented in Figure 3-2. This pattern is not so 
clear in Figure 3-5, but it should be noted that the small numbers of spectra, sometimes less than 
10 per peptide from triplicate preparations, offer large uncertainties. Thus, instances in which the 
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Figure 3-7. Number of spectra for shared modification sites between the biotin hydrazide labels 
and the alkoxyamine label. Results are from triplicate preparations. Alkoxyamine results are 
from the 75% spike sample.   
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number of spectra for the 10% spike appear to be higher than those of the 25% spike are not 
significant.   
We also compared the number of modified peptide spectra to the number of unmodified 
peptide spectra, but only for peptides detected in all four spike samples (10, 25, 50, and 75%). 
These fractions were calculated by dividing the number of modified peptide spectra by the total 
number of spectra (modified + unmodified) for each individual peptide and are presented in 
Figure 3-8. To be included in this plot, the modified peptide had to be detected in at least two 
trials for each of the 10, 25, 50, and 75% spike samples. Examining the plot, we see a similar 
trend as that in Figure 3-2. This is due to the fact that as the number of modified peptide spectra 
for a particular peptide increased, the number of unmodified peptide spectra remained roughly 
the same. In general, the peptides carrying lysine modifications had much higher fractions than 
the peptides carrying histidine modifications. Spectral counts for these unmodified peptides 
never totaled above 30, thus, small numbers of modified peptide spectra gave large fractions and 
uncertainties for each of these peptides.  The one exception was K-378, in which over 500 
unmodified peptide spectra were identified per sample per trial, but no more than 20 modified 
peptide spectra were identified in these same analyses. On the other hand, fractions for the 
cysteine and histidine-modified peptides were much lower, a result of moderate spectral counts 
for modified peptides and higher spectral counts (>100) for unmodified peptides. The fractions 
for the 10% spike sample were accompanied by large uncertainties, similar to those depicted in 
Figure 3-5. The C-34-containing peptide differences were more extreme, like those at K-378. 
While our label was able to offer better detection of this site compared to Label 3, the small 
fractions demonstrated this site is still difficult to label and detect.  
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In terms of MS/MS spectra, the modified peptide spectra for H-146 (Figure 3-4) 
demonstrated good runs of b, y, and b
2+
 ions, which confirmed the peptide identification. Its 
spectrum was also characterized by a more intense and shifted b2 ion (corresponding to cleaved 
label mass) and intense y8 ions, the latter being a result of the proline effect.
187
  Both modified 
and non-modified peptide spectra for this peptide presented strong b7 ions and doubly charged b 
ions. The intense blue peaks were identified as doubly charged b ions, not ions derived from 
alkoxyamine label fragmentation. While these peak intensities dominated the spectra, the singly 
charged b and y ions still remained abundant and with good intensity. Few to none of the 
modified peptide spectra contained reduced or full label modified peptides. Identification of 
these products would indicate inefficient alkylation or inefficient binding or washing, 
respectively. Most importantly, significant fragmentation of the labeling group was not evident 
Figure 3-8. Comparison of modified peptide spectra to unmodified peptide spectra for selected 
peptides. Fractions were determined by dividing the number of modified peptide spectra by the 
total number of spectra (modified + unmodified) for a particular peptide and averaging over 
three trials. Error bars represent standard deviations of the ratios.  
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in the spectrum and intensity was not lost in this way. A more complete set of modified peptide 
spectra and their non-modified counterparts can be viewed in Appendix 4. Some modified 
peptide spectra showed a few unidentified moderate to high intensity peaks that could possibly 
have resulted from fragmentation of the label. Generally though, b or y ion intensities dominated 
the spectrum and overall, the majority of the modified peptide spectra offered good runs for at 
least three of the b, b
2+
, y, and y
2+
 series and coverage of the modification site.  
3.5.4 Limitations 
As mentioned previously, a major downfall of using streptavidin products is nonspecific 
binding of non-biotinylated material. Because elution of biotinylated material from streptavidin 
is difficult to achieve, many scientists resort to on-bead digestion.
188
 Despite repeated washes 
prior to digestion, nonspecific material commonly remains, which can result in high backgrounds 
and false positive identifications. The use of a cleavable label is thought to minimize these 
complications since carbonylated material is cleaved from the beads, which are then discarded 
and not involved in the digestion process. However, we still observed large backgrounds in our 
control samples. It should be noted that although we focused on the identification of 
modification sites, other non-modified HSA peptides were identified. These peptides could very 
well have been cleaved from a captured HSA peptide carrying a carbonyl, but we have no way to 
separate these from peptides resulting from non-specific binding.  
Also, the structure of the label most likely played a crucial role in the ionization, 
fragmentation, and detection of modified peptides. Previous studies have suggested mass 
spectrometry analysis of the larger, more hydrophilic labels is less efficient than analysis of their 
smaller, hydrophobic counterparts.
94,189
  In our previous study, alkyl labels did not perform better 
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than hydrazide reagents overall, but did offer improved responses for certain modification sites, 
such as C-34, K-162, K-351, and H-288. This indicates that environmental conditions impacted 
the labeling process. For instance, K-351, a residue on albumin’s surface,190 was not identified in 
our studies as being modified. This suggests that other factors (hydrophilicity/hydrophobicity, 
etc.) besides accessibility play a role in residue modification or mass spectrometric detection. 
Using the alkoxyamine, about half as many peptide spectra were identified for modified lysines 
as were for the biotin hydrazide reagents, but nearly twice the amount of spectra were identified 
for modified histidines with the alkoxyamine. Thus, the long, pegylated chain on the 
alkoxyamine affinity tag could have caused a decrease in ionization efficiency for some labeled 
peptides, but still fared better than the long, pegylated biotin hydrazide label (Label 3) in terms 
of the number of modification sites identified. This makes sense because, although both labels 
are pegylated, the alkoxyamine is slightly smaller, offering better detectability in the mass 
spectrometer. 
Spike experiments were modified in various fashions to determine if improvements in 
detection could be observed. Numerous experiments involving varying amounts of streptavidin 
beads and total protein (carbonylated HSA spikes in regular HSA) were performed and repeated. 
Thermo Scientific reports the binding capacity of the beads to be ≥ 2 mg biotinylated 
material/mL of resin. (The resin is a slurry which contains roughly equal volumes of beads and 
storage solution.) Optimum experiments resulted from following those exact recommendations 
and using 500 µL slurry + 500 µg protein. Altered experiments included: 250 µL slurry + 500 µg 
protein,  250 µL slurry + 750 µg protein, 500 µL slurry + 1000 µg protein, 500 µL slurry + 1500 
µg protein,  and 1000 µL slurry + 1000 µg protein. In each of these experiments, either a 
decreased amount of modified spectra or absolutely no modified spectra were identified in 
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comparison to the 1 µL:1 µg sample. In their review, Dundas and coworkers made the claim that 
the addition of more streptavidin beads does not correlate with more identifications.
191
 Multiple 
streptavidin bead manufacturers advise adhering to bead capacity recommendations to obtain 
capture of the target molecule; our experiments confirm this advice. Steric hindrance between 
bead and label should not have been a problem considering the length of the alkoxyamine spacer 
arm. However, the addition of excess protein could have promoted protein aggregation, which 
can lead to limited label accessibilities. Too many streptavidin beads can lead to aggregation and 
a concomitant decrease in binding capacity. Separate experiments involving increased 
reducing/alkylating agents (DTT/IAA) and incorporation of urea washes prior to 
reduction/alkylation were also unsuccessful. Excess DTT/IAA can lead to precipitation and 
disulfides in the alkoxyamine label may not have been able to withstand the harsh urea washes, 
leading to premature cleavage and loss of the modification site.   
3.5.5 SpectraST 
SpectraST was proposed as an alternative peptide identification tool in 2007. Instead of 
performing a statistical validation of the comparison of sample MS/MS to theoretical peptide 
spectra as in Peptide Prophet, this validation technique involves spectrum matching. Real sample 
spectra are added to a library and then experimental MS/MS spectra are searched against this 
library.
192
 Additional material was identified using this analysis technique as can be seen below 
in Tables 3-1 and 3-2. This analysis technique is useful in a targeted study; however, false 
positive identifications are more likely to occur. Thus, the use of this software was primarily 
exploratory. We showed that upon identifying certain modified peptides in a global analysis, we 
could target those particular peptides and identify more spectra based on spectral matching. 
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However, SpectraST would be better suited for strictly targeted analyses and thus no other 
samples were analyzed with this software.  
Samples were prepared in which 100% carbonylated HSA was labeled and enriched; no 
spiking was performed. Two initial HSA samples were created: a control sample (no acrolein) 
and a treated sample (+ acrolein). Upon enrichment, bound (labeled, attached to beads) and 
nonbound (nonlabeled, not attached to beads) fractions were collected for each sample, giving a 
total of four samples prior to digestion. Samples were then analyzed via LC-MS/MS. Data was 
analyzed with Sequest software and simplified with Peptide Prophet. Experiments were repeated 
multiple times. Some sample sets were also simplified with SpectraST software to see if 
increased numbers of modified peptide spectra could be identified. A SpectraST library was 
created from the Peptide Prophet output for a treated sample and contained modified peptide 
spectra for C-34, C-487, H-67, H-146, H-288, H-367, K-162, K-359, and K-545. C-34 is the only 
free cysteine available for modification in HSA,
24
 thus the modified peptide spectrum for C-487 
was most likely a false positive identification (only one spectrum was identified). The 
modification was included in the library though in order to observe how SpectraST would 
respond. Data from the preparation of a second treated sample was then compared to the spectra 
in this library and also analyzed using Peptide Prophet. The corresponding data sets for each of 
these analyses are presented in Tables 3-1 (green) and 3-2 (blue).  
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SAMPLE NAME 
# TOTAL 
SPECTRA* 
MODIFIED PEPTIDE # SPECTRA 
MODIFIED 
RESIDUE 
CHARGE 
Control (Bound) 6880  RPC494.19FSALEVDETYVPK 16 C-487 3 
Treated (Bound) 11000 
SLH528.24TLFGDK 8 H-67 2 
RH528.24PYFYAPELLFFAK 175 H-146 +2/+3 
SH528.24CIAEVENDEMPADLPSLAADFVESK 15 H-288 3 
CCAAADPH528.24ECYAK 29 H-367 2 
YK519.27AAFTECCQAADK  27 K-162 +2/+3 
TTYETTLEK519.27CCAAADPHECYAK 7 K-359 3 
EQLK519.27AVMDDFAAFVEK 25 K-545 +2/+3 
 ALVLIAFAQYLQQC494.19PFEDHVK 100 C-34 +2/+3 
 RPC494.19FSALEVDETYVPK 23 C-487 3 
Control (Nonbound) 9031  RPC494.19FSALEVDETYVPK 35 C-487 3 
Treated (Nonbound) 5586  RPC494.19FSALEVDETYVPK 12 C-487 3 
 
 
SAMPLE NAME 
# TOTAL 
SPECTRA* 
MODIFIED PEPTIDE # SPECTRA 
MODIFIED 
RESIDUE 
CHARGE 
Control (Bound) 4556 N/A N/A N/A N/A 
Treated (Bound) 7782 
RH528.24PYFYAPELLFFAK 69 H-146 +2/+3 
SH528.24CIAEVENDEMPADLPSLAADFVESK 14 H-288 3 
CCAAADPH528.24ECYAK 16 H-367 2 
YK519.27AAFTECCQAADK  18 K-162 +2/+3 
TTYETTLEK519.27CCAAADPHECYAK 5 K-359 3 
EQLK519.27AVMDDFAAFVEK 7 K-545 +2/+3 
 ALVLIAFAQYLQQC494.19PFEDHVK 33 C-34 +2/+3 
Control (Nonbound) 6676 N/A N/A N/A N/A 
Treated (Nonbound) 3798 N/A N/A N/A N/A 
Table 3-1. Peptide Prophet Analysis: List of modified HSA peptides with mass shifts for 
modified cysteine (C), histidine (H), and lysine (K). *0.9 minimum probability for included 
spectra. 
Table 3-2. SpectraST Analysis: List of modified HSA peptides with mass shifts for modified 
cysteine (C), histidine (H), and lysine (K). *0.9 minimum probability for included spectra. 
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Based on this analysis, we can see that more total spectra and modified spectra were 
identified using SpectraST. Roughly 2000-3000 more spectra were identified for each sample 
and over double the amount of modified peptide spectra were identified versus Peptide Prophet. 
The percent of modified peptide spectra increased from 2.08% (Peptide Prophet) to 3.51% 
(SpectraST). One peptide, SLHTLFGDK, was identified by spectrum matching using SpectraST, 
but not by theoretical spectrum comparison using Peptide Prophet. The peptide 
RPCFSALEVDETYVPK, carrying a modification on C-487, was identified in all control and 
treated samples during the SpectraST analysis, but was not identified in the Peptide Prophet 
analysis. As predicted, false positive identifications occurred using SpectraST. 
An example spectrum for the peptide RHPYFYAPELLFFAK carrying a modification on 
the histidine (H-146) can be seen in Figures 3-4. Comparing the library and query spectra in 
Figure 3-4, we can see that the query spectrum was deemed a match based on the large number 
of matched peaks (in red). Black peaks in the query spectrum do not match assigned peaks in the 
library spectrum. Blue peaks in the library spectrum represent unassigned peaks. The red labels 
for the b and y ions signify that those particular ions were also found in the query spectrum. In 
summation, SpectraST software behaved as expected, providing more hits for modified peptide 
spectra, but also more false positive identifications. This was simply an exploratory study, and 
thus we did not analyze other sample data with this software. 
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Figure 3-9. SpectraST spectrum for RH528.24PYFYAPELLFFAK in the +2 
charge state. The x-axis represents mass to charge (m/z) and the y-axis 
represents Relative Abundance. In the Query spectrum, red lines signify a 
peak match to those in the library spectrum. 
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3.6 CONCLUSION 
 A new method involving the use of a cleavable biotin tag and streptavidin bead 
enrichment was validated for HSA samples. On-bead digestion was avoided while still 
maintaining the ability to identify modification sites. Experiments aimed at correlating the 
percent of carbonylated HSA with the number of modified spectra highlighted issues with 
nonspecific binding and limited ranges of detection. However, it was discovered that the 
alkoxyamine offered the highest labeling efficiency of all labels tested in the past and greater 
coverage of modification sites than biotin hydrazide reagents, particularly Label 3. This work 
coincided with previous research indicating that many affinity labels prefer certain peptides in 
terms of labeling and detection. Future work should focus on protocol improvements concerning 
non-specific binding and detection limits and also validation of the method in a more complex 
sample matrix, with the hopes of one day applying the method to real biological samples.  
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Chapter 4 – APPLICATION: INVESTIGATION OF PROTEIN 
CARBONYLATION IN HUMAN PLASMA COLLECTED FROM 
CHRONIC KIDNEY DISEASE (CKD) PATIENTS ON DIALYSIS 
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4.1 ABSTRACT 
 Studies suggest a correlation between CKD progression and increasing oxidative stress, 
particularly at the final stage of the disease when patients are placed on dialysis and the highest 
oxidation levels have been observed. Being that we are focused on identifying sites and 
mechanisms of protein oxidative carbonylation with various tools, here we are applying our 
analytical methods and investigating protein carbonylation in the plasma of CKD patients. The 
overall goal of the study is to prepare and analyze CKD samples using our own methods in order 
to help us better understand the nature of oxidative damage to plasma proteins. This work was 
preliminary and mainly served as a means of method application. Although various protocols 
utilizing UV-Vis spectroscopy, fluorescence techniques, and mass spectrometry were used to 
investigate oxidative carbonylation in these samples, the data was not consistent enough to 
determine overall oxidation patterns.   
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4.2 INTRODUCTION 
Chronic kidney disease (CKD) has gained status as a worldwide “public health problem” 
over the last ten years. The disease has become so prevalent across the globe that in 2006, March 
was deemed National Kidney Month and the second Thursday of March as World Kidney 
Day.
193
 The Centers for Disease Control and Prevention (CDC) deemed CKD as the 13
th
 leading 
cause of death in the United States in 2011.
194
 An estimated 25 million people in the US, which 
is equivalent to about 12% of the population, have been diagnosed with CKD. The disease is 
most common in older populations; nearly 50% of the elderly over the age of 70 have CKD.
195
 
In the simplest of terms, CKD is defined as a condition affecting the performance of the 
kidneys. According to the National Kidney Foundation’s Kidney Disease Outcomes Quality 
Initiative (KDOQI), CKD is diagnosed if a patient has kidney damage or a decreased glomerular 
filtration rate (GFR) for more than 3 months, neither of which stems from a particular cause.
195–
200
 If an individual’s GFR is measured below 60 mL/min per 1.73 m2, this indicates about 50% 
loss of kidney function and the risk for CKD complications increases.
200
 One’s GFR naturally 
decreases with age due to the loss of muscle mass over time. This factor contributes to higher 
incidence of CKD amongst the elderly.
200
 As can be seen in Table 4-1,
197
 which was recreated 
from Anderson and Glynn, there are five main stages of CKD as determined by GFR:  
 
 
 
 
 
Table 4-1. The CKD stages according to the National Kidney Foundation 
KDOQI. 
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Sadly, there is no cure for CKD. The disease progresses until the patient’s kidneys can no 
longer function independently and the patient must receive dialysis or a transplant. As observed 
in Table 4-1, this constitutes Stage V of CKD. Upon receiving such assistance, the patient is 
diagnosed with End Stage Renal Disease (ESRD).
195,196,200,201
 In terms of dialysis, the two most 
common types are hemodialysis (HD) and peritoneal dialysis (PD). The first instance of 
continuous HD performed in the United States occurred in 1960 in Seattle, Washington. A 
Teflon tubing shunt was inserted into the patient’s arm vein and connected to Skeggs-Leonards 
dialyzers.
202
  These machines passed blood and dialysate, contained in a household freezer, in 
opposite directions across a membrane, allowing for the removal of excess waste from the blood 
via diffusion
203
 and are similar to present-day dialysis machines. This patient successfully 
received dialysis for 11 years before succumbing to a heart attack.
202
 
 The first instance of PD in the United States also occurred around this time in San 
Francisco, California. However, survival rates were low and the process was not fully automated 
until 1976.
202
 At this time, continuous ambulatory peritoneal dialysis (CAPD) was developed in 
Austin, Texas. A catheter is inserted into the peritoneal cavity. Dialysate is introduced into the 
cavity and prompts diffusion, resulting in waste removal across the peritoneum membrane. The 
waste is extracted and dialysate replaced multiple times a day. CAPD allows for more freedom in 
that the patient is not attached to a machine for prolonged amounts of time; although, patients are 
at higher risks for infection.
204
  
Kidney transplantation is the closest option to a cure, but waiting lists can be long and 
risk of organ rejections high. However, survival rates of transplant patients are higher than those 
of dialysis patients.
196
 While both types of treatment incur yearly costs around $22 billion,
201
 the 
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establishment of the Medicare ESRD Program in 1973 offers monetary assistance for ESRD 
patients receiving dialysis and/or a transplant.
202
   
Although our work was merely application based and no biological conclusions were 
made, connections between oxidation and CKD have been elucidated previously. Oxidative 
stress plays a role not only in CKD, but also in an assortment of other associated conditions, such 
as aging, inflammation, diabetes, cardiovascular disease (CVD), atherosclerosis, etc. This 
complicates the assignment of biomarkers to particular conditions. Regardless,  studies indicate 
an increase in oxidative stress in both CKD and ESRD patients and generally even higher 
oxidative stress when compound conditions are present.
85,205,206
 These systems are in a pro-
oxidant state in which antioxidant defenses are decreased and production of ROS is increased.
5
 
In terms of CKD, research shows an increase in protein carbonyl content and a decrease in 
protein thiol content in stages 3-5 CKD patients, signifying increased oxidation and decreased 
antioxidant defenses, respectively.
207
  In terms of ESRD, an increase in oxidative stress has been 
observed and postulated to be a result from various factors depending on the type of 
dialysis.
84,86,208
  
This project was in collaboration with Dr. Donald Brophy (VCU School of 
Pharmacy/Department of Pharmacotherapy and Outcomes Science) and Erika Martin (VCU 
School of Pharmacy/Coagulation Advancement Lab). We received 50 plasma samples: 20 CKD 
patients on HD, 20 CKD patients on PD, and 10 healthy controls. This was the first study in 
which we were applying our proteomic methods to true biological samples and also our first 
attempts at working with blood samples. The overall goal of the study was to detect and 
relatively quantify oxidative damage to plasma proteins and develop an assay for monitoring 
oxidative damage during disease progression. Also, since the method development work in 
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Chapters 2 and 3 was occurring concomitantly with this application, the methods utilized for this 
study do not always reflect the optimized methods from these chapters. 
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4.3 EXPERIMENTAL DESIGN 
4.3.1 Materials 
 Urea, 10xPBS, water (HPLC), methanol (HPLC), DMSO, DTT, TFA, Tween® 20, 
Brilliant blue, BSA (Fraction V), and Biotinylated BSA were purchased from Fisher Scientific 
(Pittsburgh, PA). HSA, (+)-Biotin hydrazide, NaBH3CN, SDS, IAA, and CaCl2 were purchased 
from Sigma-Aldrich (St. Louis, MO). TCA and GuHCl were obtained from Acros Organics (Fair 
Lawn, NJ). The BCA Protein Assay, Biotin Quantitation kits, EZ-Link Biotin-LC-Hydrazide, 
and EZ-Link Biotin-PEG4-Hydrazide were purchased from Thermo Scientific (Rockford, IL). 
Oasis MCX extraction cartridges were purchased from Waters Corporation (Milford, MA). 
Sequencing grade modified trypsin was obtained from Promega (Madison, WI). Mini 
PROTEAN® TGX
TM
 gels, 10x TGS Buffer, 10xTBS, 10x TG Buffer, Laemmli sample buffer, 
Mini Trans-Blot filter paper, Immun-Blot PVDF Membranes for Protein Blotting, and Blotting 
Grade Blocker were obtained from Bio-Rad (Hercules, CA). The OxyBlot Protein Oxidation 
Detection kit was purchased from Millipore (Billerica, MA). The Enhanced Chemiluminescence 
(ECL) Plus Western Blotting Detection System and PD midiTrapTM G-25 columns were 
obtained from GE Healthcare (Pittsburgh, PA). FTC, HCl salt was purchased from Marker Gene 
Technologies, Inc. (Eugene, OR). 
4.3.2 Plasma Preparation 
The Coagulation Advancement Lab provided the CKD plasma samples. Prior to our 
involvement in the study, blood was drawn from volunteers/patients via arm vein or dialysis 
access into 4.5 mL Vacutainer tubes containing 3.2% sodium citrate (Becton Dickinson, Franklin 
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Lakes, NJ). The blood was centrifuged for 10 min at 3500 rpm and plasma drawn off for analysis 
and long term storage. 
4.3.3 Protein Labeling 
 The plasma was diluted in PBS at a 1:100 ratio. Biotin hydrazide (Label 1) was prepared 
in DMSO at 50 mM and added to a final concentration of 5 mM. The samples were incubated at 
room temperature for 2 h using an Eppendorf ThermoMixer. To reduce and stabilize hydrazone 
bonds formed during labeling, NaBH3CN was prepared in PBS at 30 mM and added to a final 
concentration of 15 mM. The samples were incubated at room temperature for 1 h. To precipitate 
the proteins, 100% TCA was added at 20% of the total solution. Following a 15 min slushy ice 
incubation, protein pellets were washed three times with ice cold acetone. The supernatant was 
removed and the pellets resuspended in PBS at a concentration of 1-2 mg/mL. 
4.3.4 Protein Digestion 
 Following labeling, 8 M urea was added to the protein solutions as a denaturant. To 
reduce disulfide bonds, DTT was added to a final concentration of 10 mM and samples were 
incubated on the ThermoMixer for 1 h at 37°C. To alkylate cysteines, IAA was added to a final 
concentration of 20 mM and samples were again incubated as described above. Following 
dilution with PBS, CaCl2
 
was added to a final concentration of 1 mM and overnight trypsin 
digestion was performed at 37°C and 300 rpm on the ThermoMixer. Formic acid was added to 
halt digestion and the acidified peptide samples were concentrated with individual Oasis MCX 
columns using the protocol supplied by Waters Corporation. Three 1-mL fractions were eluted 
from each column and then all fractions were dried with a Speed Vac concentrator. After 
evaporation, dried peptides were dissolved in 95/5 0.1% aqueous TFA/ACN. The solution 
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concentrations were established using a BCA assay kit following the protocol provided by 
Thermo Scientific Pierce.  
4.3.5 Mass Spectrometry 
 Peptide solutions were analyzed using LC-MS/MS on a Thermo (San Jose, CA) LTQ XL 
linear ion trap mass spectrometer with a nanospray ionization source. Utilizing a Thermo (San 
Jose, CA) Finnigan Micro ASII autosampler and Surveyor Plus HPLC System, peptides were 
separated on a C-18 reverse-phase column (150 µm × 10 cm, 5 µm particles, 300 Å pores) from 
Column Technology (Fremont, CA). Triplicate injections, each 20 µL, were made for each 
sample. Gradient elution from the column was accomplished using two mobile phases: A (0.1% 
formic acid in water) and B (0.1% formic acid in methanol) at a flow rate between 0.5-1 μL/min. 
For each 160 minute run, the gradient began with 5% B, rose to 25% B within 15 min, 90% B 
within 115 min, and then decreased back to 5% B within 145 min. Peptides were ionized using a 
nanospray source at 1.8 kV. Precursor ions were obtained via a full scan in the range of 300-
2000 m/z. A data-dependent scan procedure was used for the MS/MS analysis, in which ten 
resultant ions from the full scan were selected and subjected to further fragmentation using CID. 
Analysis was completed in the positive ion mode with active dynamic exclusion, in which a 
precursor ion was excluded from the analysis for 180 seconds if it was selected for further 
fragmentation twice within 30 seconds.  
4.3.6 Database Searches and Analysis 
 The MS/MS spectra were analyzed using software distributed by Thermo, specifically 
Finnigan Xcalibur Bioworks 3.2 and the Sequest search engine used for peptide/protein 
identification. Searches were performed against an NCBI RefSeq database for Homo sapiens, 
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which was obtained on January 15, 2013 and contained 71,806 entries.  Database sequences were 
also reversed to enable decoy searches and false discovery rate approximations.
154
 No more than 
two missed cleavage sites were allowed. A fixed modification was set for carbamidomethylation 
(alkylated cysteines with mass shifts of +57. 021464 Da) and differential modifications were set 
for: biotinylation at arginine (+199.066655), lysine (+241.088455), and proline (+257.107175) 
and oxidation at methionine (+15.994915), histidine (+15.994915), and cysteine (+15.994915, 
+31.98983, +47.984745). Trans-Proteomic Pipeline (TPP) (Version 4.6.3; Institute for Systems 
Biology in Seattle, Washington) was used to refine Sequest search results. In order to validate 
peptide-matched MS/MS spectra, PeptideProphet was used and only peptides with a minimum 
probability of 0.9 were accepted.
209
 Semi-quantitation was achieved using spectral counting 
(SC).
133
 
4.3.7 Western Blotting 
 Western blotting was performed according to the manual provided with the commercial 
OxyBlot Protein Oxidation Detection Kit. Plasma proteins were isolated via TCA precipitation 
and reconstituted in 5% SDS in PBS. Equal amounts of protein (4 µg) were labeled with 7.5 µL 
DNPH in 2M hydrochloric acid and incubated at room temperature for 15 min. Proteins were 
neutralized and reduced with 5 µL neutralization solution and 1 µL 5% 2-mercaptoethanol, 
respectively. The samples, along with an oxidized protein standard and protein standard ladder, 
were loaded onto a 4-20% gradient polyacrylamide SDS-PAGE gel and run in TGS buffer at 100 
V and 90 mA for 1 h and 30 min. Proteins were then transferred to a PVDF membrane and run in 
TG buffer at 100 V and 300 mA for 1 h and 15 min. Following immunoblot, the membrane was 
blocked with 5% non-fat dry milk in 1X TBS-T for 1 h and then incubated with rabbit anti-DNP 
antibody at a 1:1200 dilution in 5% BSA and TBS-T overnight at 4°C. The membrane was 
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washed with TBS-T and incubated with goat anti-rabbit IgG antibody (HRP conjugated) at a 
1:2400 dilution in 3% non-fat dry milk and TBS-T for 1 h at room temperature. The membrane 
was washed with TBS-T and then developed using the ECL Plus Western Blotting Detection 
System according to the manufacturer’s protocol.  
4.3.8 Biotin Quantitation Assay 
 Plasma proteins were precipitated with TCA and reconstituted in PBS and 8 M urea. 
Each sample was incubated with an excess (5 mM) of one of three biotin hydrazide reagents: 
standard biotin hydrazide (Label 1), EZ-link hydrazide-LC-biotin (Label 2), or EZ-link 
hydrazide-PEG4-biotin (Label 3), and then reduced with NaBH3CN. Excess materials were 
removed using PD midiTrap
TM
 G-25 columns and proteins were eluted in PBS.  The protein 
concentrations were determined using the BCA assay. 
The extent of biotinylation was assessed following the protocol provided by Thermo 
Scientific Pierce. Biotinylated protein was added to a solution containing HABA-avidin 
complex. Biotin’s stronger affinity for avidin causes the displacement of HABA, invoking an 
absorbance change detectable with UV-visible spectroscopy. Using the extinction coefficient of 
34,000 M
-1
cm
-1
,
89
 the known protein concentrations, and the change in absorbance before and 
after biotinylated protein addition, the biotin to protein ratios were calculated and the extent of 
biotinylation determined. Commercially available biotinylated BSA was used as a standard; the 
manufacturer reports nine equivalents of biotin per BSA molecule. 
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4.3.9 FTC Assay 
The following procedure was adapted from the methods of Mohanty et al.
155
 Standards 
were prepared according to the protocol in section 2.3.10.1. CKD samples were prepared 
accordingly. Plasma proteins were isolated via TCA precipitation and reconstituted in 6M 
GuHCl in MES. Protein concentrations were determined using the BCA Assay kit. Protein 
solutions were diluted to 10 µg/µL with MES and incubated with 304 µM FTC (10:1 FTC:HSA) 
overnight at room temperature with gentle rotation. Proteins were then isolated via TCA 
precipitation and reconstituted in 450 µL 3M GuHCl in PBS. Fluorescence measurements were 
made using a Varian Cary Eclipse Fluorescence Spectrophotometer. The instrument was zeroed 
with PBS and sample measurements were made one at a time with an excitation wavelength of 
492 nm and an emission wavelength of 550 nm. The slit widths were 5 nm and measurements 
were made at medium scan speed.  Fluorescence anisotropy measurements were made according 
to the procedure described in Section 2.3.10.3. Plasma diluted in PBS was used as a control.  
 
 
 
 
 
 
 
 
109 
 
4.4 RESULTS 
4.4.1 Western Blotting 
 Western blotting is a commonly used technique to separate the components of a mixture 
for visualization; proteins are separated by molecular weight on SDS-PAGE gels, transferred to a 
membrane via immunoblot, and then often visualized using a combination of an HRP-conjugated 
antibody and a chemiluminescent reagent. Prior to Western blotting, DNPH was used to 
derivatize plasma protein carbonyls in various CKD patient samples. The general reaction was 
redrawn from Hensley and Floyd and is presented in Scheme 4-1.
210
 DNPH is the most 
commonly used reagent for oxidative modification labeling, detection, and quantification. The 
two most popular methods involving DNPH are spectrophotometric and Western blotting 
methods developed by Levine et al.
211
  
 
 
  
 
 
 Not only is chemiluminescence a highly sensitive technique, but it can be achieved with a 
variety of substances. In our system, we used hydrogen peroxide (H2O2) as the oxidant, 
horseradish peroxidase (HRP) as the catalyst, and luminol as the light-emitting molecule. The 
general reaction was redrawn from Marquette & Blum and is presented below in Scheme 4-2.212 
Scheme 4-1. Reaction between a protein carbonyl and DNPH to form the derivatized product. 
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HRP, which has specificity for H2O2, will complex with the oxidant. This complex oxidizes 
luminol to form a dianion in the excited state, 3-aminophthalate. As this molecule decays from 
the excited state to the ground state, light is emitted, which is detected and visualized.
212,213
 
 
 
 
 
 
Observable changes in Western blot band intensities were used as a measure of 
carbonylation. Hence, lighter bands indicated less carbonylation while darker bands indicated 
more carbonylation. Patterns in band intensities were observed for the various CKD samples. 
Figures 4-1 and 4-2 demonstrate these patterns for two sets of patient samples. Each set of 
samples were prepared twice and analyzed on separate days, creating four total analyses. The 
first set of samples included sample numbers: 907 (control), 935 (HD), and 967 (PD). The 
second set of samples included sample numbers: 910 (control), 930 (HD), and 952 (PD).    
 
 
 
 
Scheme 4-2. Chemiluminescence reaction. Catalyst/cooxidant represents HRP/H2O2 in our 
experiments and hv denotes emitted light. The asterisk signifies an excited state. 
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Figure 4-1. SAMPLE SET #1: Duplicate Western blot analyses of patient samples 
907, 935, and 967. The lane numbers correspond to: 2=907 no DNPH, 3=907 + 
DNPH, 4=Empty lane, 5=935 no DNPH, 6=935 + DNPH, 7=Empty lane, 8=967 no 
DNPH, 9=967 + DNPH, 10=Oxidized protein standard with corresponding molecular 
weights in red. 
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Figure 4-2. SAMPLE SET #2: Duplicate Western blot analyses of patient samples 
910, 930, and 952. The lane numbers correspond to: 2=910 no DNPH, 3=910 + 
DNPH, 4=Empty lane, 5=930 no DNPH, 6=930 + DNPH, 7=Empty lane, 8=952 no 
DNPH, 9=952 + DNPH, 10=Oxidized protein standard with corresponding molecular 
weights in red.  
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While bands for the PD patient sample proteins were consistently darker than the other 
bands indicating increased carbonylation in these samples, the bands for the HD patient samples 
were not as consistent, although did appear darker than the control bands in most instances. 
Background-level intensities for the control bands were expected due to inherent oxidation 
present in human blood. The method provides a qualitative measure of carbonylation, but lacks 
specificity and is not amenable to screening large sample sets.  
4.4.2 Biotin Quantitation Assay 
The following biotin to protein ratios were determined for two subsets of patient samples 
and can be seen in Table 4-2. Carbonyls were derivatized with one of three biotin hydrazide 
reagents: standard biotin hydrazide (Label 1), EZ-link hydrazide-LC-biotin (Label 2), or EZ-link 
hydrazide-PEG4-biotin (Label 3). Biotin:protein ratios separated by commas indicate repeat 
experiments were performed. 
 
Table 4-2. Calculated biotin to protein ratios for two subsets of CKD patient samples. 
 
 
 
 
 
 
 
 
Biotin:Protein Ratios 
Subset # Patient # Label 1 Label 2 Label 3 
1 
Control 905 0.94, 0.20, 0.24 0.29 5.70 
HD 928 0.57, 0.46, 0.22 - 4.04 
PD 954 1.11, 0.71, 0.28 - 3.45 
2 
Control 909 <0 0.27 9.28, 7.15 
HD 922 <0 0.33 5.57, 4.13 
PD 951 <0 0.16 11.10, 11.86 
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For patient sample numbers 905, 928, and 954 in Subset #1, the biotin:protein ratios 
calculated when using Label 1 varied greatly across three interday analyses. The %RSD values 
for patient sample numbers 905, 928, and 954 were 90.5%, 43.0%, and 59.3%, respectively. 
However, the assay effectively relies on measuring the change in absorbance of avidin-bound 
HABA and there are high uncertainties when only a small amount is displaced by biotin. The 
majority of the measurements for Labels 1 and 2-derivatizated samples from both Subsets #1 and 
#2 were at or close to 0 indicating very limited derivatization by these tagging reagents. Overall, 
ratios for Label 3-derivatized samples were much higher than those for Labels 1 and 2-
derivatized samples. This is a result we would expect since Label 3 offers the highest labeling 
efficiency when compared to Labels 1 and 2 when using the biotin quantitation assay as a 
measurement tool (Figure 2-2).  
4.4.3 FTC Assay 
 As described in Chapter 2, the FTC assay was validated using carbonylated HSA spiked 
into regular HSA and plasma, but was not applied to biological samples. Upon receiving the 
CKD samples, we took this as our first opportunity to test our assay. Two sets of patient samples 
were analyzed with the assay and results are presented below. The first set, referred to as CKD 
Sample Set 1, included: Control 909, HD 922, and PD 951. The second set, referred to as CKD 
Sample Set 2, included: Control 906, HD 938, and PD 956. Carbonylated proteins in all six 
plasma samples were labeled with FTC and analyzed with fluorescence spectroscopy. To assess 
interday precision, CKD Sample Set 1 was prepared three times, each on a different day. The 
emission spectra from each of these three analyses are depicted in Figure 4-3. Because CKD 
Sample Set 1 produced variable results across the days, CKD Sample Set 2 was prepared to test 
preparation and instrument reproducibility. These results are shown in Figure 4-4. 
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Figure 4-3. CKD Sample Set 1: emission spectra from three 
interday FTC assay analyses of patient samples 909, 922, and 951.   
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Figure 4-4. CKD Sample Set 2 emission spectra from: A. First sample preparation on Day 1. B. 
Second sample preparation on Day 2. C. First sample preparation solutions reanalyzed on Day 1. 
D. Second sample preparation solutions reanalyzed on Day 2. 
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 To ensure that our fluorescent label was indeed reacting with carbonyl sites on the protein 
and that there was no label detachment occurring between the protein reconstitution and 
fluorescence measurements, we investigated binding between protein and FTC label by 
measuring anisotropy.  Triplicate anisotropy measurements were made for each of the patient 
samples in CKD Sample Set 1: Control 909, HD 922, and PD 951. Results are depicted below in 
Figure 4-5. R values are averages of nine measurements with error bars representing the 
standard deviations. Free FTC (100 µM) exhibited an average r value of 0.026. Patient sample r 
values were much higher than that of free FTC, suggesting that the FTC label was indeed bound 
to the protein.  
 
 
 
 
 
 
 
 
 
 
Figure 4-5. Average anisotropy (r) values and standard deviations for 
triplicate analyses of patient samples control 909, HD 922, and PD 951. 
Free FTC represents 100 µM FTC in PBS. 
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4.4.4 Mass Spectrometry 
Of the 50 patient samples, five have been analyzed with our protocol: Sample numbers 
907 (healthy control), 924 and 935 (HD patients), and 962 and 967 (PD patients). ). It was not 
possible to definitively identify any peptides in these samples that carried an expected 
modification along with the biotin labeling group.  No enrichment was used in these studies and 
past experience in the research group suggests that it was unlikely to find carbonylation 
modifications under these circumstances. As an alternative approach that would not require 
labeling, methionine and histidine oxidation levels were characterized for various proteins. These 
could also offer insight as to the level of oxidative stress in the patient. Figure 4-6 illustrates the 
percent oxidation values calculated using spectral counts for non-labeled samples (no biotin 
hydrazide). This was done to minimize sample preparation time and to potentially reduce 
adventitious oxidation. These samples were also analyzed a second time with LC-MS/MS, hence 
the error bars representing the deviations. The second LC-MS/MS analysis served to assess 
instrument reproducibility. Varying oxidation levels were detected amongst the five patient 
samples; however, due to the fact that methionine oxidation can be induced during sample 
preparation and/or reversed by certain enzymes, these experiments present some risks. The CKD 
project was terminated so additional samples were not processed by this approach. 
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Figure 4-6. Average percentage of methionine/histidine oxidation for three LC-MS/MS 
analyses of sample numbers 907, 924, 935, 962, and 967. Percents were determined by: 
#𝑜𝑥𝑖𝑑𝑖𝑧𝑒𝑑 𝑠𝑝𝑒𝑐𝑡𝑟𝑎
#𝑡𝑜𝑡𝑎𝑙 𝑠𝑝𝑒𝑐𝑡𝑟𝑎
 𝑥 100. 
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4.5 DISCUSSION 
4.5.1 Analytical Assays 
 Going into this project, we had no idea as to how much carbonylation would be detected 
in the control and patient samples aside from what we had gleaned from the literature. Based on 
correlations between final stage CKD patients and increased carbonylation in the literature, we 
expected to encounter this correlation in our research. Pertaining to distinguishing carbonylation 
patterns between HD and PD patients, we were unsure what to expect being that oxidation had 
been observed and reported in both HD and PD patient samples.
5,8,84,86,207
 
 Initial attempts at distinguishing carbonylation patterns proved successful in that we were 
able to reproducibly visualize what appeared to be increased carbonylation in PD patients using 
Western blotting. However, labeling of the carbonylation sites with DNPH using the OxyBlot kit 
was often interrupted by precipitation observed during incubation of the plasma with the 
acidified DNPH solution. No precipitation was encountered in experiments presented in the 
Section 4.4.1, but it continued to be a reoccurring problem throughout derivatization procedures. 
Before other options could be explored, such as labeling with biotin hydrazide and detecting with 
streptavidin Poly-HRP, it was decided that Western blotting was too costly and time consuming 
for analyzing 50 or more patient samples with a minimum of three replicates each.  
 As discovered in Chapter 2, considerable uncertainties accompany the biotin quantitation 
assay (Figure 2-2). Inherent uncertainty resides in the assay because measurements are made 
against a non-zero background. Bound HABA absorbs around 500 nm and as biotinylated 
material replaces the HABA, a decrease in absorbance is observed. Thus, resulting biotin to 
protein ratios are based on a change in absorbance and small changes will always offer large 
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standard deviations, even with numerous experimental repeats. Since we didn’t know what to 
expect for the CKD patient samples in terms of biotin to protein ratios, we can only conclude by 
stating that Label 3 functioned as the most efficient affinity label. Label 3 showed higher 
preference for carbonylated material in the CKD plasma samples, similar to experiments in 
Chapter 2 in which Label 3 showed a higher preference for carbonylated HSA. High biotin to 
protein ratios could also have resulted from reaction of Label 3 with a variety of carbonylated 
species, which would require mass spectrometry for full elucidation. We did not proceed with 
these experiments since we were focused on establishing a quick assay which would give us 
relative quantitation values in a clinical setting.  
 We had hoped that since the FTC assay was validated with carbonylated HSA that we 
would be able to use the assay to establish general carbonylation patterns, but large variations in 
fluorescence intensities across interday experimental and instrumental analyses prevented us 
from doing so. We also questioned the binding stability of the label. Anisotropy experiments 
allowed us to confirm binding between FTC label and protein. As shown in Figure 2-4, FTC 
label bound to protein causes a decrease in rotation of the fluorophore and, upon interaction with 
polarized light, does not disrupt the polarization. Free FTC label would rotate more freely and 
would disrupt the polarized light, leading to emission in the form of depolarized light.  In 
accordance with the literature,
160
 we expected high anisotropy values for non-labeled plasma, 
medium anisotropy values for FTC labeled-proteins, and low anisotropy values for free FTC 
label, and we achieved just that. Non-labeled plasma exhibited an anisotropy around 0.4, CKD 
patient samples exhibited an anisotropy around 0.9-1.2, and free FTC label exhibited an 
anisotropy around 0.026. Due to the mid-range values obtained for the patient samples, we were 
able to infer that the majority of the FTC label was indeed bound to plasma protein. Nonetheless, 
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the high variability in the FTC measurements in plasma made it an unsuitable assay for the 
samples. 
The sensitivities of the various assays also most likely played a role in the experimental 
results. UV-Visible spectroscopy is the fastest technique, but is known for offering less 
sensitivity than other analytical techniques. Thus, it is mainly used for turbidity, concentration, 
and enzymatic activity measurements. One of the oldest techniques in analytical chemistry 
dating back to the 1850s, fluorescence spectroscopy, offers greater sensitivity than UV-Visible 
spectroscopy.
214
 According to the manufacturer, the Varian Cary Eclipse Fluorometer offers 
detection limits of the fluorophore in the picomolar range. In terms of electrophoresis and 
Western blotting, SDS-PAGE techniques combined with coomassie blue staining as detection 
offer visualization of proteins at the low nanogram scale.
215
 In our experiments, the use of the 
OxyBlot Protein Oxidation Detection Kit and ECL reagents also contributed to the sensitivity 
and selectivity of the experiments, hence the varying band intensities and the minimal 
backgrounds, respectively. According to the manufacturer, the OxyBlot kit offers a limit of 
detection of five femtomoles and ECL techniques are known to be 10-100 times more sensitive 
than other luminescence detection methods.
216
 Although UV-Visible and fluorescence 
spectroscopy are not destructive to samples as in Western blotting, there are potential solution 
interferences in the spectroscopic techniques (in Western blotting, excess material is separated 
out).  The lower sensitivity and lack of matrix effects was most likely the cause for success with 
Western blotting. Unfortunately, analyzing 150 samples (a minimum of three repeats per sample) 
with Western blotting would not be time efficient or cheap.  
Pertaining to mass spectrometry experiments, no biotinylated peptides were identified 
during these analyses, most likely because our protocol did not include an enrichment step. 
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Previous experiments in our lab have shown that it is more difficult to detect biotinylated 
material without enriching first. Regardless, varying levels of methionine and histidine oxidation 
were detected, but the reversibility of methionine oxidation was a concern. As can be seen in 
Scheme 4-3, which was recreated from Schöneich’s work, methionine is involved in multiple 
redox processes.
38
 Methionine oxidation can be irreversible depending on the mechanism 
following radical formation, but is most often in a reversible state in which enzymes like MsrA 
and MsrB can reverse the oxidation. Both MsrA and MsrB proteins are expressed in the liver, 
which serves as the main source for blood proteins. MsrA and MsrB activities have been 
detected in neutrophils, a key component in plasma,
217
 which means these enzymes could very 
well have played a role in methionine sulfoxide detoxification in these experiments. Another 
factor in reversibility is the methionine location in the protein; buried methionines would not be 
as accessible as those on the protein surface.
14
 No form of cysteine oxidation (sulfenic, sulfinic, 
or sulfonic acid) was identified, thus reversibility of cysteine oxidation was not considered.  
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Scheme 4-3. Redox processes of methionine (Met). [1] represents a two-electron oxidation with 
subsequent reduction. [2] represents a one-electron oxidation with irreparable damage. Common 
oxidants are pictured in the black box. MetSO = methionine sulfoxide. 
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4.5.2 Other Factors to Consider 
 Protein carbonyls are chemically stable species, especially once reacted with an affinity 
label such as biotin hydrazide. Without a label though, there is a limit to their survival upon 
storage, even at -80 degrees Celsius. While one study claims that protein carbonyls are stable for 
three months upon storage at -80 degrees Celsius,
218
 another study claims that non-labeled 
protein carbonyls can degrade over time due to reaction with lysines on other proteins to form 
Schiff bases. Thus, carbonyl sites must be derivatized immediately.
177
 Ideally, we strived to 
derivatize carbonyls as soon as possible; however, being that we were not present for the CKD 
blood sample collection, we do not have full record of the samples’ history prior to receiving 
them. Our collaborators received the blood, isolated the plasma, analyzed the samples, and then 
froze them while also documenting any samples that were thawed and refrozen. The time from 
which the blood was drawn to the time when the samples were in our collaborators’ possession is 
the gray area – it was unknown how long the samples were in transit and how the samples were 
handled.  
This study ultimately confirmed that the application of proteomics-based analytical 
methods to biological samples has numerous challenges, as discussed in Chapter 2.
96
 These were 
the initial studies in the lab with blood samples and a whole array of new challenges arose in 
regards to biological sample preparation. Limitations included: initial sample handling, sample 
availability, protein solubility, instrumental sensitivity, reproducibility, etc. Time was another 
factor; experiments took anywhere from 2 days for simpler assays to 7-9 days for mass 
spectrometry-based analyses. Finally, the CKD study ended before we were able to work with 
fresh samples and employ more orthogonal techniques to establish the oxidation levels in the 
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samples. However, this work was a useful stepping stone in terms of analytical method 
development relating to blood samples. 
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4.6 CONCLUSION 
 In conclusion, we applied our analytical methods to plasma samples for the first time in 
this study. Disappointingly, no oxidation patterns were apparent in the samples that we had from 
the CKD studies. While the Western blotting results consistently suggested higher oxidation 
levels in the PD patient samples, other means of analysis failed to confirm this. Causes for this 
outcome may include but are not limited to the fact that: methionine oxidation is reversible, 
oxidation can be induced during sample preparation, and/or the CKD samples were over two 
years old. Despite this outcome, this project marked the beginning of blood analyses in which 
existing protocols were adapted to the plasma samples. Although this project was eventually 
terminated, it proved our methods were adaptable to blood samples and could potentially provide 
useful data with a fresh set of biological samples. For a new set of patient samples, our top 
priorities would be incorporating an enrichment step into the biotinylation protocol and acquiring 
quantitative mass spectrometry data through the use of stable isotope labeling. 
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Chapter 5 - APPLICATION: INVESTIGATION OF PROTEIN 
CARBONYLATION IN HUMAN PLASMA/SERUM COLLECTED FROM 
TRAUMA PATIENTS 
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5.1 ABSTRACT 
Trauma-induced oxidative changes and patterns in blood proteins have been investigated 
over the years. Most notably are patterns that have been elucidated amongst the acute phase 
proteins, proteins which are key responders to inflammation. In this study, we investigated 
protein carbonylation in plasma/serum collected from trauma patients over the course of many 
days using our own methods we had optimized. The overall goal was to apply these existing 
analytical methods in order to characterize oxidation levels in patient blood samples, similar to 
our aim in the CKD study. Carbonylated proteins were labeled with biotin hydrazide and a 
portion analyzed via Western blotting. The remaining sample was affinity enriched, digested, 
and then quantitated via iTRAQ labeling and mass spectrometry.  Due to the abundance of 
certain proteins in blood, such as human serum albumin, techniques are necessary to decrease the 
concentration of said proteins in order to observe the potential changes in low abundance 
proteins. Not only were we able to increase the number of modified protein identifications using 
the ProteoMiner depletion techniques, but we were also able to visualize and quantitate temporal 
changes in particular oxidized proteins. The study demonstrated that our methods were 
applicable to this sample set and that the oxidation profiles of a large number of proteins could 
be simultaneously tracked via quantitative mass spectrometry.  
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5.2 INTRODUCTION 
In the United States, trauma is the leading cause of death for Americans aged 1 to 44 
years old and the third ranked cause of death for all ages. Every year, emergency room visits 
total about 41 million, with about 2 million of those resulting in hospital admissions.
219
 This 
leads to trauma-related costs totaling roughly $406 billion.
220
 Each year, about 180,000 deaths 
result from trauma-related injuries, which amounts to about 30% of all deaths in the United 
States followed by cancer at 16% and heart disease at 12%.
219
 Severe trauma or infection often 
result in a condition known as sepsis, which is one of the leading causes of death in intensive 
care units. In the United States, about 700,000 sepsis cases are treated each year.
79
  
Trauma and sepsis patients experience moderate to severe inflammation, which has been 
correlated with oxidative stress in a tremendous number of literature reports throughout the 
years. Cytokines, released in response to inflammation, produce ROS, along with the leukocytes 
that consume oxygen as they travel toward the inflammation site.
221
  Sepsis and subsequent 
organ failure have been linked to mitochondrial damage, in which the release of superoxide, 
nitric oxide, and cytokines/leukocytes can hinder mitochondrial function.
77
 A decrease in 
antioxidant levels has also been observed in the plasma of trauma patients
80
 and in damaged 
mitochondrial systems,
77
 which further complicates the body’s ability to combat oxidative stress. 
With such imbalances between ROS production and antioxidant protection, oxidative stress 
would undeniably be present in such systems.  
Since the mid-1950s, research has been published linking various inflammation-related 
proteins to trauma and injury.
222
 These changes are most often observed by examining blood 
protein concentrations. The fact that large amounts of blood serum and plasma can be easily and 
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rapidly collected, each of which contain equally large amounts of protein (on the mg scale), 
makes blood the most commonly biological fluid used in protein analyses. Blood proteins are 
linked to various tissues throughout the human body and thus, provide real time information 
about a person’s health and/or disease state.9  The blood proteins of most interest in trauma 
patients are called acute phase proteins (APPs). There are two types: positive APPs experience 
concentration increases and negative APPs experience concentration decreases, both by a 
minimum of 25% during trauma-related events. Changes in these proteins have been observed 
not only during trauma, but also during conditions such as: infection, burns, surgery, 
inflammation, and cancer.
223
 These proteins would be of most interest to us in terms of 
investigating carbonylated protein levels in trauma patients. Inflammation, regardless of the 
source, triggers activation of cytokines, most notably the interleukins, which ultimately induce 
hepatic production or reduction of the acute phase proteins. This process is called the acute phase 
response (APR).
223–225
 An overview of the process is illustrated below in Figure 5-1. Examples 
of these particular proteins include, but are not limited to: C-reactive protein, fibrinogen, α1-
antitrypsin, haptoglobin, serum amyloid A, and ceruloplasmin (positive APPs) along with 
transthyretin, albumin, transferrin, and retinol-binding protein (negative APPs).
224,225
 For 
instance, C-reactive protein functions to identify foreign cells, activate the complement system, 
prohibit superoxide generation from neutrophils, etc. These are pro-inflammatory effects and 
justify the protein’s increase in concentration, just as the negative APPs are decreased due to 
their anti-inflammatory effects or simple lack of inflammation-related functions.
223
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Many studies have been published in which blood protein carbonylation has been 
investigated in trauma patient samples. Early studies, such as those performed by Winterbourn et 
al., focused on quantifying total protein carbonyl content via ELISA. For trauma and sepsis 
patients, initial protein carbonyl concentrations were ten times those of carbonyl concentrations 
in normal patients and levels remained elevated in injury patients ten days following the 
traumatic event/diagnosis of sepsis.
57,80
 These results were corroborated by similar experiments 
and outcomes achieved by Abu-Zidan et al.
75
 More recently, researchers have examined blood 
protein levels in patients with burn injuries, which are classified as one of the severest types of 
trauma. These studies incorporated immunoaffinity chromatography and quantitative mass 
spectrometric proteomics techniques and resulted in confirmation of changes in important APP 
Figure 5-1. Illustration depicting the acute phase response. Inflammation leads to cytokine and 
immune cell activation, which contribute to hepatic production of APPs. (Reproduced from work 
by W.B. Saunders in Advanced Neonatal Care (2003).) 
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concentrations along with possible identification of proteins specific to burn injury.
76,78
  Such 
studies show promise for the application of our analytical techniques to trauma patient samples. 
This project was in collaboration with Dr. Dayanjan Shanaka Wijesinghe (VCU Medical 
Center/Department of Biochemistry & Molecular Biology) and Dr. Suresh Narayanasamy, a 
former graduate student in Dr. Gronert’s Research Group (VCU Department of Chemistry). Over 
the course of five months, one set of trauma patient samples and one set of elective surgery 
patients were received through Dr. Wijesinghe. Each set contained 4-10 blood samples per 
patient. Dual studies of the samples were completed: lipidomics by Dr. Wijesinghe and 
proteomics on our end. The first set of samples was subjected to Western blot analysis, affinity-
enrichment techniques, iTRAQ labeling, and subsequent mass spectrometry analysis. The second 
set of samples was also subjected to the same techniques as the first set, but only after low-
abundance protein enrichment in order to equalize protein concentrations. Dr. Narayanasamy and 
I worked together on labeling blood proteins, but then I focused on Western blotting and he on 
iTRAQ labeling/mass spectrometry. The main goal of this project was to apply our analytical 
methods to plasma/serum samples in order to characterize oxidation in these patient blood 
samples. A broader, discovery-based approach was taken being that we were not targeting 
specific proteins and ultimately testing our recently developed analytical methods.  To the best of 
our knowledge, we had not seen a method such as ours published in the literature. Although 
quantitative mass spectrometry had been applied to trauma patients previously,
76
 we were 
unaware of an applicable method combining biotin/avidin affinity enrichment along with 
iTRAQ-based mass spectrometry for these types of samples. Finally, since the method 
development work in Chapters 2 and 3 was occurring concomitantly with this application, the 
methods utilized for this study were not those optimized in that method development work.  
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5.3 EXPERIMENTAL DESIGN 
5.3.1 Materials 
Urea, 10xPBS, water (HPLC), methanol (HPLC), DMSO, DTT, TFA, Tween® 20, 
Brilliant blue, BSA (Fraction V), and Biotinylated BSA were purchased from Fisher Scientific 
(Pittsburgh, PA). (+)-Biotin hydrazide, NaBH3CN, SDS, IAA, and CaCl2 were purchased from 
Sigma-Aldrich (St. Louis, MO). TCA was supplied by Acros Organics (Fair Lawn, NJ). 
Ammonium bicarbonate was obtained from J.T. Baker (Phillipsburg, NJ). The BCA Protein 
Assay, Streptavidin Poly-HRP, and Streptavidin UltraLink Resin were purchased from Thermo 
Scientific (Rockford, IL). Sep-Pak C18 cartridges were purchased from Waters Corporation 
(Milford, MA). Sequencing grade modified trypsin and TMB stabilized substrate were obtained 
from Promega (Madison, WI). The iTRAQ reagent kits were obtained from AB SCIEX 
(Framingham, MA). ProteoMiner low-abundance protein enrichment kits, Mini PROTEAN® 
TGX
TM
 gels, 10x TGS Buffer, 10xTBS, 10x TG Buffer, Laemmli sample buffer, Mini Trans-
Blot filter paper, Immun-Blot PVDF Membranes for Protein Blotting, and Blotting Grade 
Blocker were obtained from Bio-Rad (Hercules, CA). FTC, HCl salt was purchased from Marker 
Gene Technologies, Inc. (Eugene, OR).  
5.3.2 Preparation of Plasma/Serum 
The plasma and serum samples were provided by Dr. Martin Mangino (VCU Medical 
Center/Department of Surgery). We received four samples: trauma Patients W and X in Sample 
Set 1 and elective surgery Patients Y and Z in Sample Set 2. Following the traumatic event, 
blood was collected in 4.5 mL Vacutainer tubes containing 3.2% sodium citrate (Becton 
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Dickinson, Franklin Lakes, NJ) from Patients W and X. For Patient W, blood was collected for 
eight consecutive days (Day 1 – Day 8). For Patient X, blood was collected for six consecutive 
days (Day 0 – Day 5). The tubes were mixed by inversion and then incubated for 30 min at room 
temperature in order to allow the blood to clot. Samples were centrifuged at 1,000-2,000 x g for 
10 min at 4°C. Serum was drawn off and stored in polypropylene tubes at -80°C. Following 
elective surgery, blood was collected in 4.5 mL Vacutainer tubes containing 3.2% sodium citrate 
(Becton Dickinson, Franklin Lakes, NJ) from Patients Y and Z. For Patient Y, blood was 
collected for seven consecutive days (Day 1 – Day 7). For Patient Z, blood was collected for four 
consecutive days (Day 1 – Day 4) and then on Day 7 and Day 11. The blood was not allowed 
time to clot in these cases and samples were immediately centrifuged at 1,000-2,000 x g for 10 
min at 4°C. Plasma was drawn off and stored in polypropylene tubes at -80°C.  
5.3.3 Protein Biotinylation 
Within a week of sample collection, the serum and plasma proteins were biotinylated. 
Serum and plasma samples were thawed on ice for 30 min and then diluted in PBS at a 1:4 ratio. 
Initial protein amounts in each diluted sample ranged from approximately 3-4 mg. Biotin 
hydrazide (Label 1) was prepared in DMSO at 50 mM and added to a final concentration of 5 
mM. The samples were incubated at room temperature for 1 h using an Eppendorf ThermoMixer. 
SDS was added at a final concentration of 1% followed by a second addition of biotin hydrazide 
and sample incubation continued for 1 h. To reduce and stabilize hydrazone bonds formed during 
labeling, NaBH3CN was prepared in PBS at 30 mM and added to a final concentration of 15 
mM. The samples were incubated at room temperature for 1 h. To precipitate the proteins, 100% 
TCA was added at 20% of the total solution. Following a 30-minute slushy ice incubation, 
protein pellets were washed three times with ice cold acetone. The supernatant was removed and 
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the pellets resuspended in PBS and 2.5% SDS at protein concentrations ranging from 2-6 
mg/mL, as determined by the BCA Assay.  
 5.3.4 ProteoMiner Depletion 
Following biotinylation and reduction for patient samples Y and Z, the samples were 
divided into two aliquots: one aliquot was subjected to Western blotting and the second was 
subjected to high abundance protein depletion using the ProteoMiner ligand-based affinity 
columns. Plasma samples were prepared according to the manufacturers’ protocol. The spin 
columns were washed with PBS and then incubated with 1 mg plasma proteins with gentle 
rotation, at room temperature for 2 h. The columns were washed three times with PBS in order to 
remove nonbound material. Bound proteins were eluted with three-20 μL aliquots of elution 
reagent (8M Urea, 2% CHAPS) making for a total of 60 μL per sample. Sample concentrations 
were determined using the BCA Assay. 
5.3.5 Western Blotting 
Directly following biotinylation and reduction, an aliquot of the samples were analyzed 
using Western blotting (these samples were not affinity-depleted). Equal amounts of biotinylated 
protein (10 µg) were incubated with 50% Laemmli buffer and 5% 2-mercaptoethanol for 5 min 
at 95°C. The samples, along with a protein standard ladder, were loaded onto a 4-20% gradient 
polyacrylamide SDS-PAGE gel and run in TGS buffer at 100 V and 90 mA for 1 h and 30 min. 
Proteins were then transferred to a PVDF membrane and run in TG buffer at 100 V and 300 mA 
for 1 h and 15 min. Following immunoblot, the membrane was blocked with 5% non-fat dry milk 
in 1X TBS-T for 1 h and then incubated with Streptavidin Poly-HRP at a 1:5000 dilution in 5% 
BSA and TBS-T overnight at 4°C. The membrane was washed with TBS-T and incubated with 
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TMB substrate for 5 min for visualization of protein bands. For patient samples Y and Z, 
Western Blotting was performed prior to ProteoMiner depletion.   
5.3.6 Affinity Enrichment and Tryptic Digestion 
 Streptavidin UltraLink resin (200 μL/sample) was washed three times with PBS. 
Biotinylated/reduced serum and ProteoMiner depleted plasma samples were added to the resin 
(200 μg/sample) and incubated with gentle rotation, at room temperature overnight. The resin 
was first washed three times with PBS in order to remove nonbound protein and then washed 
twice with 8 M urea and 10 mM DTT in PBS. Proteins were then incubated with 8 M urea and 
10 mM in DTT in PBS for 1 h at 500 rpm, 37°C in order to promote denaturation and reduction. 
To alkylate reduced cysteines, IAA was added to 55 mM final concentration and incubation 
continued for 1 h at 500 rpm, 37°C, in the dark. Following was a second addition of DTT in 
order to saturate unreacted IAA during a 1 h, 500 rpm, 37°C incubation. The resin was washed 
four times with 50 mM aqueous ammonium bicarbonate in order to remove reagents. Digestion 
commenced through the addition of calcium chloride to a final concentration of 1 mM and 
trypsin at a 1:50 trypsin:protein ratio and continued for 16 h at 500 rpm, 37°C. The beads were 
washed four times with 95/5 0.1% TFA/ACN and washes were pooled together in order to retain 
as many peptides as possible. The peptide samples were desalted by passing samples through 
C18, reversed-phase SPE cartridges and dried using Speed Vac concentration.  
5.3.7 iTRAQ Labeling 
 Peptides were dissolved in 20 μL iTRAQ dissolution buffer (0.5 M triethylammonium 
bicarbonate, pH 8.5). iTRAQ 8-plex reagents were used to label peptides. The labels were 
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dissolved in 80 μL of isopropyl alcohol, added to peptide solutions, and incubated at 300 rpm, 
room temperature, for two h. All respective samples were combined for each patient and dried 
using Speed Vac concentration. Each peptide sample was resuspended in 20 μL of 0.1% aqueous 
formic acid.  
5.3.8 Mass Spectrometry 
 Peptide solutions were analyzed using LC-MS/MS on a Thermo (Waltham, MA) LTQ 
Orbitrap Velos mass spectrometer with a Waters nanoACQUITY UPLC system. Total sample 
injection volumes were 2 µL. Loading times were minimized using a nanoACQUITY trapping 
column. Peptides were separated on a C-18, reverse-phase nanoACQUITY column (100 µm × 
100 mm, 1.7 µm particles). Gradient elution from the column was accomplished using two 
mobile phases: A (0.1% formic acid in water) and B (0.1% formic acid in acetonitrile) at a flow 
rate set to 0.4 μL/min. For each 120 minute run, the gradient began with 1% B, rose to 15% B 
within 25 min, 25% B within 35 min, 35% B within 40 min, and ended with 85% B within 20 
min. Peptides were ionized using a nanospray source at 3.5 kV. Precursor ions were obtained via 
a full scan in the range of 400-2000 m/z at 60,000 resolution. A ten-event data-dependent scan 
procedure was used for the MS/MS analysis, in which higher energy C-trap dissociation (HCD) 
was used to fragment iTRAQ-labeled ions at a collision energy of 40 and activation time of 0.1 
ms. Analysis was completed in the positive ion mode with active dynamic exclusion, in which a 
precursor ion was excluded from the analysis for 180 seconds if it was selected for further 
fragmentation twice within 30 seconds.  
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5.3.9 Database Searches and Analysis 
 Peptide identifications were made using an X! Tandem variation in the Trans-Proteomic 
Pipeline (TPP) software (Version 4.6.3; Institute for Systems Biology in Seattle, Washington). 
Searches were performed against an NCBI RefSeq database for Homo sapiens, which was 
obtained on January 15, 2013 and contained 71,806 entries.  Database sequences were also 
reversed to enable decoy searches and false discovery rate approximations.
154
 No more than one 
missed cleavage site was allowed. Fixed modifications were set for carbamidomethylation 
(alkylated cysteines with mass shifts of +57.021464 Da) and 8-plex iTRAQ label additions on 
lysine and peptide N-terminus (+304.205360 Da). A differential modification was set for 
methionine sulfoxide (+15.994915 Da). In order to validate peptide-matched MS/MS spectra 
suggested by X! Tandem, PeptideProphet was used and only peptides with a minimum peptide-
spectrum matches (PSMs) score of 0.9 were accepted.
209
 The false positive rates (FPs) were 
approximated by calculating: 2 x accepted decoy identifications.
226
 Quantitative mass 
spectrometry data was prepared in the following manner to make it presentable via histogram 
plots. The data was corrected via trypsin ratios and normalized to the first day for each sample 
(i.e. 0 or 1). Data was then averaged and displayed on histograms, with standard deviations 
representing errors between the three injections for each sample. For each patient sample, the ten 
proteins that exhibited the most distinct changes in carbonylation across the collection days were 
reported.   
5.3.10 FTC Assay 
The following procedure was adapted from the methods of Mohanty et al.
155
 Standards 
were prepared according to the protocol in section 2.3.10.1. Trauma patient serum, which was 
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stored at -80°C, was thawed and diluted in PBS. Protein concentration was determined using the 
BCA Assay according to the manufacturers’ protocol (10-13 mg/mL). The serum was further 
diluted to create 10 mg/mL solutions and incubated with 304 µM FTC (10:1 FTC:HSA) 
overnight at room temperature with gentle rotation. Proteins were then isolated via TCA 
precipitation and reconstituted in 450 µL 3M GuHCl in PBS. Fluorescence measurements were 
made using a Varian Cary Eclipse Fluorescence Spectrophotometer. The instrument was zeroed 
with PBS and sample measurements were made one at a time with an excitation wavelength of 
492 nm and an emission wavelength of 550 nm. The slit widths were 5 nm and measurements 
were made at medium scan speed.   
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5.4 RESULTS 
5.4.1 Western Blotting: Patients W, X, Y, and Z 
 For these experiments, we again took advantage of the strong noncovalent interaction 
between biotin and avidin.
156
 Being that our serum and plasma proteins were labeled with biotin 
hydrazide, streptavidin poly-HRP was used to detect these modified proteins and TMB substrate 
was used for visualization. For trauma patients W and X, we analyzed 8 and 6 serum samples, 
respectively via Western blotting. This provided us with a visual estimation of protein oxidation 
in the patients over the course of 8 or 6 consecutive days following the traumatic event and can 
be seen below in Figure 5-2. Most notable in these two analyses would be Lanes 2 and 5 for 
Patient W and Lane 0 for Patient X, which show many intense bands across the entire lane. It is 
unclear why these samples behaved differently than the others and this may have been an artifact 
of the sample collection procedure. For patients Y and Z, we analyzed 7 and 6 plasma samples, 
respectively via Western blotting. Results are below in Figure 5-3. Patient Y samples were 
collected over 7 consecutive days, but Patient Z samples were only collected over 4 consecutive 
days with the last two samples being collected a couple days apart from one another. Some 
variations in band intensities across the time points can be seen in these analyses, but they 
weren’t as pronounced as those in Figure 5-2. For all four patients, samples were analyzed twice 
via Western Blotting, with the two blots correlating for each patient (only one blot/patient is 
pictured below in Figures 5-2 and 5-3). This confirmed Western blot technique reproducibility. 
A second set of Patient X samples were labeled and analyzed via Western Blotting. These results 
also correlated with those from the initial labeling experiment, confirming reproducibility of 
biotinylation.  
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Figure 5-2. Western blot analyses of trauma patient 
samples W and X. Std. represents a protein standard ladder 
with corresponding molecular weights in red. The lane 
numbers represent the days following the traumatic injury. 
 
 
143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3. Western blot analyses of trauma patient samples Y 
and Z. Std. represents a protein standard ladder with 
corresponding molecular weights in red. The lane numbers 
represent the days following the traumatic injury. 
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5.4.2 FTC Assay: Patient X  
 As described in Chapter 2, the FTC assay was validated using carbonylated HSA spiked 
into regular HSA and plasma. The assay was applied to CKD patient samples in Chapter 4, but 
results varied. This left us unsure of the assay’s capabilities. Upon receiving the trauma samples, 
we took this as second opportunity to test our assay. Patients W and X showed the most 
interesting oxidation trends based on Western blotting results, but due to limited serum for 
Patient W, we could only apply replicates of our FTC assay to serum from Patient X. 
Carbonylated proteins in all six serum samples for Patient X were labeled with FTC and 
analyzed with fluorescence spectroscopy three times, each on a different day. The emission 
spectra from each of these three analyses are depicted in Figure 5-4. The patient samples from 
Day 0 demonstrated the highest carbonylation levels in all three analyses, albeit varying 
fluorescence intensities across the three analysis days. The relative values for other collection 
days showed greater variability.  
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Figure 5-4. Emission spectra from triplicate FTC assay analyses of 
Patient X. 
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5.4 iTRAQ Quantitation: Patients W and X  
 When performing a discovery-based proteomics experiment, a researcher not only desires 
to determine what is present, but also how much is present, with the latter always proving to be 
the most difficult to accomplish.
227
 Quantitative mass spectrometry dates back to the early 1980s 
in which internal standards were used as a means of quantitation.
228
 The use of chemical labels in 
quantitative proteomics was first demonstrated by Gygi et al. in 1999.
132
 Five years later, 
isobaric tags for relative and absolute quantitation (iTRAQ) were introduced by Ross et al.
229
  In 
this technique, peptides are reacted with the moiety pictured in Figure 5-5A.
229
 The reporter 
group is composed of N-methylpiperazine, which contains various nitrogen isotopes that exhibit 
different low mass reporter ions in fragmentation spectra. The intensities of these ions are used to 
quantitate peptides and proteins in a given sample. The carbonyl is a mass balance group that is 
neutral during fragmentation. The N-Hydroxysuccinimide (NHS) ester is protein reactive and 
forms an amide upon reaction with N-termini or lysines, which is demonstrated in Figure 5-
5B.
136,229,230
  Figure 5 was recreated from the work by Ross and coworkers.  
  
 
 
 
 
 
Figure 5-5. A. Components of an iTRAQ label. B. Product following reaction between iTRAQ 
label and a peptide (indicated by amide bond). Below the product are the various isotopic 
components for each different label. 
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Prior to Orbitrap analysis, all samples for each respective patient were combined to create 
two total samples, one for Patient W and one for Patient X. Data was collected for three 
injections for each sample. With a minimum PSM score of 0.9, 832 PSMs were identified for 
Patient W. With two of those being identified as decoy proteins, this suggests a FP of 0.5% for 
Patient W. This is based on the theory by Elias and Gygi in which it is assumed that false 
positive identifications will occur in targeted matches as often they will in decoy matches, and 
thus the amount of decoy matches is doubled, divided by the total PSMs, and multiplied by 
two.
226,231
 Upon rejection of the decoy matches, 23 carbonylated proteins were identified for 
Patient W. Again, with a minimum score of 0.9, 2244 PSMs were identified for Patient X. Three 
of those were identified as decoy proteins, which implies a FP of 0.3% for Patient X.
231
 Upon 
rejection of the decoy matches, 37 carbonylated proteins were identified for Patient X. Figures 
5-6 and 5-7
231
 display the changes in selected carbonylated proteins over the various time points 
for both Patient W and X, respectively. The entire data sets are located in Appendix 3, Tables 
A6 and A7. All figures were reprinted with permission from Dr. Narayanasamy. 
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Figure 5-6. Carbonylated protein levels for ten proteins that exhibited the most change over the 
course of eight days for Patient W. All data was normalized to Day 1. 
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Figure 5-7. Carbonylated protein levels for ten proteins that exhibited the most change over the 
course of six days for Patient X. All data was normalized to Day 0. 
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5.4.4 ProteoMiner Depletion and iTRAQ Quantitation: Patients Y and Z  
Blood is a prime matrix for proteomics work. It is one of the most abundant and 
attainable biological fluids in the human body. And in terms of proteomics, there are about 7500 
identifiable proteins in human plasma (Human Plasma Proteome Project).
232
 While this provides 
an array of opportunities for discovery proteomics, the fact that about 50 proteins dominate 99% 
of the entire proteomic composition of plasma complicates detection techniques. Various 
techniques have been used to equalize protein concentrations such as: precipitation methods, 
fractionation (HPLC), 2-D gel electrophoresis, or immunoaffinity devices.
233,234
  However, a new 
technique has been developed within the last ten years that utilizes specificity between ligands 
and proteins. The ligands are developed based on solid-phase peptide synthesis methods 
pioneered by Merrifield.
235
  Generating a library of hexapeptides from the twenty natural amino 
acids results in nearly 64 million ligands, which is generally enough for reaction with most 
proteins present in a biological sample. The ligands are synthesized onto beads (one ligand per 
bead). When a mixture of proteins is added, the high concentration proteins rapidly saturate their 
respective ligands and excess are washed away. Meanwhile, the low concentration proteins bind 
entirely with their respective ligands, with no excess to be washed away. In this sense, high 
concentration proteins are depleted and low concentration proteins are enriched to decrease the 
dynamic range of all protein concentrations.
233,234
 A schematic of the process can be seen below 
in Figure 5-8.  
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Prior to Orbitrap analysis, all samples for each respective patient were combined to create 
two total samples, one for Patient Y and one for Patient Z. Data was collected for three injections 
for each sample. With a minimum PSM score of 0.9, 4051 PSMs were identified for Patient Y 
with a false positive rate of 0.1%. Upon rejection of the decoy matches, 59 carbonylated proteins 
were identified for Patient Y. Again, with a minimum score of 0.9, 3443 PSMs were identified 
for Patient Z with a false positive rate of 0.2%. Upon rejection of the decoy matches, 47 
carbonylated proteins were identified for Patient Z. Figures 5-9 and 5-10
231
 show carbonylation 
levels for selected proteins over the various time points for both  Patient Y and Z, respectively. 
The entire data sets are located in Appendix 3, Tables A8 and A9. All figures were reprinted 
with permission from Dr. Narayanasamy. 
 
Figure 5-8. ProteoMiner concept depicting equalization of proteins. (Redrawn from a poster 
titled “Enriching Low-Abundance Proteins Using ProteoMiner™ Protein Enrichment 
Technology,” by S. Freeby et al.) 
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Figure 5-9. Carbonylated protein levels for ten proteins that exhibited the most change over the 
course of four days for Patient Y. All data was normalized to Day 1. 
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Figure 5-10. Carbonylated protein levels for ten proteins that exhibited the most change over 
the course of four days for Patient Z. All data was normalized to Day 1. 
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5.5 Discussion 
5.5.1 Western Blotting 
Unusual carbonylation patterns were visualized in Western blots for Patients W and X. 
Protein oxidation appeared to increase, then decrease, and repeat across the timepoints for 
Patient W; whereas, for Patient X, protein oxidation was initially very high, decreased, and then 
slowly increased over the course of four days. Three of the lanes in these Western blots 
suggested intense carbonylation across a wide range of proteins – lanes 2 and 5 for Patient W 
and lane 0 for Patient X. However, quantitative mass spectrometry results did not correlate with 
these patterns. Thus, we attributed these results to artifacts of initial sample processing and 
instead, focused our attention on changes to particular bands, such as the fluctuating intensity of 
the HSA band around 60 kDa. Due to the fact that we were not present for the initial sample 
collection and handling, we believe that oxidation could have been induced by exposure to air 
and/or long delays before freezing. On the other hand, carbonylation patterns were 
indistinguishable in Western blots for Patients Y and Z – only minimal variations in band 
intensities were observed. Patients Y and Z were elective surgery patients, thus, samples were 
collected under a better controlled environment and outcomes were more predictable for these 
patients.  
5.5.2 FTC Assay: Patient X 
 The carbonylation trends exhibited in the emission spectra roughly correlated with one 
another across the three days, with Day 0 showing the highest intensity and Day 1 showing low 
intensity. However, fluorescence intensity ranges fluctuated across the three analyses with 
 
 
155 
 
unusually high intensities in the third analysis. This is similar to the issues that arose in the CKD 
samples. While differences in protein carbonylation in the samples could be distinguished, 
resulting fluorescence intensities were not as consistent across multiple analyses as we had 
hoped. This variability could be a result of excess fluorescent label remaining in the samples 
during analysis. Unreacted tagging reagents, particularly fluorescent labels, can be difficult to 
completely remove from solution.
93
 Due to limited sample, more experimental repeats could not 
be performed. Initial validation experiments with HSA produced expected results; however, the 
assay has performed poorly in our studies with biological samples. 
5.5.3 iTRAQ: Patients W and X 
 Temporal protein carbonylation trends were observed for a handful of APPs, which 
correlated with results from many previously published studies involving the analysis of trauma 
patient blood with mass spectrometry techniques.
76,78,79
 In Patient W, we observed general 
carbonylation increases in alpha-1-antitrypsin and complement C3 proteins (positive APPs) and 
a decrease in serum albumin protein (negative APP). Interestingly, significant drops in 
fibrinogen carbonylation levels were observed for all three fibrinogen chains (alpha, beta, and 
gamma) on Days 2 and 5. In contrast, samples from these two days exhibited the highest 
carbonylation levels via Western blotting (Figure 5-2). These observations further our claim that 
results for these two days were artifacts of sample handling. Finally, fibrinogen is an interesting 
protein to study in trauma patients since it is involved in the clotting process;
10
 however, we 
cannot draw conclusions concerning this particular protein for multiple reasons. First, serum is 
clotted and this would affect overall fibrinogen concentrations. Second, we did not measure 
overall protein concentrations – only carbonylation levels. This creates ambiguity as to whether 
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increasing carbonylation levels are a result of increasing protein concentrations or more protein 
is actually being carbonylated.  
 In Patient X, we observed strong carbonylation increases in many of the positive APPs 
such as: alpha, beta, and gamma fibrinogen chains, alpha-1-antichymotrypsin, alpha-1-
antitrypsin, haptoglobin, alpha-2-macroglobulin, and ceruloplasmin. As can be seen in Figures 
5-6 and 5-7, the carbonylated protein abundances for Patient X were nearly 5 fold higher than 
those for Patient W in some instances, which could be explained by the fact that Patient X had a 
complicated recovery period and did not survive. Day 0 data did not correlate between Western 
blotting and mass spectrometry experiments because the mass spectrometry data was normalized 
to Day 0. We did not give as much concern to Day 0 anyways since the Western blotting results 
for this day were attributed to artifacts of sample handling.  
5.5.4 ProteoMiner and iTRAQ: Patients Y and Z 
 Again, we observed temporal carbonylation trends in APPs, particularly serum amyloid 
and C-reactive proteins. Both are positive APPs and the carbonylation levels increased for these 
proteins in each patient sample, as expected. Interestingly, these two proteins have been reported 
to exhibit the most rapid change during inflammation, generally increasing anywhere between 5-
fold and 1000-fold.
225
 Increases in these two proteins were more pronounced for Patient Z, 
suggesting a more difficult recovery period. This is merely postulation though being that we 
were not privy to details concerning the patients’ conditions or recoveries. Moderate oxidation 
changes were observed in this set of patients versus the first possibly due to the fact that Patients 
Y and Z were elective surgery patients rather than trauma patients, in which the injuries were 
less predictable. However, the ProteoMiner depletion was effective and led to a greater number 
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of protein quantifications. Nearly twice as many carbonylated proteins were identified in Patients 
Y and Z plasma versus Patients W and X serum. This implies that lower abundance proteins are 
being carbonylated in inflammation-associated samples, but we are limited by our detection 
capabilities in terms of identifying these particular proteins. Despite this limitation, we 
confirmed that techniques such as ProteoMiner depletion offer an opportunity to detect and 
investigate some of these lower abundance species. Investigating carbonylation in these lower 
abundance species might lead us to identifying a more prominent marker of inflammation.   
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5.6 Conclusion 
 Upon successfully applying some of our analytical methods to trauma patient samples, 
we were able to visualize and quantitate temporal protein carbonylation patterns. Western 
blotting results illustrated interesting carbonylation changes over time and quantitative mass 
spectrometry confirmed these results, along with identifying carbonylation changes in important 
inflammation-associated proteins. ProteoMiner experiments proved successful in that we were 
able to identify a larger and more diverse amount of carbonylated proteins via mass 
spectrometry. These analytical protocols were not only unique to this field of study, but also hold 
promise for application to future blood samples. We anticipate receiving a larger sample set and 
continuing our applications in the hopes of confirming the utility of our methods and working 
toward protein carbonylation biomarker identification. With more samples, we also hope to 
incorporate Chapter 3 methods involving the cleavable biotin affinity tag and streptavidin bead 
enrichment into our workflow as an alternative novel method application. The ultimate goal for 
this study is the development of therapeutic interventions which would one day assist in 
emergency room preventative care.       
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APPENDICES 
Appendix 1 
Table A1 
The table below depicts elution profiles for the monomeric avidin columns. Two commercially 
purchased biotinylated proteins were used: HRP and BSA, reported to have 1 and 9 
biotin/protein, respectively. Both were dissolved in 500 µL PBS giving BSA a concentration of 2 
mg/mL and HRP a concentration of 1 mg/mL. Samples were enriched following the procedure 
detailed in Section 2.3.7. Six two-mL aliquots were collected for both nonbound proteins (NB) 
and bound proteins (B). Protein concentrations in the first four NB fractions and all six B 
fractions were determined with the BCA assay. No bound protein was eluted for HRP, but 73% 
of biotinylated BSA was recovered. Total protein recovery (in NB fractions) for HRP was 40%.  
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Appendix 2 
Table A2 
The table below depicts the number of modifications for each particular peptide in the first 
analysis of the 0, 25, 50, and 75% spike samples. Nonbound samples produced no modified 
peptides. 
TRIAL 1 
    SAMPLE NAME 
RESIDUE MODIFIED PEPTIDE 0%  25%  50%  75%  
Cleaved and Alkylated:         
C-34 
ALVLIAFAQYLQQC494.19PFEDHVK  (+2) 
 
2 7 5 
 ALVLIAFAQYLQQC494.19PFEDHVK  (+3) 
    H-67 SLH528.24TLFGDK (+2) 
   
5 
H-128 LVRPEVDVMCTAFH528.24DNEETFLKK (+3) 
 
2 
 
5 
H-146 
H528.24PYFYAPELLFFAK (+2) 
  
2 5 
H528.24PYFYAPELLFFAK (+3) 
 
2 3 5 
RH528.24PYFYAPELLFFAK (+2) 
 
10 20 30 
RH528.24PYFYAPELLFFAK (+3) 
 
14 25 45 
H-242 VH528.24TECCHGDLLECADDR (+3) 
   
1 
H-288 SH528.24CIAEVENDEMPADLPSLAADFVESK (+3) 
 
12 12 21 
H-367 CCAAADPH528.24ECYAK (+2) 
 
16 19 28 
K-51 LVNEVTEFAK519.27TCVADESAENCDK (+3) 
   
4 
K-162 
YK519.27AAFTECCQAADK  (+2) 
 
2 1 5 
YK519.27AAFTECCQAADK  (+3) 8 8 10 13 
K-262 ADLAK519.27YICENQDSISSK (+3) 
   
2 
K-359 TYETTLEK519.27CCAAADPHECYAK (+3) 
 
5 5 10 
K-378 VFDEFK519.27PLVEEPQNLIK  (+3) 
 
2 
 
7 
K-414 K519.27VPQVSTPTLVEVSR  (+3) 
   
3 
K-545 
EQLK519.27AVMDDFAAFVEK (+2) 
   
2 
EQLK519.27AVMDDFAAFVEK (+3) 
 
1 3 6 
Cleaved and Reduced:         
C-289  SHC437.16IAEVENDEMPADLPSLAADFVESK (+3) 
   
1 
H-288 SH471.21CIAEVENDEMPADLPSLAADFVESK (+3) 
   
1 
 
TOTAL SPECTRA 4791 6170 5965 5137 
 
TOTAL HSA SPECTRA 4738 6127 5927 5116 
 
TOTAL MODIFIED SPECTRA 8 76 107 204 
 
% MODIFIED 0.17 1.24 1.81 3.99 
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Table A3 
The table below depicts the number of modifications for each particular peptide in the second 
analysis of the 0, 25, 50, and 75% spike samples. Nonbound samples produced no modified 
peptides. 
TRIAL 2 
    SAMPLE NAME 
RESIDUE MODIFIED PEPTIDE 0% 25% 50% 75% 
Cleaved and Alkylated:         
C-34 
ALVLIAFAQYLQQC494.19PFEDHVK  (+2) 
  
7 5 
 ALVLIAFAQYLQQC494.19PFEDHVK  (+3) 
 
3 13 5 
H-67 SLH528.24TLFGDK (+2) 
   
3 
H-146 
H528.24PYFYAPELLFFAK (+2) 
   
3 
H528.24PYFYAPELLFFAK (+3) 
  
2 2 
RH528.24PYFYAPELLFFAK (+2) 
 
11 12 30 
RH528.24PYFYAPELLFFAK (+3) 
 
22 26 58 
H-288 SH528.24CIAEVENDEMPADLPSLAADFVESK (+3) 
 
24 19 34 
H-367 CCAAADPH528.24ECYAK (+2) 
 
19 18 27 
K-51 LVNEVTEFAK519.27TCVADESAENCDK (+3) 
   
4 
K-162 
YK519.27AAFTECCQAADK  (+2) 
   
1 
YK519.27AAFTECCQAADK  (+3) 
 
4 6 8 
K-262 ADLAK519.27YICENQDSISSK (+3) 
   
3 
K-359 TYETTLEK519.27CCAAADPHECYAK (+3) 
 
1 
 
5 
K-378 VFDEFK519.27PLVEEPQNLIK  (+3) 
 
8 7 18 
K-545 
EQLK519.27AVMDDFAAFVEK (+2) 
    EQLK519.27AVMDDFAAFVEK (+3) 
 
1 2 5 
Cleaved and Reduced:         
C-289  SHC437.16IAEVENDEMPADLPSLAADFVESK (+3) 
 
2 
 
4 
H-288 SH471.21CIAEVENDEMPADLPSLAADFVESK (+3) 
   
2 
 
TOTAL SPECTRA 4053 7110 6041 9015 
 
TOTAL HSA SPECTRA 3996 7076 6006 8981 
 
TOTAL MODIFIED SPECTRA 0 95 112 217 
 
% MODIFIED 0.00 1.34 1.86 2.42 
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Table A4 
The table below depicts the number of modifications for each particular peptide in the third 
analysis of the 0, 25, 50, and 75% spike samples. Nonbound samples produced no modified 
peptides. 
TRIAL 3 
    SAMPLE NAME 
RESIDUE MODIFIED PEPTIDE 0% 25% 50% 75% 
Cleaved and Alkylated:         
C-34 
ALVLIAFAQYLQQC494.19PFEDHVK  (+2) 
 
3 3 10 
 ALVLIAFAQYLQQC494.19PFEDHVK  (+3) 
   
11 
H-67 SLH528.24TLFGDKLCTVATLR (+3) 
  
1 2 
H-128 LVRPEVDVMCTAFH528.24DNEETFLKK (+3) 
   
1 
H-146 
H528.24PYFYAPELLFFAK (+2) 
  
4 6 
H528.24PYFYAPELLFFAK (+3) 
   
3 
RH528.24PYFYAPELLFFAK (+2) 
 
12 19 43 
RH528.24PYFYAPELLFFAK (+3) 
 
12 22 54 
H-288 SH528.24CIAEVENDEMPADLPSLAADFVESK (+3) 
 
10 19 26 
H-367 CCAAADPH528.24ECYAK (+2) 
 
11 16 25 
K-162 
YK519.27AAFTECCQAADK  (+2) 
   
1 
YK519.27AAFTECCQAADK  (+3) 1 4 6 1 
K-359 TYETTLEK519.27CCAAADPHECYAK (+3) 
   
3 
K-378 VFDEFK519.27PLVEEPQNLIK  (+3) 
  
4 5 
K-545 
EQLK519.27AVMDDFAAFVEK (+2) 
    EQLK519.27AVMDDFAAFVEK (+3) 
  
1 3 
Cleaved and Reduced:         
C-289  SHC437.16IAEVENDEMPADLPSLAADFVESK (+3) 
    H-288 SH471.21CIAEVENDEMPADLPSLAADFVESK (+3) 
    
 
TOTAL SPECTRA 6868 5154 6140 6642 
 
TOTAL HSA SPECTRA 6824 5101 6111 6614 
 
TOTAL MODIFIED SPECTRA 1 52 95 194 
 
% MODIFIED 0.01 1.02 1.55 2.93 
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Table A5 
The table below depicts the number of modifications for each particular peptide in all four 
analyses of the 10% spike sample.  
 
 
 
 
 
 
    Trial/Sample Name 
    Trial 1 Trial 2 Trial 3 Trial 4 
RESIDUE MODIFIED PEPTIDE (CHARGE) 
10% 
LABELED 
10% 
NB 
10% 
LABELED 
10% 
NB 
10% 
LABELED 
10% 
NB 
10% 
LABELED 
10% 
NB 
Cleaved and Alkylated:                 
C-34 
ALVLIAFAQYLQQC494.19PFEDHVK  (+2)   
1 
 
2 
   
 ALVLIAFAQYLQQC494.19PFEDHVK  (+3)       
2 
 
H-146 
H528.24PYFYAPELLFFAK (+2)   
1 
     
H528.24PYFYAPELLFFAK (+3)   
1 
     
RH528.24PYFYAPELLFFAK (+2) 5  
14 
 
12 
   
RH528.24PYFYAPELLFFAK (+3)   
36 
 
23 
   
H-288 SH528.24CIAEVENDEMPADLPSLAADFVESK (+3) 5  
18 
 
18 
 
2 
 
H-367 CCAAADPH528.24ECYAK (+2) 2  
25 
 
23 
   
K-51 LVNEVTEFAK519.27TCVADESAENCDK (+3)   
1 
 
3 
   
K-162 
YK519.27AAFTECCQAADK  (+2)         
YK519.27AAFTECCQAADK  (+3) 1  
7 
 
9 
  
1 
K-359 TYETTLEK519.27CCAAADPHECYAK (+3)   
2 
     
K-378 VFDEFK519.27PLVEEPQNLIK  (+3)   
10 
 
7 
   
K-545 
EQLK519.27AVMDDFAAFVEK (+2)         
EQLK519.27AVMDDFAAFVEK (+3)   
3 
 
2 
   
Cleaved and Reduced:                 
C-289 
 SHC437.16IAEVENDEMPADLPSLAADFVESK 
(+3)   
 
     
H-288 
SH471.21CIAEVENDEMPADLPSLAADFVESK 
(+3)   
 
     
 
TOTAL SPECTRA 4220 3330 6406 2851 4929 4367 6696 6714 
 
TOTAL HSA SPECTRA 4191 3317 6377 2664 4886 4329 6640 6658 
TOTAL SPECTRA FOR MODIFIED PEPTIDES 13 0 119 0 99 0 4 1 
% MODIFIED PEPTIDES 0.31 0.00 1.87 0.00 2.03 0.00 0.06 0.02 
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Appendix 3 
Table A6 
The following are changes in carbonylation protein relative abundances in blood serum samples 
that were collected from Patient W over the course of eight days. The changes were not 
normalized to Day 1. No PeptideProphet scores below 0.9 were accepted. The proteins were 
grouped using ProteinProphet; however, the alpha-2-macroglobulin and pregnancy zone protein 
group did not contain related proteins like the other groups. The relative abundances were 
calculated by dividing the reporter ion intensity by the total intensity for the eight reporter ions 
for each PSM and then averaging all PSMs composing the various protein groups.  
Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM 
Count  
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6  Day 7 Day 8 
Streptavidin 
not 
available 
940 21.3% 14.6% 9.5% 9.9% 13.6% 10.3% 10.1% 10.7% 
Serum albumin ALB 461 21.5% 20.5% 8.9% 12.0% 12.2% 9.6% 7.5% 7.8% 
Trypsin (Pig) 
not 
available 
84 15.8% 14.5% 8.0% 13.0% 13.3% 12.4% 11.2% 11.8% 
Ig gamma chain 
C region 
IGHG 61 18.7% 16.6% 6.6% 9.0% 12.9% 11.9% 11.2% 13.0% 
Fibrinogen 
alpha chain 
FGA 57 12.4% 4.2% 12.6% 20.8% 3.3% 20.6% 12.8% 13.4% 
Complement 
C3 
C3 33 12.9% 13.0% 7.4% 9.0% 14.9% 17.6% 12.1% 13.1% 
Alpha-1-
antitrypsin 
SERPINA1 31 7.7% 11.7% 8.7% 13.5% 18.5% 15.1% 12.0% 12.8% 
Ig kappa chain 
C region 
IGKC 28 18.4% 12.8% 9.0% 11.0% 13.0% 11.3% 11.3% 13.2% 
Decoy 
not 
available 
16 10.7% 8.6% 9.9% 15.1% 16.9% 11.3% 13.2% 14.4% 
Vitronectin VTN 12 14.5% 15.8% 9.9% 12.5% 16.4% 13.1% 8.2% 9.6% 
Fibrinogen beta 
chain 
FGB 11 10.6% 3.1% 13.8% 21.4% 3.0% 21.1% 13.6% 13.5% 
Complement 
C4-A & B 
C4A & 
C4B 
10 16.0% 12.0% 9.7% 13.0% 17.2% 11.0% 9.4% 11.6% 
Ig alpha chain 
C region 
IGHA 10 13.9% 14.6% 9.8% 9.5% 12.6% 13.1% 12.6% 13.9% 
Fibrinogen 
gamma chain 
FGG 7 19.9% 8.8% 10.3% 14.2% 9.0% 14.0% 11.4% 12.5% 
Serotransferrin TF 6 30.0% 26.1% 5.5% 7.6% 8.1% 7.7% 7.6% 7.3% 
Hemoglobin 
subunit beta 
HBB 5 18.4% 26.7% 5.6% 14.1% 7.7% 13.1% 6.3% 8.1% 
Keratin, type II 
cytoskeletal 1 
KRT1 4 22.5% 16.7% 6.7% 9.5% 12.4% 10.6% 8.3% 13.4% 
Trypsin-1 & 2 
PRSS1 & 
PRSS2 
4 19.2% 17.2% 7.9% 11.3% 11.3% 11.5% 10.0% 11.7% 
Alpha-2-
macroglobulin 
& Pregnancy 
zone protein 
A2M & 
PZP 
2 15.9% 14.2% 9.3% 10.9% 11.8% 15.1% 10.4% 12.4% 
Apolipoprotein 
A-I 
APOA1 2 24.6% 17.6% 8.3% 11.0% 9.2% 11.8% 7.6% 9.8% 
 
 
184 
 
Hemoglobin 
subunit alpha 
HBA 2 19.3% 27.0% 3.9% 17.3% 6.5% 12.5% 5.9% 7.6% 
Keratin, type I 
cytoskeletal (9, 
10, 12, 14-17, 
19) 
KRT9, 10, 
12, 14-17, 
19 
2 21.9% 14.5% 7.4% 10.2% 13.1% 11.8% 8.3% 12.6% 
Apolipoprotein 
B-100 
APOB 1 13.4% 6.5% 6.7% 13.1% 17.3% 14.7% 14.3% 13.9% 
Decoy 
not 
available 
1 16.7% 10.0% 7.9% 10.5% 9.8% 8.2% 17.1% 19.8% 
Protein 
FAM98B 
FAM98B 1 11.9% 16.9% 9.5% 11.3% 20.4% 8.5% 10.6% 10.9% 
Serum amyloid 
A-1 & 2 protein 
SAA1 & 
SAA2 
1 3.1% 11.6% 11.7% 23.1% 22.5% 10.9% 6.0% 11.1% 
T-cell receptor 
alpha chain V 
region PY14 
not 
available 
1 22.7% 2.5% 14.7% 1.3% 49.7% 1.5% 3.6% 4.0% 
 
Table A7 
The following are changes in carbonylation protein relative abundances in blood serum samples 
that were collected from Patient X over the course of six days. The changes were not normalized 
to Day 1. No PeptideProphet scores below 0.9 were accepted. The proteins were grouped using 
ProteinProphet; however, the alpha-2-macroglobulin and pregnancy zone protein group did not 
contain related proteins like the other groups. The relative abundances were calculated by 
dividing the reporter ion intensity by the total intensity for the six reporter ions for each PSM and 
then averaging all PSMs composing the various protein groups.  
Protein Group 
Description 
Associated 
Gene 
Supporting 
PSM 
Count  
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 
Streptavidin 
not 
available 
1661 20.1% 16.4% 15.6% 10.3% 18.8% 18.9% 
Serum albumin ALB 908 13.4% 12.0% 19.3% 23.4% 17.1% 14.7% 
Ig gamma chain 
C region 
IGHG 214 15.7% 13.3% 18.2% 20.6% 16.7% 15.4% 
Fibrinogen alpha 
chain 
FGA 199 5.4% 8.1% 13.5% 17.6% 24.8% 30.7% 
Alpha-1-
antitrypsin 
SERPINA1 143 8.0% 5.7% 12.8% 22.2% 26.1% 25.2% 
Trypsin (Pig) 
not 
available 
106 18.3% 15.2% 12.7% 17.7% 18.1% 17.9% 
Complement C3 C3 100 15.2% 8.4% 17.8% 16.0% 21.0% 21.6% 
Fibrinogen beta 
chain 
FGB 95 5.0% 7.3% 14.2% 20.9% 24.6% 28.0% 
Serotransferrin TF 83 12.2% 10.3% 25.4% 18.3% 17.0% 16.9% 
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Fibrinogen 
gamma chain 
FGG 78 6.9% 8.6% 14.9% 18.2% 24.6% 26.9% 
Ig kappa chain C 
region 
IGKC 67 17.4% 10.9% 19.6% 19.3% 16.4% 16.4% 
Alpha-2-
macroglobulin & 
Pregnancy zone 
protein 
A2M & 
PZP 
46 8.4% 6.3% 22.2% 23.8% 20.3% 19.1% 
Haptoglobin HP 40 5.1% 4.6% 14.1% 7.9% 27.2% 41.1% 
Complement C4-
A & B 
C4A & 
C4B 
39 12.6% 6.2% 17.6% 22.5% 20.2% 20.9% 
Alpha-1-
antichymotrypsin 
SERPINA3 37 3.9% 2.9% 14.3% 26.7% 27.4% 24.7% 
Apolipoprotein    
A-I 
APOA1 35 10.5% 8.2% 26.9% 29.7% 12.0% 12.7% 
Vitronectin VTN 29 13.0% 11.2% 16.9% 17.1% 20.9% 20.9% 
Decoy 
not 
available 
27 17.2% 17.2% 13.7% 18.6% 16.9% 16.3% 
Ceruloplasmin CP 25 9.3% 6.4% 15.6% 19.8% 23.6% 25.3% 
Ig alpha chain C 
region 
IGHA 24 14.2% 10.6% 22.8% 19.6% 16.0% 16.8% 
Serum amyloid 
A-1 & 2 protein 
SAA1 & 
SAA2 
21 3.9% 3.3% 18.9% 25.9% 18.5% 29.5% 
Hemopexin HPX 16 11.7% 9.8% 43.2% 12.0% 10.6% 12.6% 
Ig heavy chain 
V-III regions 
not 
available 
12 13.8% 10.9% 23.7% 21.9% 15.1% 14.5% 
Trypsin-1 & 2 
PRSS1 
&PRSS2 
10 19.5% 16.1% 10.3% 19.4% 17.9% 16.8% 
Plasma protease 
C1 inhibitor 
SERPING1 5 7.5% 6.0% 15.1% 28.5% 20.8% 22.1% 
Apolipoprotein 
B-100 
APOB 4 13.6% 9.5% 14.5% 24.9% 19.4% 18.1% 
Ig lambda chain 
C region 
IGLC 4 15.9% 13.8% 15.8% 21.4% 17.0% 16.0% 
Alkaline 
ceramidase 1 
ACER1 3 12.5% 11.6% 22.2% 24.4% 15.6% 13.6% 
Keratin, type I 
cytoskeletal (9, 
10, 12, 14-17, 
19) 
KRT9, 10, 
12, 14-17, 
19 
3 25.4% 12.2% 13.7% 15.5% 18.8% 14.5% 
Keratin, type II 
cytoskeletal 1 
KRT1 3 21.0% 11.4% 14.2% 15.3% 19.4% 18.7% 
Protein AMBP AMBP 2 19.8% 7.0% 11.6% 19.1% 20.2% 22.2% 
Angiotensinogen AGT 1 10.3% 6.3% 14.0% 15.5% 28.9% 25.0% 
C-reactive 
protein 
CRP 1 5.1% 5.6% 16.2% 30.5% 24.6% 18.0% 
Decoy 
not 
available 
1 16.2% 10.6% 16.0% 24.6% 15.9% 16.7% 
Decoy 
not 
available 
1 5.1% 5.4% 41.6% 14.8% 20.6% 20.6% 
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Hemoglobin 
subunit beta 
HBB 1 12.6% 7.5% 12.5% 25.5% 18.7% 23.1% 
Ig kappa chain 
V-III regions 
not 
available 
1 15.5% 11.4% 19.9% 21.1% 14.4% 17.7% 
Ig mu chain C 
region 
IGHM 1 12.8% 10.1% 24.4% 21.1% 16.0% 15.6% 
Kininogen-1 KNG1 1 11.7% 12.8% 24.2% 21.6% 14.2% 15.6% 
Protein FAM98B FAM98B 1 11.7% 11.7% 13.6% 12.0% 24.5% 26.4% 
 
Table A8 
The following are changes in carbonylation protein relative abundances in ProteoMiner-depleted 
blood serum samples that were collected from Patient Y over the course of four days. The 
changes were not normalized to Day 1. No PeptideProphet scores below 0.9 were accepted. The 
proteins were grouped using ProteinProphet; however, the alpha-2-macroglobulin and pregnancy 
zone protein group did not contain related proteins like the other groups. The relative abundances 
were calculated by dividing the reporter ion intensity by the total intensity for the six reporter 
ions for each PSM and then averaging all PSMs composing the various protein groups.  
Protein Group Description 
Associated 
Gene 
Supporting 
PSM Count  
Day 1 Day 2 Day 3 Day 4 
Complement C4-A & B C4A & C4B 589 36.8% 24.8% 15.6% 22.8% 
Fibrinogen alpha chain FGA 402 32.3% 21.9% 19.1% 26.7% 
Complement C3 C3 279 36.5% 23.8% 17.1% 22.6% 
Fibrinogen beta chain FGB 249 31.9% 22.3% 19.8% 26.0% 
Serum albumin ALB 226 31.0% 25.5% 18.1% 25.3% 
Ceruloplasmin CP 209 29.1% 28.9% 16.9% 25.1% 
Vitronectin VTN 199 32.8% 19.5% 16.9% 30.7% 
Fibrinogen gamma chain FGG 192 33.4% 21.4% 18.7% 26.4% 
Thrombin F2 186 31.4% 25.0% 18.2% 25.5% 
Apolipoprotein A-I APOA1 164 34.3% 27.7% 17.6% 20.4% 
Serum amyloid A-1 & 2 protein SAA1 & SAA2 144 15.9% 11.8% 18.9% 53.4% 
Apolipoprotein B-100 APOB 114 33.1% 20.8% 17.9% 28.2% 
Ig gamma chain C region IGHG 110 36.0% 27.5% 14.8% 21.7% 
Clusterin CLU 100 28.8% 24.8% 19.6% 26.8% 
Apolipoprotein E APOE 97 28.4% 19.7% 20.4% 31.5% 
Alpha-1-antitrypsin SERPINA1 86 27.9% 27.0% 15.3% 29.8% 
C-reactive protein CRP 77 15.4% 11.5% 15.2% 57.9% 
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Lipopolysaccharide-binding protein LBP 71 20.2% 17.2% 17.2% 45.4% 
Ig mu chain C region IGHM 65 34.1% 25.7% 17.0% 23.1% 
Serum paraoxonase/ arylesterase 1 PON1 62 36.2% 25.8% 14.8% 23.3% 
Apolipoprotein A-IV APOA4 59 28.2% 19.9% 22.5% 29.5% 
Ig kappa chain C region IGKC 59 34.2% 23.6% 20.8% 21.4% 
Alpha-1-antichymotrypsin SERPINA3 43 28.4% 20.4% 17.9% 33.3% 
Alpha-2-macroglobulin & Pregnancy 
zone protein 
A2M & PZP 32 34.2% 27.1% 16.4% 22.4% 
Complement C1q subcomponent 
subunit C 
C1QC 31 38.7% 21.7% 18.2% 21.3% 
C4b-binding protein alpha chain C4BPA 24 28.1% 33.6% 15.7% 22.6% 
Galectin-3-binding protein LGALS3BP 24 28.7% 23.1% 25.0% 23.2% 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
ITIH4 24 27.2% 27.7% 19.7% 25.4% 
Streptavidin not available 23 34.2% 24.9% 18.5% 22.4% 
Complement C1s subcomponent C1S 20 31.7% 22.9% 16.1% 29.3% 
Trypsin (Pig) not available 16 29.5% 27.0% 17.3% 26.2% 
Angiotensinogen AGT 15 25.9% 18.7% 23.0% 32.5% 
Decoy not available 15 29.3% 19.6% 24.0% 27.1% 
Complement C1q subcomponent 
subunit B 
C1QB 14 33.3% 28.3% 14.3% 24.1% 
Decoy not available 11 29.6% 25.6% 19.3% 25.6% 
Ig alpha chain C region IGHA 9 32.0% 26.4% 17.4% 24.2% 
Carboxypeptidase N catalytic chain CPN1 8 24.0% 18.3% 26.1% 31.6% 
Haptoglobin HP 6 37.3% 33.8% 13.7% 15.1% 
Vitamin K-dependent protein S PROS1 6 37.3% 33.8% 13.7% 15.1% 
C4b-binding protein beta chain C4BPB 5 32.8% 32.0% 15.1% 20.1% 
Complement component C9 C9 4 30.2% 27.4% 15.1% 27.3% 
Ig lambda chain C region IGLC 4 39.9% 27.9% 13.8% 18.4% 
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Phospholipid transfer protein PLTP 4 25.3% 23.1% 23.4% 28.2% 
Serum amyloid A-4 protein SAA4 4 30.1% 26.7% 17.2% 26.0% 
Apolipoprotein A-II APOA2 3 32.8% 17.4% 17.9% 31.9% 
Apolipoprotein C-III APOC3 3 33.7% 29.7% 17.1% 19.4% 
Apolipoprotein M APOM 3 29.1% 18.0% 24.0% 28.9% 
Coiled-coil domain-containing protein 
40 
CCDC40 3 29.1% 18.0% 24.0% 28.9% 
Complement C1q subcomponent 
subunit A 
C1QA 3 36.4% 23.4% 13.7% 26.5% 
Decoy not available 3 32.5% 23.1% 20.2% 24.2% 
Serum amyloid P-component APCS 3 31.7% 26.9% 14.5% 26.9% 
Collectin-10 COLEC10 2 31.5% 20.7% 20.8% 27.0% 
Decoy not available 2 29.9% 31.9% 14.4% 23.8% 
Fibulin-1 FBLN1 2 30.6% 24.2% 19.1% 26.1% 
Hemoglobin subunit beta HBB 2 28.7% 32.9% 15.8% 22.6% 
Ig kappa chain V-IV regions not available 2 33.0% 25.0% 19.6% 22.3% 
Complement C1r subcomponent C1R 1 29.8% 21.2% 23.5% 25.6% 
Complement C5 C5 1 32.2% 29.1% 18.6% 20.0% 
Complement factor H CFH 1 32.2% 28.4% 19.0% 20.3% 
Decoy not available 1 28.7% 29.4% 17.2% 24.7% 
Hemopexin HPX 1 20.2% 25.5% 26.9% 27.4% 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
ITIH3 1 26.3% 9.0% 21.8% 42.9% 
Leucine-rich alpha-2-glycoprotein LRG1 1 23.9% 14.8% 17.8% 43.6% 
Microtubule cross-linking factor 1 MTCL1 1 31.5% 20.1% 17.1% 31.3% 
Steryl-sulfatase STS 1 36.6% 24.4% 15.2% 23.8% 
WD repeat domain phosphoinositide-
interacting protein 1 
WIPI1 1 28.2% 23.4% 24.9% 23.5% 
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Table A9 
The following are changes in carbonylation protein relative abundances in ProteoMiner-depleted 
blood serum samples that were collected from Patient Z over the course of four days. The 
changes were not normalized to Day 1. No PeptideProphet scores below 0.9 were accepted. The 
proteins were grouped using ProteinProphet; however, the alpha-2-macroglobulin and pregnancy 
zone protein group did not contain related proteins like the other groups. The relative abundances 
were calculated by dividing the reporter ion intensity by the total intensity for the six reporter 
ions for each PSM and then averaging all PSMs composing the various protein groups.  
Protein Group Description 
Associated 
Gene 
Supporting 
PSM 
Count  
Day 1 Day 2 Day 3 Day 4 
Complement C4-A & B C4A & C4B 634 25.8% 24.1% 24.8% 25.3% 
Fibrinogen alpha chain FGA 293 26.8% 24.6% 25.4% 23.3% 
Fibrinogen beta chain FGB 279 27.2% 26.0% 23.9% 23.0% 
Complement C3 C3 278 26.2% 25.9% 24.1% 23.8% 
Fibrinogen gamma chain FGG 193 26.1% 25.3% 24.2% 24.4% 
Vitronectin VTN 179 26.7% 21.9% 20.4% 31.0% 
Thrombin F2 165 26.0% 24.3% 23.4% 26.2% 
Ceruloplasmin CP 162 26.7% 25.5% 23.8% 23.9% 
Apolipoprotein A-I APOA1 143 29.7% 25.6% 24.2% 20.5% 
Serum amyloid A-1 & 2 protein 
SAA1 & 
SAA2 
139 5.0% 3.7% 30.5% 60.8% 
Serum albumin ALB 124 25.8% 18.7% 34.9% 20.6% 
Apolipoprotein B-100 APOB 110 31.1% 22.9% 21.4% 24.6% 
Serum paraoxonase/ arylesterase 1 PON1 95 27.7% 26.1% 25.0% 21.2% 
Ig gamma chain C region IGHG 81 33.1% 24.0% 23.3% 19.6% 
Clusterin CLU 75 28.3% 28.0% 19.7% 24.1% 
C-reactive protein CRP 72 8.2% 6.5% 44.1% 41.2% 
Ig kappa chain C region IGKC 61 27.9% 24.6% 23.0% 24.6% 
Ig mu chain C region IGHM 52 30.3% 25.6% 23.0% 21.0% 
Apolipoprotein A-IV APOA4 48 31.2% 29.2% 20.7% 18.9% 
Lipopolysaccharide-binding protein LBP 43 18.4% 16.7% 36.6% 28.3% 
Complement C1q subcomponent subunit 
C 
C1QC 32 21.8% 20.6% 29.9% 27.6% 
Alpha-1-antitrypsin SERPINA1 31 26.0% 23.2% 24.1% 26.7% 
Apolipoprotein E APOE 30 25.2% 21.2% 25.3% 28.3% 
Galectin-3-binding protein LGALS3BP 25 26.3% 24.0% 23.6% 26.1% 
Alpha-1-antichymotrypsin SERPINA3 24 19.0% 16.5% 25.8% 38.7% 
C4b-binding protein alpha chain C4BPA 14 26.2% 23.1% 24.6% 26.1% 
Ig kappa chain V-I regions not available 14 35.0% 24.0% 22.2% 18.8% 
Trypsin (Pig) not available 11 26.3% 24.3% 25.7% 23.7% 
Streptavidin not available 10 28.0% 23.1% 26.5% 22.4% 
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Decoy not available 7 6.5% 40.8% 26.4% 26.3% 
Alpha-2-macroglobulin & Pregnancy 
Zone Protein 
A2M & PZP 6 28.3% 23.1% 25.0% 23.6% 
Phosphatidylinositol-glycan-specific 
phospholipase D 
GPLD1 6 30.6% 27.1% 24.8% 17.6% 
Complement C1s subcomponent C1s 4 26.0% 21.7% 24.5% 27.8% 
Inter-alpha-trypsin inhibitor heavy chain 
H4 
ITIH4 4 26.2% 19.8% 26.3% 27.7% 
Apolipoprotein C-III APOC3 3 25.9% 25.8% 22.0% 26.3% 
Carboxypeptidase N catalytic chain CPN1 3 17.3% 18.0% 36.2% 28.5% 
Complement C1q subcomponent subunit 
B 
C1QB 3 26.0% 23.7% 24.1% 26.2% 
Decoy not available 3 24.2% 25.2% 25.7% 24.9% 
Decoy not available 3 25.3% 29.0% 24.3% 21.4% 
Haptoglobin HP 3 25.1% 18.4% 34.3% 22.2% 
Apolipoprotein A-II APOA2 2 34.1% 20.3% 24.7% 20.0% 
Complement C1q subcomponent subunit 
A 
C1QA 2 25.2% 30.1% 24.7% 20.0% 
Complement C1r subcomponent C1R 2 28.5% 23.5% 25.4% 22.7% 
Fibronectin FN1 2 20.7% 26.1% 29.2% 24.0% 
Vitamin K-dependent protein S PROS1 2 27.0% 22.8% 24.9% 25.4% 
Apolipoprotein M APOM 1 25.9% 26.0% 27.4% 20.7% 
C4b-binding protein beta chain C4BPB 1 31.6% 24.6% 21.5% 22.3% 
Coiled-coil domain-containing protein 40 CCDC40 1 23.2% 23.2% 25.2% 28.3% 
Decoy not available 1 28.9% 25.4% 21.6% 24.1% 
E3 ubiquitin-protein ligase HUWE1 1 28.9% 23.2% 16.9% 31.0% 
Serum amyloid P-component APCS 1 32.2% 30.0% 17.8% 20.0% 
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Appendix 4 
The following are mass spectra corresponding to Chapters 2 and 3. Generally, two spectra are 
included for each peptide: a modified and unmodified (in that order). Some modified peptide 
spectra did not have unmodified counterparts. In some cases, both the 2+ and 3+ peptides were 
modified and thus spectra are included for both charge states.  
Mass Spectra Description Page Numbers 
Chapter 2 (Peptide Enrichment) – Label 1 192-203 
Chapter 2 (Peptide Enrichment) – Label 2 204-221 
Chapter 2 (Peptide Enrichment) – Label 3 222-231 
Chapter 2 (Protein Enrichment) – Label 2 232-234 
Chapter 2 (Protein Enrichment) – Label 4 235-253 
Chapter 3 – 25% spike sample 254-267 
Chapter 3 – 50% spike sample 268-286 
Chapter 3 – 75% spike sample 287-314 
 
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2197.1416, m/z 733.0520
File: 20120529_09_BHZ_2.13731.13731.3, Scan: 13731, Exp. m/z: 733.78, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2041.0405 1021.0239
689.3665 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 673.3632
6 Y 10 599.8290
7 A 9 518.2973
1330.6514 8 P 8
730.3506 9 E 7 434.2524
1572.7781 10 L 6 369.7311
1685.8621 11 L 5 625.3708 313.1890
1832.9305 12 F 4 256.6470
1979.9989 13 F 3 183.1128
2051.0361 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 298.146388 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20120529_09_BHZ_2.14811.14811.3, Scan: 14811, Exp. m/z: 634.06, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
391.2201 196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191
6 Y 10
7 A 9
1032.5050 8 P 8
9 E 7 434.2524
1274.6317 10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESK, MH+ 3272.4908, m/z 1091.5018
File: 20120529_10_BHZ_2.16285.16285.3, Scan: 16285, Exp. m/z: 1092.03, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
523.2446 262.1259 2 H 26 3185.4588 1593.2330
342.1412 3 C 25 2750.2535 1375.6304
398.6833 4 I 24 2590.2229 1295.6151
434.2018 5 A 23 2477.1388 1239.0731
498.7231 6 E 22 2406.1017 1203.5545
1095.5074 548.2573 7 V 21 2277.0591
612.7786 8 E 20 2177.9907 1089.4990
9 N 19 2048.9481
10 D 18 967.9562
11 E 17 1819.8782 910.4428
12 M 16
13 P 15
1881.7928 14 A 14 1462.7424 731.8748
1996.8198 15 D 13 696.3563
2109.9038 16 L 12
2206.9566 1103.9819 17 P 11
2293.9886 18 S 10 533.7744
2407.0727 19 L 9 490.2584
2478.1098 20 A 8 433.7163
2549.1469 21 A 7 398.1978
2664.1738 22 D 6 362.6792
2811.2423 23 F 5 305.1658
2910.3107 24 V 4 231.6316
3039.3533 25 E 3 363.1874 182.0974
3126.3853 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
H: 298.146388 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESKDVCK, MH+ 3476.5654, m/z 1159.5266
File: 20120529_08_BHZ_2.15216.15216.3, Scan: 15216, Exp. m/z: 1159.82, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 31   
225.0982 113.0527 2 H 30 3389.5333 1695.2703
193.0680 3 C 29 3252.4744
249.6101 4 I 28 3092.4438
285.1286 5 A 27 2979.3597
349.6499 6 E 26 2908.3226
399.1841 7 V 25 2779.2800
463.7054 8 E 24 2680.2116
520.7269 9 N 23 2551.1690
1155.4735 578.2404 10 D 22 2437.1261
642.7617 11 E 21 2322.0992 1161.5532
12 M 20 2193.0566
1512.6093 756.8083 13 P 19 2062.0161
1583.6464 792.3268 14 A 18
849.8403 15 D 17
906.3824 16 L 16
1908.8102 17 P 15
1995.8422 998.4247 18 S 14 784.8849
2108.9263 1054.9668 19 L 13 741.3688
2179.9634 20 A 12
2251.0005 1126.0039 21 A 11
2366.0275 22 D 10 613.7897
2513.0959 1257.0516 23 F 9 556.2762
2612.1643 24 V 8 482.7420
2741.2069 25 E 7 433.2078
2828.2389 1414.6231 26 S 6 368.6865
2956.3339 1478.6706 27 K 5 325.1705
3071.3608 28 D 4 261.1230
3170.4292 29 V 3 203.6095
3330.4598 30 C 2 307.1434 154.0753
  31 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3, 30]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1960.8713, m/z 654.2953
File: 20120529_09_BHZ_2.05151.05151.3, Scan: 5151, Exp. m/z: 654.52, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
295.6596 2 K 13 1797.8080
3 A 12 1371.5667 686.2870
4 A 11 1300.5296 650.7684
5 F 10
6 T 9
7 E 8
1269.5754 8 C 7
1429.6060 9 C 6
1557.6646 10 Q 5 266.6399
1628.7017 11 A 4 202.6106
1699.7388 12 A 3 167.0921
1814.7658 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
K: 298.146337 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1662.7250, m/z 554.9132
File: 20120529_10_BHZ_2.04488.04488.3, Scan: 4488, Exp. m/z: 555.22, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
146.5864 2 K 13 1499.6616
182.1050 3 A 12 1371.5667
217.6235 4 A 11 1300.5296
291.1577 5 F 10 1229.4924
6 T 9 1082.4240
7 E 8
8 C 7
1131.4597 566.2335 9 C 6
1259.5183 10 Q 5 266.6399
1330.5554 11 A 4
1401.5925 12 A 3 167.0921
1516.6194 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KVPQVSTPTLVEVSR, MH+ 1938.0841, m/z 969.5457
File: 20120529_10_BHZ_2.08591.08591.2, Scan: 8591, Exp. m/z: 970.35, Charge: 2
b+ # Seq # y+
1 K 15  
2 V 14
623.3698 3 P 13
4 Q 12 1315.7216
5 V 11
6 S 10
7 T 9
1135.6292 8 P 8
1236.6769 9 T 7 803.4621
10 L 6
1448.8294 11 V 5
12 E 4 490.2620
1676.9404 13 V 3
14 S 2 262.1510
 15 R 1 175.1190
[Click] to move table
Modifications:
K: 298.146337 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
198
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KVPQVSTPTLVEVSR, MH+ 1639.9377, m/z 820.4725
File: 20120529_08_BHZ_2.07533.07533.2, Scan: 7533, Exp. m/z: 820.76, Charge: 2
b+ b2+ # Seq # y+ y2+
129.1022 65.0548 1 K 15   
228.1707 114.5890 2 V 14
163.1153 3 P 13
453.2820 227.1446 4 Q 12 658.3644
276.6788 5 V 11
320.1949 6 S 10 544.8009
740.4301 370.7187 7 T 9 501.2849
837.4829 419.2451 8 P 8 450.7611
938.5306 469.7689 9 T 7 402.2347
1051.6146 526.3109 10 L 6 702.4145 351.7109
1150.6830 575.8452 11 V 5 295.1688
640.3665 12 E 4 245.6346
1378.7940 689.9007 13 V 3 181.1133
733.4167 14 S 2 131.5791
  15 R 1 175.1190 88.0631
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2880.4171, m/z 1440.7122
File: 20120529_10_BHZ_2.15512.15512.2, Scan: 15512, Exp. m/z: 1440.88, Charge: 2
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2769.3850 1385.1962
386.1129 193.5601 3 C 19 2655.3421
258.0814 4 E 18 2495.3115
314.6234 5 L 17 2366.2689
388.1576 6 F 16 2253.1849
452.6789 7 E 15 2106.1164
1032.4091 516.7082 8 Q 14
573.2502 9 L 13
1202.5147 601.7610 10 G 12
1331.5573 666.2823 11 E 11
747.8139 12 Y 10
13 K 9
2067.9303 1034.4688 14 F 8 480.7849
2195.9889 1098.4981 15 Q 7 407.2507
2310.0318 1155.5195 16 N 6 343.2214
2381.0689 17 A 5 286.1999
2494.1530 1247.5801 18 L 4 250.6814
2607.2371 19 L 3 387.2714 194.1394
2706.3055 1353.6564 20 V 2 274.1874 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
K: 298.146337 [13]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2582.2708, m/z 1291.6390
File: 20120529_08_BHZ_2.14921.14921.2, Scan: 14921, Exp. m/z: 1291.89, Charge: 2
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2471.2387 1236.1230
193.5601 3 C 19 2357.1958
258.0814 4 E 18 2197.1652
314.6234 5 L 17 2068.1226
388.1576 6 F 16
452.6789 7 E 15
516.7082 8 Q 14
573.2502 9 L 13
1202.5147 601.7610 10 G 12
666.2823 11 E 11 690.8853
747.8139 12 Y 10 626.3640
1622.7156 811.8614 13 K 9 544.8324
885.3956 14 F 8 480.7849
949.4249 15 Q 7 407.2507
2011.8855 1006.4464 16 N 6 343.2214
2082.9226 17 A 5 286.1999
2196.0067 1098.5070 18 L 4 250.6814
2309.0907 1155.0490 19 L 3 387.2714 194.1394
2408.1591 1204.5832 20 V 2 274.1874 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2880.4171, m/z 960.8106
File: 20120529_09_BHZ_2.15582.15582.3, Scan: 15582, Exp. m/z: 961.31, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2769.3850 1385.1962
193.5601 3 C 19 2655.3421 1328.1747
258.0814 4 E 18 2495.3115
314.6234 5 L 17 2366.2689
388.1576 6 F 16 2253.1849
452.6789 7 E 15 2106.1164
516.7082 8 Q 14 1977.0739
573.2502 9 L 13 1849.0153
601.7610 10 G 12 1735.9312
666.2823 11 E 11 1678.9097
747.8139 12 Y 10 1549.8672
960.9346 13 K 9 1386.8038
2067.9303 14 F 8 960.5625 480.7849
2195.9889 15 Q 7 407.2507
2310.0318 1155.5195 16 N 6 343.2214
2381.0689 17 A 5 286.1999
2494.1530 18 L 4 250.6814
2607.2371 19 L 3 194.1394
2706.3055 20 V 2 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
K: 298.146337 [13]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2582.2708, m/z 861.4285
File: 20120529_10_BHZ_2.16044.16044.3, Scan: 16044, Exp. m/z: 862.02, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2471.2387 1236.1230
193.5601 3 C 19 2357.1958 1179.1015
258.0814 4 E 18 2197.1652
5 L 17 2068.1226
388.1576 6 F 16 1955.0385
452.6789 7 E 15 1807.9701
516.7082 8 Q 14 1678.9275
573.2502 9 L 13 1550.8689
601.7610 10 G 12 1437.7849
666.2823 11 E 11 1380.7634
747.8139 12 Y 10 1251.7208
13 K 9 1088.6575
1769.7840 14 F 8
1897.8425 949.4249 15 Q 7 407.2507
2011.8855 16 N 6 343.2214
2082.9226 17 A 5 286.1999
2196.0067 18 L 4 250.6814
2309.0907 19 L 3 194.1394
2408.1591 20 V 2 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2844.4939, m/z 948.8362
File: 20120529_21_LC_2.17264.17264.3, Scan: 17264, Exp. m/z: 949.78, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2773.4568
284.1969 142.6021 3 V 19 2660.3728
199.1441 4 L 18 2561.3043
255.6861 5 I 17 2448.2203
291.2047 6 A 16 2335.1362
364.7389 7 F 15 2264.0991
400.2575 8 A 14 2117.0307
464.2867 9 Q 13 2045.9936
545.8184 10 Y 12 1917.9350 959.4711
602.3604 11 L 11 1754.8717
1331.7722 666.3897 12 Q 10 1641.7876
730.4190 13 Q 9 1513.7290
1974.0704 14 C 8 1385.6704
2071.1231 1036.0652 15 P 7 436.2191
2218.1915 1109.5994 16 F 6 774.3781 387.6927
2347.2341 1174.1207 17 E 5 314.1585
2462.2611 1231.6342 18 D 4 498.2671 249.6372
2599.3200 1300.1636 19 H 3 192.1237
2698.3884 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 411.230415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2490.2849, m/z 830.7665
File: 20120529_22_LC_2.17580.17580.3, Scan: 17580, Exp. m/z: 831.25, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
142.6021 3 V 19 2306.1638
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16 1980.9272
364.7389 7 F 15 1909.8901
400.2575 8 A 14 1762.8217
464.2867 9 Q 13 1691.7846
545.8184 10 Y 12
602.3604 11 L 11 1400.6627
666.3897 12 Q 10
730.4190 13 Q 9 1159.5200
14 C 8 1031.4614
1716.9141 858.9607 15 P 7
1863.9825 932.4949 16 F 6 774.3781 387.6927
1993.0251 997.0162 17 E 5 627.3097 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2310.2256, m/z 770.7467
File: 20120529_22_LC_2.14531.14531.3, Scan: 14531, Exp. m/z: 771.56, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2154.1245 1077.5659
802.4505 401.7289 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11
6 Y 10 599.8290
7 A 9 518.2973
1443.7354 8 P 8
1572.7780 9 E 7 434.2524
1685.8621 10 L 6 369.7311
1798.9461 11 L 5 313.1890
1946.0145 12 F 4 256.6470
2093.0829 13 F 3 183.1128
2164.1201 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 411.230388 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20120529_22_LC_2.20904.20904.3, Scan: 20904, Exp. m/z: 633.91, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191 673.3632
6 Y 10
7 A 9
1032.5050 8 P 8
1161.5476 9 E 7 434.2524
1274.6317 10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
1300
207
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SLHTLFGDKLCTVATLR, MH+ 2343.2675, m/z 1172.1374
File: 20120529_21_LC_2.12447.12447.2, Scan: 12447, Exp. m/z: 1172.25, Charge: 2
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 17   
201.1234 101.0653 2 L 16 2256.2355 1128.6214
338.1823 169.5948 3 H 15 2143.1514
439.2300 220.1186 4 T 14 2006.0925
276.6606 5 L 13
699.3824 350.1949 6 F 12
756.4039 378.7056 7 G 11
436.2191 8 D 10 794.4391
1410.7562 705.8818 9 K 9
1523.8403 10 L 8 467.2629
1683.8709 842.4391 11 C 7 410.7209
1784.9186 892.9629 12 T 6 330.7056
13 V 5 280.1817
1955.0241 14 A 4 230.6475
2056.0718 15 T 3 195.1290
2169.1559 1085.0816 16 L 2 288.2030 144.6051
  17 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [11]
K: 411.230437 [9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SLHTLFGDKLCTVATLR, MH+ 1932.0371, m/z 966.5222
File: 20120529_22_LC_2.12047.12047.2, Scan: 12047, Exp. m/z: 966.66, Charge: 2
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 17   
201.1234 101.0653 2 L 16 1845.0051 923.0062
169.5948 3 H 15 1731.9210
220.1186 4 T 14
276.6606 5 L 13
350.1949 6 F 12
378.7056 7 G 11 617.3346
436.2191 8 D 10 588.8239
500.2665 9 K 9 531.3104
556.8086 10 L 8 467.2629
636.8239 11 C 7 410.7209
1373.6881 687.3477 12 T 6 330.7056
736.8819 13 V 5 280.1817
772.4005 14 A 4 230.6475
1644.8414 822.9243 15 T 3 195.1290
879.4663 16 L 2 288.2030 144.6051
  17 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [11]Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 2073.9554, m/z 691.9900
File: 20120529_21_LC_2.06036.06036.3, Scan: 6036, Exp. m/z: 692.38, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
2 K 13 1910.8921
3 A 12 1371.5667 686.2870
4 A 11 650.7684
5 F 10
6 T 9
7 E 8 491.1918
691.8334 8 C 7
1542.6901 9 C 6 692.3032 346.6552
1670.7487 10 Q 5 266.6399
1741.7858 11 A 4 202.6106
1812.8229 12 A 3 167.0921
1927.8499 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
K: 411.230437 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1662.7250, m/z 554.9132
File: 20120529_21_LC_2.04782.04782.3, Scan: 4782, Exp. m/z: 555.16, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
146.5864 2 K 13 1499.6616
182.1050 3 A 12 1371.5667
217.6235 4 A 11 1300.5296 650.7684
291.1577 5 F 10 1229.4924
6 T 9 1082.4240
7 E 8
971.4291 8 C 7
1131.4597 566.2335 9 C 6
1259.5183 10 Q 5
1330.5554 11 A 4 202.6106
1401.5925 12 A 3 167.0921
1516.6194 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2456.3258, m/z 819.4468
File: 20120529_20_LC_2.14045.14045.3, Scan: 14045, Exp. m/z: 820.16, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
247.1441 124.0757 2 F 16 2357.2574
181.5892 3 D 15 2210.1890
491.2136 246.1105 4 E 14 2095.1620
319.6447 5 F 13 1966.1194
6 K 12 1819.0510
1274.6602 7 P 11
8 L 10 1182.6729 591.8401
9 V 9 535.2980
1615.8553 10 E 8 485.7638
1744.8979 11 E 7 421.2425
1841.9506 921.4790 12 P 6
1970.0092 985.5082 13 Q 5 615.3824 308.1949
2084.0522 1042.5297 14 N 4 487.3239 244.1656
2197.1362 1099.0717 15 L 3 373.2809 187.1441
2310.2203 16 I 2 260.1969 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 411.230437 [6]Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2045.0954, m/z 682.3700
File: 20120529_21_LC_2.22641.22641.3, Scan: 22641, Exp. m/z: 682.45, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 1946.0270
181.5892 3 D 15 1798.9585
246.1105 4 E 14 1683.9316
319.6447 5 F 13 1554.8890
383.6921 6 K 12 1407.8206
863.4298 432.2185 7 P 11 640.3665
488.7606 8 L 10 591.8401
9 V 9 1069.5888
10 E 8
11 E 7
1430.7202 715.8637 12 P 6
1558.7788 779.8930 13 Q 5 308.1949
1672.8217 14 N 4 244.1656
1785.9058 15 L 3 187.1441
1898.9898 16 I 2 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2993.5012, m/z 998.5053
File: 20120529_20_LC_2.15710.15710.3, Scan: 15710, Exp. m/z: 999.76, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2882.4691 1441.7382
193.5601 3 C 19 2768.4262 1384.7167
258.0814 4 E 18 2608.3956
314.6234 5 L 17 2479.3530
6 F 16 2366.2690
452.6789 7 E 15 2219.2005
8 Q 14 2090.1580
573.2502 9 L 13 1962.0994
1202.5147 601.7610 10 G 12 1849.0153
1331.5573 666.2823 11 E 11 1791.9938
747.8139 12 Y 10 1662.9513
2033.9460 13 K 9 1499.8879
2181.0144 14 F 8 480.7849
2309.0730 1155.0401 15 Q 7 407.2507
2423.1159 1212.0616 16 N 6 343.2214
2494.1530 17 A 5 286.1999
2607.2371 18 L 4 250.6814
2720.3212 1360.6642 19 L 3 194.1394
2819.3896 20 V 2 274.1874 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
K: 411.230437 [13]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2582.2708, m/z 861.4285
File: 20120529_22_LC_2.15876.15876.3, Scan: 15876, Exp. m/z: 862.02, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2471.2387 1236.1230
193.5601 3 C 19 2357.1958 1179.1015
258.0814 4 E 18 2197.1652
314.6234 5 L 17 2068.1226
6 F 16 1955.0385
452.6789 7 E 15 1807.9701
516.7082 8 Q 14 1678.9275
573.2502 9 L 13 1550.8689
601.7610 10 G 12 1437.7849
666.2823 11 E 11 1380.7634
747.8139 12 Y 10 1251.7208
13 K 9 1088.6575
1769.7840 885.3956 14 F 8
1897.8425 949.4249 15 Q 7
2011.8855 1006.4464 16 N 6 343.2214
2082.9226 17 A 5 286.1999
2196.0067 18 L 4 250.6814
2309.0907 19 L 3 194.1394
2408.1591 20 V 2 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
215
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KQTALVELVK, MH+ 1539.9291, m/z 513.9812
File: 20120529_21_LC_2.08681.08681.3, Scan: 8681, Exp. m/z: 514.39, Charge: 3
b+ b2+ # Seq # y+ y2+
540.3327 270.6700 1 K 10   
2 Q 9 1000.6037 500.8055
3 T 8
4 A 7 386.2524
5 L 6 350.7338
1052.6285 526.8179 6 V 5 294.1918
1181.6711 7 E 4 244.6576
1294.7552 8 L 3 180.1363
1393.8236 697.4154 9 V 2 123.5942
  10 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 411.230437 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
216
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KVPQVSTPTLVEVSR, MH+ 2051.1682, m/z 1026.0877
File: 20120529_21_LC_2.09359.09359.2, Scan: 9359, Exp. m/z: 1026.35, Charge: 2
b+ b2+ # Seq # y+ y2+
270.6700 1 K 15   
320.2042 2 V 14 756.4250
368.7306 3 P 13 706.8908
432.7599 4 Q 12 658.3644
482.2941 5 V 11 594.3352
1050.6129 525.8101 6 S 10 544.8009
7 T 9 501.2849
1248.7133 624.8603 8 P 8 450.7611
1349.7610 675.3841 9 T 7 402.2347
1462.8451 10 L 6 351.7109
11 V 5 589.3304 295.1688
12 E 4 245.6346
895.5159 13 V 3 181.1133
939.0319 14 S 2 262.1510 131.5791
  15 R 1 175.1190 88.0631
[Click] to move table
Modifications:
K: 411.230437 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KVPQVSTPTLVEVSR, MH+ 1639.9377, m/z 820.4725
File: 20120529_22_LC_2.07816.07816.2, Scan: 7816, Exp. m/z: 820.71, Charge: 2
b+ b2+ # Seq # y+ y2+
129.1022 65.0548 1 K 15   
228.1707 114.5890 2 V 14 1511.8428
163.1153 3 P 13
227.1446 4 Q 12 658.3644
276.6788 5 V 11 594.3352
320.1949 6 S 10 544.8009
370.7187 7 T 9 501.2849
837.4829 419.2451 8 P 8 450.7611
938.5306 469.7689 9 T 7 402.2347
1051.6146 526.3109 10 L 6 702.4145 351.7109
11 V 5 295.1688
640.3665 12 E 4 245.6346
1378.7940 689.9007 13 V 3 181.1133
1465.8261 733.4167 14 S 2 131.5791
  15 R 1 175.1190 88.0631
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 2252.1454, m/z 1126.5763
File: 20120529_22_LC_2.17450.17450.2, Scan: 17450, Exp. m/z: 1126.92, Charge: 2
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
258.1084 129.5579 2 Q 15 2123.1028
371.1925 186.0999 3 L 14 1995.0442
455.7626 4 K 13 1881.9602
491.2812 5 A 12 671.8210
6 V 11
606.3356 7 M 10
8 D 9 521.2480
721.3625 9 D 8 463.7345
794.8967 10 F 7 406.2211
11 A 6 332.6869
12 A 5 297.1683
13 F 4 261.6498
14 V 3 188.1155
2106.0399 15 E 2 276.1554 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 411.230437 [4]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 1840.9150, m/z 920.9611
File: 20120529_20_LC_2.16793.16793.2, Scan: 16793, Exp. m/z: 921.08, Charge: 2
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
129.5579 2 Q 15 1711.8724
186.0999 3 L 14
250.1474 4 K 13
285.6659 5 A 12 671.8210
335.2001 6 V 11 636.3025
400.7204 7 M 10 586.7683
915.4604 8 D 9 521.2480
515.7473 9 D 8 463.7345
1177.5558 589.2815 10 F 7 406.2211
624.8001 11 A 6 332.6869
12 A 5 297.1683
13 F 4 261.6498
783.3871 14 V 3 188.1155
15 E 2 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 2252.1454, m/z 751.3867
File: 20120529_21_LC_2.17387.17387.3, Scan: 17387, Exp. m/z: 751.64, Charge: 3
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
129.5579 2 Q 15 2123.1028
186.0999 3 L 14 1995.0442
910.5179 455.7626 4 K 13 1881.9602
5 A 12 671.8210
6 V 11
1211.6639 7 M 10
8 D 9 521.2480
1441.7178 9 D 8 463.7345
1588.7862 10 F 7 406.2211
1659.8233 11 A 6 332.6869
1730.8605 12 A 5 297.1683
1877.9289 13 F 4 261.6498
1976.9973 14 V 3 188.1155
2106.0399 15 E 2 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 411.230437 [4]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2978.5517, m/z 993.5221
File: 20120529_34_PEG_2.17553.17553.3, Scan: 17553, Exp. m/z: 994.22, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2907.5146 1454.2609
284.1969 142.6021 3 V 19 2794.4306
199.1441 4 L 18 2695.3621
255.6861 5 I 17 2582.2781
291.2047 6 A 16 2469.1940
364.7389 7 F 15 2398.1569
400.2575 8 A 14 2251.0885
464.2867 9 Q 13 2180.0514
545.8184 10 Y 12 2051.9928
602.3604 11 L 11 1888.9295
666.3897 12 Q 10 1775.8454
730.4190 13 Q 9 1647.7868
2108.1282 14 C 8
2205.1809 1103.0941 15 P 7 436.2191
2352.2493 1176.6283 16 F 6 774.3781 387.6927
2481.2919 1241.1496 17 E 5 627.3097 314.1585
2596.3189 1298.6631 18 D 4 249.6372
2733.3778 1367.1925 19 H 3 383.2401 192.1237
2832.4462 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 545.288215 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2490.2849, m/z 830.7665
File: 20120529_32_PEG_2.18598.18598.3, Scan: 18598, Exp. m/z: 831.23, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
142.6021 3 V 19 2306.1638
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16 1980.9272
364.7389 7 F 15 1909.8901
400.2575 8 A 14 1762.8217
464.2867 9 Q 13 1691.7846
545.8184 10 Y 12 1563.7260
602.3604 11 L 11 1400.6627
12 Q 10
730.4190 13 Q 9 1159.5200
14 C 8 1031.4614
1716.9141 858.9607 15 P 7
1863.9825 932.4949 16 F 6 387.6927
1993.0251 997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2444.2834, m/z 815.4326
File: 20120529_33_PEG_2.14383.14383.3, Scan: 14383, Exp. m/z: 815.46, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2288.1823 1144.5948
936.5083 468.7578 3 P 13 1605.8352
4 Y 12 754.8948
1246.6400 5 F 11 673.3632
6 Y 10 599.8290
7 A 9 518.2973
1577.7932 789.4002 8 P 8
1706.8358 9 E 7 867.4975 434.2524
1819.9199 10 L 6 369.7311
1933.0039 11 L 5 625.3708 313.1890
2080.0723 12 F 4 256.6470
2227.1407 13 F 3 183.1128
2298.1779 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 545.288188 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20120529_34_PEG_2.22921.22921.3, Scan: 22921, Exp. m/z: 634.09, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
391.2201 196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191 673.3632
6 Y 10
7 A 9
1032.5050 516.7561 8 P 8
9 E 7 434.2524
1274.6317 10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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225
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESK, MH+ 3519.6326, m/z 1173.8824
File: 20120529_34_PEG_2.16718.16718.3, Scan: 16718, Exp. m/z: 1174.04, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
2 H 26 3432.6006 1716.8039
465.7121 3 C 25 2750.2535 1375.6304
4 I 24 2590.2229 1295.6151
1114.5382 557.7727 5 A 23 2477.1388
622.2940 6 E 22 2406.1017 1203.5545
7 V 21 2277.0591
8 E 20 2177.9907
793.3710 9 N 19 2048.9481 1024.9777
1700.7617 10 D 18 967.9562
11 E 17
1960.8447 12 M 16
2057.8975 13 P 15
2128.9346 14 A 14 1462.7424 731.8748
2243.9616 15 D 13 696.3563
2357.0456 1179.0264 16 L 12
2454.0984 17 P 11 582.3008
2541.1304 18 S 10 533.7744
2654.2145 19 L 9 979.5095 490.2584
2725.2516 20 A 8 433.7163
2796.2887 21 A 7 398.1978
2911.3156 22 D 6 362.6792
3058.3841 23 F 5 305.1658
3157.4525 24 V 4 231.6316
3286.4951 25 E 3 182.0974
3373.5271 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
H: 545.288188 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SHC IAEVENDEMPADLPSLAADFVESK, MH+ 2974.3444, m/z 992.1197
File: 20120529_34_PEG_2.16254.16254.3, Scan: 16254, Exp. m/z: 992.33, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
225.0982 113.0527 2 H 26 2887.3124 1444.1598
385.1288 193.0680 3 C 25 2750.2535 1375.6304
249.6101 4 I 24 2590.2229 1295.6151
285.1286 5 A 23 2477.1388 1239.0731
349.6499 6 E 22 2406.1017 1203.5545
399.1841 7 V 21 2277.0591 1139.0332
8 E 20 2177.9907
520.7269 9 N 19 2048.9481
10 D 18 1934.9052
11 E 17 1819.8782
12 M 16
1512.6093 756.8083 13 P 15
1583.6464 14 A 14 1462.7424 731.8748
15 D 13 696.3563
16 L 12
1908.8102 17 P 11
1995.8422 998.4247 18 S 10 533.7744
2108.9263 19 L 9
2179.9634 20 A 8 433.7163
2251.0005 21 A 7 398.1978
2366.0275 22 D 6 362.6792
2513.0959 23 F 5 305.1658
2612.1643 24 V 4 231.6316
2741.2069 25 E 3 182.0974
2828.2389 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 2208.0132, m/z 736.6759
File: 20120529_33_PEG_2.06517.06517.3, Scan: 6517, Exp. m/z: 737.14, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
2 K 13 2044.9499
3 A 12 686.2870
4 A 11 650.7684
5 F 10
6 T 9
7 E 8
1516.7173 8 C 7
1676.7479 9 C 6 346.6552
1804.8065 10 Q 5 266.6399
1875.8436 938.4254 11 A 4 202.6106
1946.8807 12 A 3 167.0921
2061.9077 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
K: 545.288237 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
228
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1662.7250, m/z 554.9132
File: 20120529_32_PEG_2.04893.04893.3, Scan: 4893, Exp. m/z: 555.62, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
146.5864 2 K 13 1499.6616
363.2027 182.1050 3 A 12 1371.5667
217.6235 4 A 11 1300.5296 650.7684
291.1577 5 F 10 1229.4924
6 T 9 1082.4240
7 E 8
8 C 7
1131.4597 566.2335 9 C 6
1259.5183 10 Q 5 266.6399
1330.5554 11 A 4 202.6106
1401.5925 12 A 3 167.0921
1516.6194 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 3127.5590, m/z 1043.1912
File: 20120529_32_PEG_2.16170.16170.3, Scan: 16170, Exp. m/z: 1043.53, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 3016.5269 1508.7671
193.5601 3 C 19 2902.4840 1451.7456
258.0814 4 E 18 2742.4534
314.6234 5 L 17 2613.4108
6 F 16 2500.3268
452.6789 7 E 15 2353.2583
1032.4091 516.7082 8 Q 14 2224.2158
573.2502 9 L 13 2096.1572 1048.5822
1202.5147 601.7610 10 G 12 1983.0731
666.2823 11 E 11 1926.0516
747.8139 12 Y 10 1797.0091
2168.0038 13 K 9 1633.9457
2315.0722 14 F 8 480.7849
2443.1308 15 Q 7 407.2507
2557.1737 16 N 6 343.2214
2628.2108 17 A 5 286.1999
2741.2949 18 L 4 500.3555 250.6814
2854.3790 19 L 3 194.1394
2953.4474 20 V 2 274.1874 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
K: 545.288237 [13]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QN CELFEQLGEYKFQNALLVR, MH+ 2582.2708, m/z 861.4285
File: 20120529_33_PEG_2.15743.15743.3, Scan: 15743, Exp. m/z: 862.1, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2471.2387 1236.1230
193.5601 3 C 19 2357.1958 1179.1015
258.0814 4 E 18 2197.1652
314.6234 5 L 17 2068.1226
388.1576 6 F 16 1955.0385
452.6789 7 E 15 1807.9701
516.7082 8 Q 14 1678.9275
573.2502 9 L 13
601.7610 10 G 12
666.2823 11 E 11 1380.7634
747.8139 12 Y 10 1251.7208
1622.7156 13 K 9 1088.6575
1769.7840 14 F 8
1897.8425 949.4249 15 Q 7
2011.8855 1006.4464 16 N 6 343.2214
2082.9226 17 A 5 286.1999
2196.0067 18 L 4 250.6814
2309.0907 19 L 3 194.1394
2408.1591 20 V 2 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2310.2256, m/z 770.7467
File: 20140712_09_Treated_B_2.17386.17386.3, Scan: 17386, Exp. m/z: 771.06, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2154.1245 1077.5659
802.4505 3 P 13 1605.8352 803.4212
4 Y 12 1508.7824 754.8948
5 F 11 673.3632
6 Y 10 599.8290
7 A 9 518.2973
1443.7354 722.3713 8 P 8
1572.7780 9 E 7 867.4975 434.2524
1685.8621 10 L 6 369.7311
1798.9461 11 L 5 313.1890
1946.0145 12 F 4 256.6470
2093.0829 1047.0451 13 F 3 183.1128
2164.1201 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 411.230388 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20140712_09_Treated_B_2.16713.16713.3, Scan: 16713, Exp. m/z: 634.09, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
391.2201 196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191
6 Y 10
7 A 9
1032.5050 516.7561 8 P 8
9 E 7 434.2524
10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KQTALVELVK, MH+ 1539.9291, m/z 513.9812
File: 20140712_08_Treated_B_1.12059.12059.3, Scan: 12059, Exp. m/z: 514.12, Charge: 3
b+ b2+ # Seq # y+ y2+
540.3327 270.6700 1 K 10   
2 Q 9 1000.6037 500.8055
769.4389 3 T 8 436.7762
4 A 7
953.5601 5 L 6
1052.6285 526.8179 6 V 5 294.1918
1181.6711 7 E 4 244.6576
1294.7552 647.8812 8 L 3 180.1363
1393.8236 697.4154 9 V 2 123.5942
  10 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 411.230437 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1921.7447, m/z 961.3760
File: 20140726_06_Bound_1.06810.06810.2, Scan: 6810, Exp. m/z: 961.68, Charge: 2
b+ b2+ # Seq # y+ y2+
161.0379 81.0226 1 C 13   
161.0379 2 C 12 1761.7141 881.3607
196.5564 3 A 11
232.0750 4 A 10
267.5935 5 A 9
325.1070 6 D 8 694.7897
7 P 7
1252.4655 626.7364 8 H 6 588.7499
691.2577 9 E 5 335.6469
771.2730 10 C 4 271.1256
1704.6020 11 Y 3 381.2132 191.1103
1775.6392 12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [1, 2, 10]
H: 369.147088 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1535.5711, m/z 768.2892
File: 20140726_06_Bound_1.09524.09524.2, Scan: 9524, Exp. m/z: 768.23, Charge: 2
b+ b2+ # Seq # y+ y2+
144.0114 72.5093 1 C 13   
152.5246 2 C 12 1392.5670 696.7871
188.0432 3 A 11
223.5617 4 A 10
259.0803 5 A 9
316.5938 6 D 8
729.2330 365.1201 7 P 7
433.6496 8 H 6
498.1709 9 E 5 335.6469
578.1862 10 C 4 271.1256
659.7179 11 Y 3 191.1103
1389.4656 695.2364 12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 39.994915 [1]
C: 57.021415 [2, 10]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LVRPEVDVMCTAFH DNEETFLK, MH+ 3019.4110, m/z 1007.1419
File: 20140726_06_Bound_1.22522.22522.3, Scan: 22522, Exp. m/z: 1007.79, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 22   
213.1598 107.0835 2 V 21 2906.3270 1453.6671
185.1341 3 R 20 2807.2585 1404.1329
233.6605 4 P 19 2651.1574
298.1817 5 E 18 2554.1047 1277.5560
694.4246 347.7160 6 V 17 2425.0621
405.2294 7 D 16 2325.9937
8 V 15 2210.9667
520.2839 9 M 14 2111.8983
10 C 13 1980.8578
1300.6388 11 T 12
12 A 11 1719.7795
759.8758 13 F 10
2024.9503 14 H 9
2139.9772 15 D 8 498.2376
2254.0202 16 N 7
2383.0627 17 E 6 383.7027
2512.1053 18 E 5 319.1814
2613.1530 19 T 4 254.6601
2760.2214 20 F 3 204.1363
2873.3055 21 L 2 260.1969 130.6021
  22 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [10]
H: 369.147088 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LVRPEVDVMCTAFHDNEETFLK, MH+ 2650.2639, m/z 884.0928
File: 20140726_06_Bound_1.22740.22740.3, Scan: 22740, Exp. m/z: 883.91, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 22   
213.1598 107.0835 2 V 21 2537.1799 1269.0936
185.1341 3 R 20 2438.1115 1219.5594
466.3136 233.6605 4 P 19 2282.0103
298.1817 5 E 18 2184.9576 1092.9824
347.7160 6 V 17 2055.9150
405.2294 7 D 16 1956.8466
8 V 15 1841.8196
9 M 14 1742.7512
600.2992 10 C 13
1300.6388 650.8230 11 T 12
12 A 11
13 F 10
1655.8032 14 H 9
1770.8301 885.9187 15 D 8 498.2376
1884.8731 16 N 7 880.4411 440.7242
2013.9157 17 E 6 383.7027
2142.9583 18 E 5 319.1814
2244.0059 19 T 4 254.6601
2391.0743 20 F 3 204.1363
2504.1584 21 L 2 130.6021
  22 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [10]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 2268.1423, m/z 1134.5748
File: 20140726_06_Bound_1.23754.23754.2, Scan: 23754, Exp. m/z: 1134.26, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
332.1608 2 H 14 2112.0412
760.3672 380.6872 3 P 13 803.4212
4 Y 12 754.8948
535.7531 5 F 11 673.3632
617.2847 6 Y 10 599.8290
7 A 9 518.2973
1401.6521 8 P 8 482.7788
9 E 7 867.4975 434.2524
10 L 6 369.7311
11 L 5 313.1890
1903.9312 12 F 4 256.6470
2050.9996 13 F 3 183.1128
2122.0368 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 369.147088 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 950.0012
File: 20140726_08_Bound_3.23222.23222.2, Scan: 23222, Exp. m/z: 949.97, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
294.1673 147.5873 2 H 14 871.9507
391.2201 196.1137 3 P 13 803.4212
277.6453 4 Y 12 754.8948
351.1795 5 F 11 673.3632
432.7112 6 Y 10 599.8290
7 A 9 518.2973
516.7561 8 P 8 482.7788
9 E 7 434.2524
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
13 F 3 183.1128
14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2268.1423, m/z 756.7189
File: 20140726_07_Bound_2.23640.23640.3, Scan: 23640, Exp. m/z: 756.6, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2112.0412 1056.5242
760.3672 3 P 13 1605.8352
923.4305 4 Y 12 1508.7824 754.8948
5 F 11 673.3632
6 Y 10 599.8290
7 A 9 518.2973
1401.6521 701.3297 8 P 8
1530.6947 9 E 7 434.2524
1643.7788 10 L 6 369.7311
1756.8628 11 L 5 625.3708 313.1890
1903.9312 12 F 4 256.6470
2050.9996 13 F 3 183.1128
2122.0368 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 369.147088 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20140726_07_Bound_2.22770.22770.3, Scan: 22770, Exp. m/z: 633.93, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
391.2201 196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191
6 Y 10
7 A 9
1032.5050 516.7561 8 P 8
1161.5476 9 E 7 434.2524
1274.6317 10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
242
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESK, MH+ 3343.4915, m/z 1115.1687
File: 20140726_06_Bound_1.26523.26523.3, Scan: 26523, Exp. m/z: 1115.93, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
297.6263 2 H 26 3256.4595 1628.7334
377.6416 3 C 25 2750.2535 1375.6304
434.1836 4 I 24 2590.2229
938.3971 5 A 23 2477.1388 1239.0731
534.2235 6 E 22 2406.1017 1203.5545
7 V 21 2277.0591 1139.0332
8 E 20 2177.9907 1089.4990
9 N 19 2048.9481
762.8139 10 D 18 1934.9052
11 E 17 1819.8782 910.4428
12 M 16
1881.7564 13 P 15
1952.7935 14 A 14 731.8748
2067.8205 15 D 13
2180.9045 16 L 12
2277.9573 1139.4823 17 P 11
2364.9893 18 S 10 1066.5415 533.7744
2478.0734 19 L 9
2549.1105 20 A 8 433.7163
2620.1476 21 A 7 398.1978
2735.1745 22 D 6 362.6792
2882.2430 23 F 5 305.1658
2981.3114 24 V 4 462.2558 231.6316
3110.3540 25 E 3 182.0974
3197.3860 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
H: 369.147088 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SHC IAEVENDEMPADLPSLAADFVESK, MH+ 2974.3444, m/z 992.1197
File: 20140726_06_Bound_1.26479.26479.3, Scan: 26479, Exp. m/z: 992.5, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
225.0982 113.0527 2 H 26 2887.3124 1444.1598
385.1288 193.0680 3 C 25 2750.2535 1375.6304
249.6101 4 I 24 2590.2229 1295.6151
285.1286 5 A 23 2477.1388 1239.0731
349.6499 6 E 22 2406.1017 1203.5545
399.1841 7 V 21 2277.0591 1139.0332
463.7054 8 E 20 2177.9907
1040.4465 520.7269 9 N 19 2048.9481 1024.9777
1155.4735 578.2404 10 D 18 1934.9052
11 E 17 1819.8782 910.4428
12 M 16
1512.6093 756.8083 13 P 15
1583.6464 14 A 14 731.8748
15 D 13 696.3563
16 L 12
1908.8102 17 P 11
1995.8422 18 S 10 533.7744
2108.9263 19 L 9
2179.9634 20 A 8 433.7163
2251.0005 21 A 7 398.1978
2366.0275 22 D 6 362.6792
2513.0959 23 F 5 305.1658
2612.1643 24 V 4 231.6316
2741.2069 25 E 3 182.0974
2828.2389 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KVPQVSTPTLVEVSR, MH+ 2009.0848, m/z 670.3664
File: 20140726_06_Bound_1.17052.17052.3, Scan: 17052, Exp. m/z: 670.42, Charge: 3
b+ b2+ # Seq # y+ y2+
498.2493 249.6283 1 K 15   
299.1625 2 V 14 1511.8428 756.4250
694.3705 347.6889 3 P 13 1412.7744 706.8908
4 Q 12 1315.7216
5 V 11 594.3352
6 S 10 544.8009
7 T 9
1206.6299 603.8186 8 P 8
1307.6776 654.3424 9 T 7 402.2347
1420.7617 10 L 6 702.4145 351.7109
1519.8301 11 V 5 295.1688
1648.8727 12 E 4 245.6346
1747.9411 13 V 3 181.1133
1834.9731 14 S 2 131.5791
  15 R 1 175.1190 88.0631
[Click] to move table
Modifications:
K: 369.147037 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
KVPQVSTPTLVEVSR, MH+ 1639.9377, m/z 547.3174
File: 20140726_07_Bound_2.15301.15301.3, Scan: 15301, Exp. m/z: 547.5, Charge: 3
b+ b2+ # Seq # y+ y2+
129.1022 65.0548 1 K 15   
114.5890 2 V 14 1511.8428 756.4250
163.1153 3 P 13 1412.7744
227.1446 4 Q 12 1315.7216 658.3644
552.3504 276.6788 5 V 11 1187.6630 594.3352
6 S 10 1088.5946 544.8009
7 T 9
837.4829 8 P 8
9 T 7 402.2347
10 L 6
1150.6830 11 V 5
1279.7256 12 E 4
1378.7940 13 V 3 181.1133
1465.8261 14 S 2 131.5791
  15 R 1 88.0631
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LAKTYETTLEK, MH+ 1665.8516, m/z 555.9554
File: 20140726_06_Bound_1.09965.09965.3, Scan: 9965, Exp. m/z: 556.29, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 11   
93.0679 2 A 10 1552.7675
3 K 9 1481.7304
4 T 8 492.7478
5 Y 7
1075.5241 6 E 6
1176.5717 588.7895 7 T 5
1277.6194 639.3133 8 T 4 245.6472
1390.7035 695.8554 9 L 3 389.2395 195.1234
1519.7461 10 E 2 138.5813
  11 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 369.147037 [3]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QNCELFEQLGEYKFQNALLVR, MH+ 2951.4178, m/z 984.4775
File: 20140726_06_Bound_1.25969.25969.3, Scan: 25969, Exp. m/z: 985.47, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2840.3857 1420.6965
193.5601 3 C 19 2726.3428 1363.6750
258.0814 4 E 18 2566.3122
314.6234 5 L 17 2437.2696
6 F 16 2324.1856
452.6789 7 E 15 2177.1171
1032.4091 516.7082 8 Q 14 2048.0746
573.2502 9 L 13 1920.0160
601.7610 10 G 12 1806.9319
666.2823 11 E 11 1749.9104
747.8139 12 Y 10 1620.8679
1991.8626 996.4349 13 K 9 1457.8045
2138.9310 14 F 8 480.7849
2266.9896 15 Q 7 407.2507
2381.0325 16 N 6 343.2214
2452.0696 17 A 5 286.1999
2565.1537 18 L 4 250.6814
2678.2378 19 L 3 194.1394
2777.3062 20 V 2 274.1874 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
K: 369.147037 [13]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
QN CELFEQLGEYKFQNALLVR, MH+ 2582.2708, m/z 861.4285
File: 20140726_08_Bound_3.35476.35476.3, Scan: 35476, Exp. m/z: 862.03, Charge: 3
b+ b2+ # Seq # y+ y2+
112.0394 56.5233 1 Q 21   
226.0823 113.5448 2 N 20 2471.2387 1236.1230
193.5601 3 C 19 2357.1958 1179.1015
258.0814 4 E 18 2197.1652
314.6234 5 L 17 2068.1226
388.1576 6 F 16 1955.0385
452.6789 7 E 15 1807.9701
516.7082 8 Q 14 1678.9275
9 L 13 1550.8689
601.7610 10 G 12
666.2823 11 E 11 1380.7634
747.8139 12 Y 10 1251.7208
13 K 9 1088.6575
1769.7840 14 F 8
1897.8425 15 Q 7 407.2507
2011.8855 16 N 6 343.2214
2082.9226 17 A 5 286.1999
2196.0067 18 L 4 250.6814
2309.0907 19 L 3 194.1394
2408.1591 20 V 2 137.5973
  21 R 1 175.1190 88.0631
[Click] to move table
Modifications:
C: 57.021415 [3]
Q: -17.026478 [1]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2414.2424, m/z 805.4190
File: 20140726_07_Bound_2.24031.24031.3, Scan: 24031, Exp. m/z: 805.6, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 2315.1740
181.5892 3 D 15 2168.1056
246.1105 4 E 14 2053.0786
319.6447 5 F 13 1924.0360
6 K 12 1776.9676
1232.5768 616.7920 7 P 11
8 L 10 591.8401
9 V 9 535.2980
1573.7719 10 E 8 485.7638
1702.8145 11 E 7 421.2425
1799.8672 900.4373 12 P 6
1927.9258 964.4665 13 Q 5 615.3824 308.1949
2041.9688 1021.4880 14 N 4 487.3239 244.1656
2155.0528 15 L 3 373.2809 187.1441
2268.1369 16 I 2 260.1969 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 369.147037 [6]Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2045.0954, m/z 682.3700
File: 20140726_06_Bound_1.23687.23687.3, Scan: 23687, Exp. m/z: 682.3, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 1946.0270
181.5892 3 D 15 1798.9585
246.1105 4 E 14 1683.9316
319.6447 5 F 13 1554.8890
383.6921 6 K 12 1407.8206
863.4298 432.2185 7 P 11
488.7606 8 L 10 1182.6729 591.8401
9 V 9 535.2980
10 E 8
1333.6674 11 E 7
1430.7202 715.8637 12 P 6
1558.7788 779.8930 13 Q 5 308.1949
1672.8217 836.9145 14 N 4 244.1656
1785.9058 15 L 3 187.1441
1898.9898 16 I 2 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 2031.8720, m/z 677.9622
File: 20140726_08_Bound_3.09858.09858.3, Scan: 9858, Exp. m/z: 678.25, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
331.1599 2 K 13 1868.8087
366.6785 3 A 12 1371.5667 686.2870
402.1971 4 A 11 1300.5296 650.7684
5 F 10
6 T 9
7 E 8
1340.5761 670.7917 8 C 7
1500.6067 9 C 6
1628.6653 10 Q 5 266.6399
1699.7024 11 A 4 202.6106
1770.7395 12 A 3 167.0921
1885.7665 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
K: 369.147037 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1662.7250, m/z 554.9132
File: 20140726_08_Bound_3.07239.07239.3, Scan: 7239, Exp. m/z: 555.3, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
146.5864 2 K 13 1499.6616
363.2027 182.1050 3 A 12 1371.5667
217.6235 4 A 11 1300.5296
291.1577 5 F 10 1229.4924
6 T 9 1082.4240
7 E 8
8 C 7
1131.4597 566.2335 9 C 6
1259.5183 10 Q 5 266.6399
1330.5554 11 A 4 202.6106
1401.5925 12 A 3 167.0921
1516.6194 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2824.4412, m/z 1412.7243
File: 20150202_08_25Percent_Beads_1.28278.28278.2, Scan: 28278, Exp. m/z: 1413.06, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2753.4041 1377.2057
284.1969 142.6021 3 V 19 2640.3201
397.2809 199.1441 4 L 18 2541.2516
255.6861 5 I 17 2428.1676
291.2047 6 A 16 2315.0835
364.7389 7 F 15 2244.0464
400.2575 8 A 14 2096.9780 1048.9926
464.2867 9 Q 13 2025.9409
545.8184 10 Y 12 949.4448
11 L 11 867.9131
666.3897 12 Q 10
730.4190 13 Q 9 747.3418
1954.0177 14 C 8
2051.0704 1026.0389 15 P 7 436.2191
2198.1388 1099.5731 16 F 6 387.6927
2327.1814 1164.0944 17 E 5 627.3097 314.1585
2442.2084 1221.6078 18 D 4 249.6372
2579.2673 1290.1373 19 H 3 383.2401 192.1237
2678.3357 1339.6715 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 391.177715 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2490.2849, m/z 1245.6461
File: 20150202_10_25Percent_Beads_3.28166.28166.2, Scan: 28166, Exp. m/z: 1245.85, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
284.1969 142.6021 3 V 19 2306.1638 1153.5855
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113 1047.5093
291.2047 6 A 16 1980.9272
364.7389 7 F 15
400.2575 8 A 14 881.9145
464.2867 9 Q 13 846.3959
545.8184 10 Y 12 782.3666
602.3604 11 L 11 700.8350
666.3897 12 Q 10 644.2929
730.4190 13 Q 9 580.2636
810.4343 14 C 8
1716.9141 858.9607 15 P 7 436.2191
932.4949 16 F 6 387.6927
997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2824.4412, m/z 942.1519
File: 20150202_09_25Percent_Beads_2.28585.28585.3, Scan: 28585, Exp. m/z: 942.52, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2753.4041 1377.2057
142.6021 3 V 19 2640.3201
199.1441 4 L 18 2541.2516
255.6861 5 I 17 2428.1676
291.2047 6 A 16 2315.0835
364.7389 7 F 15 2244.0464
400.2575 8 A 14 2096.9780
464.2867 9 Q 13 2025.9409
545.8184 10 Y 12 1897.8823 949.4448
602.3604 11 L 11 1734.8190
666.3897 12 Q 10 1621.7349
730.4190 13 Q 9 1493.6763
1954.0177 14 C 8 1365.6177
2051.0704 1026.0389 15 P 7
2198.1388 1099.5731 16 F 6 774.3781 387.6927
2327.1814 1164.0944 17 E 5 314.1585
2442.2084 1221.6078 18 D 4 249.6372
2579.2673 1290.1373 19 H 3 383.2401 192.1237
2678.3357 1339.6715 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 391.177715 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2490.2849, m/z 830.7665
File: 20150202_09_25Percent_Beads_2.28410.28410.3, Scan: 28410, Exp. m/z: 831.04, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
142.6021 3 V 19 2306.1638
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16 1980.9272
364.7389 7 F 15 1909.8901
400.2575 8 A 14 1762.8217
464.2867 9 Q 13 1691.7846
545.8184 10 Y 12
602.3604 11 L 11 1400.6627
666.3897 12 Q 10 1287.5786
730.4190 13 Q 9 1159.5200
810.4343 14 C 8 1031.4614
1716.9141 858.9607 15 P 7
1863.9825 932.4949 16 F 6 387.6927
1993.0251 997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 2290.1729, m/z 1145.5901
File: 20150202_09_25Percent_Beads_2.24714.24714.2, Scan: 24714, Exp. m/z: 1146.03, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
343.1761 2 H 14 2134.0718
782.3978 3 P 13 803.4212
4 Y 12 754.8948
5 F 11 1345.7191 673.3632
6 Y 10 599.8290
7 A 9 518.2973
8 P 8 482.7788
9 E 7 867.4975 434.2524
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
2073.0302 13 F 3 183.1128
2144.0674 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 950.0012
File: 20150202_08_25Percent_Beads_1.23029.23029.2, Scan: 23029, Exp. m/z: 950.22, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14
391.2201 196.1137 3 P 13 803.4212
277.6453 4 Y 12 1508.7824 754.8948
351.1795 5 F 11 673.3632
432.7112 6 Y 10 599.8290
7 A 9 518.2973
8 P 8 482.7788
9 E 7 867.4975
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
13 F 3 183.1128
14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1926.7488, m/z 963.8780
File: 20141212_09_25Percent_Labeled_1.09716.09716.2, Scan: 9716, Exp. m/z: 964.13, Charge: 2
b+ b2+ # Seq # y+ y2+
144.0114 72.5093 1 C 13   
152.5246 2 C 12 1783.7447 892.3760
188.0432 3 A 11 1623.7141
223.5617 4 A 10
259.0803 5 A 9
632.1803 316.5938 6 D 8
729.2330 365.1201 7 P 7
629.2384 8 H 6
693.7597 9 E 5 335.6469
773.7750 10 C 4 271.1256
855.3067 11 Y 3 191.1103
12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 39.994915 [1]
C: 57.021415 [2, 10]
H: 391.177688 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2490.2849, m/z 1245.6461
File: 20141212_09_25Percent_Labeled_1.20594.20594.2, Scan: 20594, Exp. m/z: 1245.79, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
284.1969 142.6021 3 V 19 2306.1638
397.2809 199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16
364.7389 7 F 15
400.2575 8 A 14 881.9145
464.2867 9 Q 13 846.3959
545.8184 10 Y 12 782.3666
602.3604 11 L 11
666.3897 12 Q 10 644.2929
730.4190 13 Q 9 580.2636
810.4343 14 C 8
1716.9141 858.9607 15 P 7 436.2191
1863.9825 932.4949 16 F 6 387.6927
1993.0251 997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESK, MH+ 3365.5221, m/z 1122.5122
File: 20150124_09_25Percent_Beads_2.29502.29502.3, Scan: 29502, Exp. m/z: 1122.61, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
308.6416 2 H 26 3278.4901 1639.7487
776.3065 388.6569 3 C 25 2750.2535 1375.6304
889.3906 445.1989 4 I 24 2590.2229 1295.6151
480.7175 5 A 23 2477.1388 1239.0731
545.2388 6 E 22 2406.1017 1203.5545
594.7730 7 V 21 2277.0591 1139.0332
659.2943 8 E 20 2177.9907
9 N 19 2048.9481
1546.6512 10 D 18 1934.9052
11 E 17 1819.8782 910.4428
12 M 16
1903.7870 952.3971 13 P 15
1974.8241 14 A 14 731.8748
2089.8511 15 D 13 696.3563
2202.9351 16 L 12
2299.9879 1150.4976 17 P 11
2387.0199 1194.0136 18 S 10 1066.5415 533.7744
2500.1040 19 L 9 490.2584
2571.1411 20 A 8 433.7163
2642.1782 21 A 7 398.1978
2757.2051 22 D 6 362.6792
2904.2736 23 F 5 305.1658
3003.3420 24 V 4 231.6316
3132.3846 25 E 3 182.0974
3219.4166 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESKDVCK, MH+ 3476.5654, m/z 1159.5266
File: 20150124_08_25Percent_Beads_1.28011.28011.3, Scan: 28011, Exp. m/z: 1159.73, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 31   
225.0982 113.0527 2 H 30 3389.5333 1695.2703
193.0680 3 C 29 3252.4744
249.6101 4 I 28 3092.4438
285.1286 5 A 27 2979.3597
349.6499 6 E 26 2908.3226
399.1841 7 V 25 2779.2800
463.7054 8 E 24 2680.2116
520.7269 9 N 23 2551.1690
1155.4735 578.2404 10 D 22 2437.1261
642.7617 11 E 21 2322.0992
708.2819 12 M 20 2193.0566
1512.6093 756.8083 13 P 19 2062.0161
792.3268 14 A 18 1964.9633 982.9853
15 D 17
906.3824 16 L 16
1908.8102 954.9087 17 P 15
1995.8422 998.4247 18 S 14 784.8849
2108.9263 19 L 13
2179.9634 1090.4853 20 A 12
2251.0005 1126.0039 21 A 11
2366.0275 1183.5174 22 D 10
2513.0959 1257.0516 23 F 9
2612.1643 1306.5858 24 V 8 482.7420
2741.2069 1371.1071 25 E 7 433.2078
2828.2389 1414.6231 26 S 6 368.6865
2956.3339 1478.6706 27 K 5 325.1705
3071.3608 28 D 4 261.1230
3170.4292 29 V 3 203.6095
3330.4598 30 C 2 307.1434 154.0753
  31 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3, 30]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2436.2731, m/z 812.7626
File: 20150124_08_25Percent_Beads_1.26694.26694.3, Scan: 26694, Exp. m/z: 813.39, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
247.1441 124.0757 2 F 16 2337.2047
181.5892 3 D 15 2190.1363
246.1105 4 E 14 2075.1093
319.6447 5 F 13 1946.0667
6 K 12 1798.9983
1254.6075 627.8074 7 P 11
1367.6916 8 L 10 591.8401
9 V 9 535.2980
1595.8026 10 E 8 485.7638
1724.8452 862.9262 11 E 7 421.2425
1821.8979 12 P 6 356.7212
1949.9565 13 Q 5 615.3824 308.1949
2063.9995 1032.5034 14 N 4 487.3239 244.1656
2177.0835 1089.0454 15 L 3 373.2809 187.1441
2290.1676 16 I 2 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 391.177737 [6]Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2045.0954, m/z 682.3700
File: 20150124_09_25Percent_Beads_2.10835.10835.3, Scan: 10835, Exp. m/z: 682.65, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 1946.0270
181.5892 3 D 15 1798.9585
246.1105 4 E 14 1683.9316
319.6447 5 F 13 1554.8890
383.6921 6 K 12 1407.8206
863.4298 432.2185 7 P 11 1279.7256
976.5138 488.7606 8 L 10 1182.6729 591.8401
9 V 9 1069.5888
10 E 8
11 E 7
1430.7202 715.8637 12 P 6
1558.7788 779.8930 13 Q 5 308.1949
1672.8217 836.9145 14 N 4 244.1656
1785.9058 15 L 3 373.2809 187.1441
1898.9898 16 I 2 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
TYETTLEK C CAAADPHE CYAK, MH+ 2909.2459, m/z 970.4202
File: 20141212_11_25Percent_Labeled_3.11746.11746.3, Scan: 11746, Exp. m/z: 970.69, Charge: 3
b+ b2+ # Seq # y+ y2+
102.0550 51.5311 1 T 21   
265.1183 133.0628 2 Y 20 2808.1982 1404.6028
197.5841 3 E 19 2645.1349
495.2086 248.1079 4 T 18 2516.0923 1258.5498
596.2562 298.6318 5 T 17 2415.0446
355.1738 6 L 16 2313.9970
419.6951 7 E 15 2200.9129
679.3314 8 K 14 2071.8703
1517.6862 9 C 13
1677.7168 10 C 12
1748.7539 874.8806 11 A 11 1232.5364
12 A 10
1890.8281 13 A 9 545.7347
2005.8551 14 D 8
2102.9078 1051.9576 15 P 7
2239.9667 1120.4870 16 H 6 404.1763
2369.0093 17 E 5 335.6469
2529.0399 18 C 4 271.1256
2692.1033 19 Y 3 191.1103
2763.1404 20 A 2 218.1499 109.5786
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [9, 10, 18]
K: 391.177737 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
TYETTLEKC CAAADPHE CYAK, MH+ 2518.0682, m/z 840.0276
File: 20141212_09_25Percent_Labeled_1.10358.10358.3, Scan: 10358, Exp. m/z: 840.35, Charge: 3
b+ b2+ # Seq # y+ y2+
102.0550 51.5311 1 T 21   
133.0628 2 Y 20 2417.0205 1209.0139
197.5841 3 E 19 2253.9572
495.2086 248.1079 4 T 18 2124.9146
298.6318 5 T 17 2023.8669
355.1738 6 L 16 1922.8192
838.3829 419.6951 7 E 15 1809.7352
966.4779 483.7426 8 K 14 1680.6926 840.8499
1126.5085 563.7579 9 C 13 1552.5976
10 C 12
11 A 11
1428.6133 12 A 10
750.3288 13 A 9
14 D 8
1711.7301 856.3687 15 P 7
1848.7890 924.8981 16 H 6
1977.8316 17 E 5 335.6469
2137.8622 18 C 4 271.1256
2300.9255 19 Y 3 191.1103
2371.9626 20 A 2 218.1499 109.5786
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [9, 10, 18]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2824.4412, m/z 1412.7243
File: 20150124_14_50Percent_Beads_1.29256.29256.2, Scan: 29256, Exp. m/z: 1413.57, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2753.4041 1377.2057
284.1969 142.6021 3 V 19 2640.3201 1320.6637
199.1441 4 L 18 2541.2516
255.6861 5 I 17 2428.1676
291.2047 6 A 16 2315.0835 1158.0454
364.7389 7 F 15 2244.0464
400.2575 8 A 14 2096.9780 1048.9926
464.2867 9 Q 13 2025.9409
545.8184 10 Y 12 949.4448
11 L 11 867.9131
666.3897 12 Q 10 811.3711
730.4190 13 Q 9 747.3418
1954.0177 14 C 8 683.3125
2051.0704 1026.0389 15 P 7 436.2191
2198.1388 1099.5731 16 F 6 774.3781 387.6927
2327.1814 1164.0944 17 E 5 314.1585
2442.2084 1221.6078 18 D 4 249.6372
2579.2673 1290.1373 19 H 3 383.2401 192.1237
2678.3357 1339.6715 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 391.177715 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2490.2849, m/z 1245.6461
File: 20150124_14_50Percent_Beads_1.29065.29065.2, Scan: 29065, Exp. m/z: 1245.92, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
284.1969 142.6021 3 V 19 2306.1638
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16
364.7389 7 F 15
400.2575 8 A 14 881.9145
464.2867 9 Q 13 846.3959
545.8184 10 Y 12 782.3666
602.3604 11 L 11 700.8350
666.3897 12 Q 10 644.2929
730.4190 13 Q 9 580.2636
810.4343 14 C 8
1716.9141 858.9607 15 P 7 436.2191
932.4949 16 F 6 387.6927
997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2824.4412, m/z 942.1519
File: 20150124_16_50Percent_Beads_3.30874.30874.3, Scan: 30874, Exp. m/z: 942.42, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2753.4041 1377.2057
142.6021 3 V 19 2640.3201
199.1441 4 L 18 2541.2516
255.6861 5 I 17 2428.1676
291.2047 6 A 16 2315.0835
364.7389 7 F 15 2244.0464
400.2575 8 A 14 2096.9780
464.2867 9 Q 13 2025.9409
545.8184 10 Y 12 1897.8823 949.4448
602.3604 11 L 11 1734.8190
666.3897 12 Q 10 1621.7349
730.4190 13 Q 9 1493.6763
1954.0177 14 C 8 1365.6177
2051.0704 1026.0389 15 P 7
2198.1388 1099.5731 16 F 6 774.3781 387.6927
2327.1814 1164.0944 17 E 5 314.1585
2442.2084 1221.6078 18 D 4 249.6372
2579.2673 1290.1373 19 H 3 192.1237
2678.3357 1339.6715 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 391.177715 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2490.2849, m/z 830.7665
File: 20150124_14_50Percent_Beads_1.29307.29307.3, Scan: 29307, Exp. m/z: 830.96, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
142.6021 3 V 19 2306.1638
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16 1980.9272
364.7389 7 F 15 1909.8901
400.2575 8 A 14 1762.8217
464.2867 9 Q 13 1691.7846
545.8184 10 Y 12 1563.7260
602.3604 11 L 11
666.3897 12 Q 10 1287.5786
730.4190 13 Q 9 1159.5200
810.4343 14 C 8 1031.4614
1716.9141 858.9607 15 P 7
1863.9825 932.4949 16 F 6 774.3781 387.6927
1993.0251 997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 383.2401 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1926.7488, m/z 963.8780
File: 20150124_15_50Percent_Beads_2.14107.14107.2, Scan: 14107, Exp. m/z: 963.96, Charge: 2
b+ b2+ # Seq # y+ y2+
144.0114 72.5093 1 C 13   
304.0420 152.5246 2 C 12 1783.7447 892.3760
188.0432 3 A 11 1623.7141
223.5617 4 A 10
259.0803 5 A 9
632.1803 316.5938 6 D 8
729.2330 365.1201 7 P 7
629.2384 8 H 6 599.7652
693.7597 9 E 5 335.6469
773.7750 10 C 4 271.1256
855.3067 11 Y 3 191.1103
12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 39.994915 [1]
C: 57.021415 [2, 10]
H: 391.177688 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1535.5711, m/z 768.2892
File: 20150124_14_50Percent_Beads_1.10562.10562.2, Scan: 10562, Exp. m/z: 768.6, Charge: 2
b+ b2+ # Seq # y+ y2+
144.0114 72.5093 1 C 13   
152.5246 2 C 12 1392.5670 696.7871
188.0432 3 A 11
223.5617 4 A 10
259.0803 5 A 9
316.5938 6 D 8 510.2162
365.1201 7 P 7
866.2919 433.6496 8 H 6 404.1763
498.1709 9 E 5 335.6469
578.1862 10 C 4 271.1256
659.7179 11 Y 3 381.2132 191.1103
695.2364 12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 39.994915 [1]
C: 57.021415 [2, 10]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESK, MH+ 3365.5221, m/z 1122.5122
File: 20150202_15_50Percent_Beads_2.27744.27744.3, Scan: 27744, Exp. m/z: 1123.17, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
308.6416 2 H 26 3278.4901 1639.7487
776.3065 388.6569 3 C 25 2750.2535 1375.6304
4 I 24 2590.2229 1295.6151
480.7175 5 A 23 2477.1388 1239.0731
6 E 22 2406.1017 1203.5545
7 V 21 2277.0591 1139.0332
659.2943 8 E 20 2177.9907
716.3157 9 N 19 2048.9481
1546.6512 773.8292 10 D 18
11 E 17 1819.8782 910.4428
12 M 16
1903.7870 952.3971 13 P 15
1974.8241 14 A 14 731.8748
2089.8511 15 D 13 696.3563
2202.9351 16 L 12 638.8428
2299.9879 1150.4976 17 P 11 582.3008
2387.0199 1194.0136 18 S 10 1066.5415 533.7744
2500.1040 19 L 9 490.2584
2571.1411 20 A 8 433.7163
2642.1782 21 A 7 398.1978
2757.2051 22 D 6 362.6792
2904.2736 23 F 5 305.1658
3003.3420 24 V 4 231.6316
3132.3846 25 E 3 363.1874 182.0974
3219.4166 1610.2119 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SHC IAEVENDEMPADLPSLAADFVESK, MH+ 2974.3444, m/z 992.1197
File: 20150202_16_50Percent_Beads_3.27653.27653.3, Scan: 27653, Exp. m/z: 992.4, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
225.0982 113.0527 2 H 26 2887.3124 1444.1598
193.0680 3 C 25 2750.2535 1375.6304
249.6101 4 I 24 2590.2229
285.1286 5 A 23 2477.1388
349.6499 6 E 22 2406.1017 1203.5545
399.1841 7 V 21 2277.0591
926.4036 463.7054 8 E 20 2177.9907
1040.4465 520.7269 9 N 19 2048.9481
10 D 18 1934.9052 967.9562
11 E 17 1819.8782 910.4428
12 M 16
1512.6093 756.8083 13 P 15
14 A 14 731.8748
15 D 13 696.3563
16 L 12
1908.8102 17 P 11
1995.8422 998.4247 18 S 10 533.7744
2108.9263 19 L 9
2179.9634 20 A 8
2251.0005 21 A 7
2366.0275 22 D 6 362.6792
2513.0959 23 F 5 305.1658
2612.1643 24 V 4 231.6316
2741.2069 25 E 3 182.0974
2828.2389 1414.6231 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 2290.1729, m/z 1145.5901
File: 20141212_17_50Percent_Labeled_2.19138.19138.2, Scan: 19138, Exp. m/z: 1145.75, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
343.1761 2 H 14 2134.0718
782.3978 391.7025 3 P 13
473.2342 4 Y 12
5 F 11 673.3632
6 Y 10
7 A 9 518.2973
8 P 8 482.7788
9 E 7 867.4975 434.2524
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
2073.0302 13 F 3 183.1128
2144.0674 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 950.0012
File: 20141212_18_50Percent_Labeled_3.19164.19164.2, Scan: 19164, Exp. m/z: 950.08, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
294.1673 147.5873 2 H 14
391.2201 196.1137 3 P 13 803.4212
277.6453 4 Y 12 754.8948
351.1795 5 F 11 673.3632
432.7112 6 Y 10 599.8290
7 A 9 518.2973
516.7561 8 P 8 482.7788
9 E 7 434.2524
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
13 F 3 183.1128
14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2290.1729, m/z 764.0625
File: 20141212_16_50Percent_Labeled_1.18972.18972.3, Scan: 18972, Exp. m/z: 764.64, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2134.0718 1067.5395
782.3978 391.7025 3 P 13 1605.8352 803.4212
945.4611 4 Y 12 1508.7824 754.8948
5 F 11 673.3632
6 Y 10 599.8290
7 A 9 518.2973
1423.6827 712.3450 8 P 8
1552.7253 9 E 7 434.2524
1665.8094 10 L 6 369.7311
1778.8934 11 L 5 625.3708
1925.9618 12 F 4 512.2867 256.6470
2073.0302 13 F 3 365.2183 183.1128
2144.0674 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20141212_16_50Percent_Labeled_1.18830.18830.3, Scan: 18830, Exp. m/z: 633.76, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
391.2201 196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191
6 Y 10
7 A 9
1032.5050 8 P 8
1161.5476 9 E 7 434.2524
1274.6317 10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 2053.9027, m/z 685.3057
File: 20141212_16_50Percent_Labeled_1.09360.09360.3, Scan: 9360, Exp. m/z: 685.53, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
683.3433 2 K 13 1890.8394 945.9233
754.3804 377.6938 3 A 12 1371.5667 686.2870
825.4175 4 A 11 650.7684
5 F 10
6 T 9
7 E 8
1362.6068 681.8070 8 C 7
1522.6374 9 C 6 692.3032 346.6552
1650.6960 10 Q 5 266.6399
1721.7331 11 A 4 202.6106
1792.7702 12 A 3 167.0921
1907.7972 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
K: 391.177737 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1662.7250, m/z 554.9132
File: 20141212_17_50Percent_Labeled_2.07788.07788.3, Scan: 7788, Exp. m/z: 555.16, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
146.5864 2 K 13 1499.6616
182.1050 3 A 12 1371.5667
217.6235 4 A 11 1300.5296 650.7684
291.1577 5 F 10 1229.4924
6 T 9
7 E 8
8 C 7
1131.4597 566.2335 9 C 6
1259.5183 10 Q 5 266.6399
1330.5554 11 A 4
1401.5925 12 A 3 167.0921
1516.6194 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
TYETTLEK C CAAADPHE CYAK, MH+ 2909.2459, m/z 970.4202
File: 20141212_18_50Percent_Labeled_3.11667.11667.3, Scan: 11667, Exp. m/z: 971.1, Charge: 3
b+ b2+ # Seq # y+ y2+
102.0550 51.5311 1 T 21   
265.1183 133.0628 2 Y 20 2808.1982 1404.6028
394.1609 197.5841 3 E 19 2645.1349
495.2086 248.1079 4 T 18 2516.0923 1258.5498
298.6318 5 T 17 2415.0446 1208.0260
355.1738 6 L 16 2313.9970
419.6951 7 E 15 2200.9129
679.3314 8 K 14 2071.8703
9 C 13
1677.7168 10 C 12
874.8806 11 A 11
12 A 10
1890.8281 945.9177 13 A 9 545.7347
2005.8551 14 D 8
2102.9078 1051.9576 15 P 7
2239.9667 16 H 6 807.3454
2369.0093 17 E 5 335.6469
2529.0399 18 C 4 271.1256
2692.1033 19 Y 3 191.1103
2763.1404 20 A 2 218.1499 109.5786
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [9, 10, 18]
K: 391.177737 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
TYETTLEKC CAAADPHE CYAK, MH+ 2518.0682, m/z 840.0276
File: 20141212_17_50Percent_Labeled_2.10652.10652.3, Scan: 10652, Exp. m/z: 840.37, Charge: 3
b+ b2+ # Seq # y+ y2+
102.0550 51.5311 1 T 21   
133.0628 2 Y 20 2417.0205
197.5841 3 E 19 2253.9572
495.2086 248.1079 4 T 18 2124.9146
596.2562 298.6318 5 T 17 2023.8669
355.1738 6 L 16 1922.8192
838.3829 419.6951 7 E 15 1809.7352
966.4779 483.7426 8 K 14 1680.6926 840.8499
563.7579 9 C 13 1552.5976
643.7732 10 C 12
11 A 11
12 A 10
13 A 9
14 D 8
1711.7301 856.3687 15 P 7
1848.7890 924.8981 16 H 6
1977.8316 17 E 5 335.6469
2137.8622 1069.4347 18 C 4 271.1256
2300.9255 1150.9664 19 Y 3 191.1103
2371.9626 20 A 2 218.1499 109.5786
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [9, 10, 18]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 2232.0927, m/z 744.7024
File: 20150124_15_50Percent_Beads_2.29332.29332.3, Scan: 29332, Exp. m/z: 745.15, Charge: 3
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
129.5579 2 Q 15 2103.0501 1052.0287
371.1925 186.0999 3 L 14 1974.9915
890.4652 445.7362 4 K 13 1861.9075
961.5023 5 A 12
6 V 11
1191.6112 7 M 10
1306.6382 8 D 9
1421.6651 9 D 8 463.7345
1568.7335 10 F 7 406.2211
1639.7706 11 A 6 332.6869
1710.8078 12 A 5 297.1683
1857.8762 13 F 4 261.6498
1956.9446 14 V 3 188.1155
2085.9872 15 E 2 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 391.177737 [4]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
284
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2436.2731, m/z 812.7626
File: 20150202_16_50Percent_Beads_3.25071.25071.3, Scan: 25071, Exp. m/z: 813.66, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 2337.2047
181.5892 3 D 15 2190.1363
246.1105 4 E 14 2075.1093
319.6447 5 F 13 1946.0667
6 K 12 1798.9983
1254.6075 7 P 11
1367.6916 8 L 10 591.8401
9 V 9 535.2980
1595.8026 10 E 8 485.7638
1724.8452 11 E 7 421.2425
1821.8979 911.4526 12 P 6 356.7212
1949.9565 975.4819 13 Q 5 615.3824 308.1949
2063.9995 1032.5034 14 N 4 487.3239 244.1656
2177.0835 15 L 3 373.2809 187.1441
2290.1676 16 I 2 260.1969 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 391.177737 [6]Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2045.0954, m/z 682.3700
File: 20150202_16_50Percent_Beads_3.07372.07372.3, Scan: 7372, Exp. m/z: 682.77, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 1946.0270
181.5892 3 D 15 1798.9585
246.1105 4 E 14 1683.9316
319.6447 5 F 13 1554.8890
383.6921 6 K 12 1407.8206
863.4298 432.2185 7 P 11 1279.7256
488.7606 8 L 10 1182.6729 591.8401
9 V 9 535.2980
10 E 8
1333.6674 11 E 7
1430.7202 715.8637 12 P 6
1558.7788 779.8930 13 Q 5 615.3824 308.1949
1672.8217 836.9145 14 N 4 244.1656
1785.9058 893.4565 15 L 3 373.2809 187.1441
1898.9898 16 I 2 260.1969 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2824.4412, m/z 942.1519
File: 20141212_25_75Percent_Labeled_3.21760.21760.3, Scan: 21760, Exp. m/z: 942.83, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2753.4041 1377.2057
142.6021 3 V 19 2640.3201
199.1441 4 L 18 2541.2516
255.6861 5 I 17 2428.1676
291.2047 6 A 16 2315.0835
364.7389 7 F 15 2244.0464
400.2575 8 A 14 2096.9780
464.2867 9 Q 13 2025.9409
545.8184 10 Y 12 1897.8823 949.4448
602.3604 11 L 11
666.3897 12 Q 10
13 Q 9 1493.6763
1954.0177 14 C 8 1365.6177
2051.0704 1026.0389 15 P 7
2198.1388 1099.5731 16 F 6 774.3781 387.6927
2327.1814 1164.0944 17 E 5 314.1585
2442.2084 1221.6078 18 D 4 249.6372
2579.2673 1290.1373 19 H 3 192.1237
2678.3357 1339.6715 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 391.177715 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQ CPFEDHVK, MH+ 2490.2849, m/z 830.7665
File: 20141212_23_75Percent_Labeled_1.20953.20953.3, Scan: 20953, Exp. m/z: 831.18, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
142.6021 3 V 19 2306.1638
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113
291.2047 6 A 16 1980.9272
364.7389 7 F 15 1909.8901
400.2575 8 A 14 1762.8217
927.5662 464.2867 9 Q 13 1691.7846
545.8184 10 Y 12
602.3604 11 L 11 1400.6627
666.3897 12 Q 10 1287.5786
730.4190 13 Q 9 1159.5200
810.4343 14 C 8 1031.4614
1716.9141 858.9607 15 P 7
1863.9825 932.4949 16 F 6 774.3781 387.6927
1993.0251 997.0162 17 E 5 627.3097 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 1123.0591 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2824.4412, m/z 1412.7243
File: 20141212_25_75Percent_Labeled_3.21237.21237.2, Scan: 21237, Exp. m/z: 1413.37, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2753.4041 1377.2057
284.1969 142.6021 3 V 19 2640.3201 1320.6637
199.1441 4 L 18 2541.2516
255.6861 5 I 17 2428.1676
291.2047 6 A 16 2315.0835
364.7389 7 F 15 2244.0464
400.2575 8 A 14 2096.9780
464.2867 9 Q 13 2025.9409
545.8184 10 Y 12 949.4448
11 L 11 867.9131
666.3897 12 Q 10
730.4190 13 Q 9 747.3418
14 C 8 683.3125
2051.0704 1026.0389 15 P 7 436.2191
2198.1388 1099.5731 16 F 6 387.6927
2327.1814 1164.0944 17 E 5 314.1585
2442.2084 1221.6078 18 D 4 249.6372
2579.2673 19 H 3 383.2401 192.1237
2678.3357 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 391.177715 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ALVLIAFAQYLQQCPFEDHVK, MH+ 2490.2849, m/z 1245.6461
File: 20141212_23_75Percent_Labeled_1.20834.20834.2, Scan: 20834, Exp. m/z: 1245.54, Charge: 2
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 21   
185.1285 93.0679 2 L 20 2419.2478 1210.1275
284.1969 142.6021 3 V 19 2306.1638 1153.5855
199.1441 4 L 18 2207.0953
255.6861 5 I 17 2094.0113 1047.5093
291.2047 6 A 16
364.7389 7 F 15
8 A 14 881.9145
464.2867 9 Q 13 846.3959
545.8184 10 Y 12 782.3666
602.3604 11 L 11 700.8350
666.3897 12 Q 10 644.2929
730.4190 13 Q 9 580.2636
14 C 8
1716.9141 858.9607 15 P 7 436.2191
932.4949 16 F 6 387.6927
1993.0251 997.0162 17 E 5 314.1585
2108.0521 1054.5297 18 D 4 249.6372
2245.1110 19 H 3 192.1237
2344.1794 1172.5933 20 V 2 246.1812 123.5942
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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290
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1926.7488, m/z 963.8780
File: 20150124_21_75Percent_Beads_2.14931.14931.2, Scan: 14931, Exp. m/z: 963.84, Charge: 2
b+ b2+ # Seq # y+ y2+
144.0114 72.5093 1 C 13   
152.5246 2 C 12 1783.7447 892.3760
188.0432 3 A 11 1623.7141
223.5617 4 A 10 1552.6770
259.0803 5 A 9
632.1803 316.5938 6 D 8
729.2330 365.1201 7 P 7
629.2384 8 H 6
693.7597 9 E 5 335.6469
10 C 4 271.1256
855.3067 11 Y 3 191.1103
12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 39.994915 [1]
C: 57.021415 [2, 10]
H: 391.177688 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
291
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
C CAAADPHECYAK, MH+ 1535.5711, m/z 768.2892
File: 20150124_21_75Percent_Beads_2.12259.12259.2, Scan: 12259, Exp. m/z: 768.61, Charge: 2
b+ b2+ # Seq # y+ y2+
144.0114 72.5093 1 C 13   
152.5246 2 C 12 1392.5670 696.7871
188.0432 3 A 11
223.5617 4 A 10
259.0803 5 A 9
316.5938 6 D 8 510.2162
365.1201 7 P 7
866.2919 433.6496 8 H 6 404.1763
498.1709 9 E 5 335.6469
578.1862 10 C 4 271.1256
659.7179 11 Y 3 381.2132 191.1103
695.2364 12 A 2 218.1499 109.5786
  13 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 39.994915 [1]
C: 57.021415 [2, 10]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 2290.1729, m/z 1145.5901
File: 20150202_22_75Percent_Beads_3.23389.23389.2, Scan: 23389, Exp. m/z: 1145.84, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
343.1761 2 H 14 2134.0718
782.3978 391.7025 3 P 13 803.4212
473.2342 4 Y 12 754.8948
5 F 11 673.3632
6 Y 10 599.8290
7 A 9 518.2973
8 P 8 482.7788
9 E 7 867.4975
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
2073.0302 13 F 3 183.1128
2144.0674 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 950.0012
File: 20150202_21_75Percent_Beads_2.22498.22498.2, Scan: 22498, Exp. m/z: 949.82, Charge: 2
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
294.1673 147.5873 2 H 14
391.2201 196.1137 3 P 13 803.4212
4 Y 12
351.1795 5 F 11 673.3632
432.7112 6 Y 10 599.8290
7 A 9 518.2973
516.7561 8 P 8 482.7788
9 E 7 867.4975 434.2524
10 L 6 369.7311
11 L 5 313.1890
12 F 4 256.6470
13 F 3 183.1128
14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SLHTLFGDK, MH+ 1408.7141, m/z 704.8607
File: 20150124_20_75Percent_Beads_1.19281.19281.2, Scan: 19281, Exp. m/z: 705.28, Charge: 2
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 9   
201.1234 101.0653 2 L 8 1321.6820 661.3447
365.1836 3 H 7
415.7075 4 T 6 340.6843
472.2495 5 L 5 290.1605
545.7837 6 F 4 233.6185
574.2944 7 G 3 160.0842
8 D 2 131.5735
  9 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 391.177688 [3]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SLHTLFGDK, MH+ 1017.5364, m/z 509.2718
File: 20150124_20_75Percent_Beads_1.15346.15346.2, Scan: 15346, Exp. m/z: 509.77, Charge: 2
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 9   
101.0653 2 L 8 930.5043 465.7558
169.5948 3 H 7
220.1186 4 T 6 340.6843
276.6606 5 L 5
350.1949 6 F 4 233.6185
756.4039 378.7056 7 G 3 160.0842
436.2191 8 D 2 262.1397 131.5735
  9 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RH PYFYAPELLFFAK, MH+ 2290.1729, m/z 764.0625
File: 20150202_20_75Percent_Beads_1.23529.23529.3, Scan: 23529, Exp. m/z: 764.37, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
2 H 14 2134.0718 1067.5395
782.3978 391.7025 3 P 13 1605.8352
945.4611 4 Y 12 1508.7824
5 F 11 673.3632
6 Y 10
7 A 9
8 P 8
1552.7253 9 E 7 434.2524
1665.8094 10 L 6 369.7311
1778.8934 11 L 5 625.3708 313.1890
1925.9618 12 F 4 256.6470
2073.0302 13 F 3 183.1128
2144.0674 14 A 2 218.1499 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Modifications:
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
RHPYFYAPELLFFAK, MH+ 1898.9952, m/z 633.6699
File: 20150202_21_75Percent_Beads_2.22613.22613.3, Scan: 22613, Exp. m/z: 633.61, Charge: 3
b+ b2+ # Seq # y+ y2+
157.1084 79.0578 1 R 15   
147.5873 2 H 14 1742.8941 871.9507
391.2201 196.1137 3 P 13 1605.8352
4 Y 12 1508.7824 754.8948
5 F 11 1345.7191
6 Y 10
7 A 9
1032.5050 516.7561 8 P 8
1161.5476 9 E 7 434.2524
1274.6317 10 L 6 369.7311
1387.7157 11 L 5 313.1890
1534.7841 12 F 4 256.6470
1681.8526 13 F 3 183.1128
1752.8897 14 A 2 109.5786
  15 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SH CIAEVENDEMPADLPSLAADFVESK, MH+ 3365.5221, m/z 1122.5122
File: 20150202_22_75Percent_Beads_3.26107.26107.3, Scan: 26107, Exp. m/z: 1123.25, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
308.6416 2 H 26 3278.4901 1639.7487
776.3065 388.6569 3 C 25 2750.2535 1375.6304
4 I 24 2590.2229 1295.6151
480.7175 5 A 23 2477.1388 1239.0731
545.2388 6 E 22 2406.1017 1203.5545
1188.5387 7 V 21 2277.0591 1139.0332
8 E 20 2177.9907
9 N 19 2048.9481
1546.6512 10 D 18 1934.9052
11 E 17 1819.8782 910.4428
12 M 16
1903.7870 952.3971 13 P 15
14 A 14 731.8748
2089.8511 15 D 13 696.3563
2202.9351 16 L 12
2299.9879 1150.4976 17 P 11 582.3008
2387.0199 18 S 10 1066.5415 533.7744
2500.1040 19 L 9 490.2584
2571.1411 20 A 8
2642.1782 21 A 7 398.1978
2757.2051 22 D 6 362.6792
2904.2736 23 F 5 305.1658
3003.3420 24 V 4 231.6316
3132.3846 25 E 3 182.0974
3219.4166 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
H: 391.177688 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
SHC IAEVENDEMPADLPSLAADFVESK, MH+ 2974.3444, m/z 992.1197
File: 20150202_22_75Percent_Beads_3.25469.25469.3, Scan: 25469, Exp. m/z: 992.35, Charge: 3
b+ b2+ # Seq # y+ y2+
88.0393 44.5233 1 S 27   
225.0982 113.0527 2 H 26 2887.3124 1444.1598
385.1288 193.0680 3 C 25 2750.2535 1375.6304
249.6101 4 I 24 2590.2229 1295.6151
285.1286 5 A 23 2477.1388
349.6499 6 E 22 2406.1017 1203.5545
399.1841 7 V 21 2277.0591 1139.0332
463.7054 8 E 20 2177.9907
520.7269 9 N 19 2048.9481
1155.4735 10 D 18 1934.9052 967.9562
11 E 17 1819.8782 910.4428
12 M 16
1512.6093 756.8083 13 P 15
1583.6464 14 A 14 1462.7424 731.8748
15 D 13 696.3563
16 L 12
1908.8102 17 P 11
1995.8422 998.4247 18 S 10 533.7744
2108.9263 19 L 9 490.2584
2179.9634 20 A 8 433.7163
2251.0005 21 A 7 398.1978
2366.0275 22 D 6 362.6792
2513.0959 23 F 5 305.1658
2612.1643 24 V 4 231.6316
2741.2069 25 E 3 182.0974
2828.2389 26 S 2 234.1448 117.5761
  27 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [3]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LVRPEVDVMCTAFH DNEETFLK, MH+ 3041.4416, m/z 1014.4854
File: 20141212_25_75Percent_Labeled_3.17922.17922.3, Scan: 17922, Exp. m/z: 1015.22, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 22   
213.1598 107.0835 2 V 21 2928.3576 1464.6824
185.1341 3 R 20 2829.2891 1415.1482
233.6605 4 P 19 2673.1880
298.1817 5 E 18 2576.1353 1288.5713
347.7160 6 V 17 2447.0927
7 D 16 2348.0243
8 V 15 2232.9973
1039.5605 9 M 14 2133.9289 1067.4681
1199.5911 10 C 13 2002.8884
11 T 12 921.9325
1371.6759 686.3416 12 A 11 871.4087
759.8758 13 F 10 835.8902
2046.9809 14 H 9
2162.0078 15 D 8 498.2376
2276.0508 16 N 7
2405.0933 17 E 6 766.3981 383.7027
2534.1359 18 E 5 319.1814
2635.1836 19 T 4 254.6601
2782.2520 20 F 3 204.1363
2895.3361 21 L 2 260.1969 130.6021
  22 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [10]
H: 391.177688 [14]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LVRPEVDVMCTAFHDNEETFLK, MH+ 2650.2639, m/z 884.0928
File: 20141212_25_75Percent_Labeled_3.17393.17393.3, Scan: 17393, Exp. m/z: 884.29, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 22   
213.1598 107.0835 2 V 21 2537.1799 1269.0936
185.1341 3 R 20 2438.1115 1219.5594
466.3136 233.6605 4 P 19 2282.0103
298.1817 5 E 18 2184.9576 1092.9824
347.7160 6 V 17 2055.9150
405.2294 7 D 16 1956.8466
8 V 15 1841.8196
520.2839 9 M 14 1742.7512
10 C 13
11 T 12
12 A 11
13 F 10
14 H 9
885.9187 15 D 8 498.2376
1884.8731 16 N 7 880.4411 440.7242
2013.9157 17 E 6
2142.9583 18 E 5 319.1814
2244.0059 19 T 4 254.6601
2391.0743 20 F 3 204.1363
2504.1584 21 L 2 130.6021
  22 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [10]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LVNEVTEFAKTCVADESAENCDK, MH+ 3020.3533, m/z 1007.4559
File: 20141212_25_75Percent_Labeled_3.16021.16021.3, Scan: 16021, Exp. m/z: 1007.65, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 23   
213.1598 107.0835 2 V 22 2907.2692 1454.1382
327.2027 164.1050 3 N 21 2808.2008
228.6263 4 E 20 2694.1579
278.1605 5 V 19 2565.1153
328.6843 6 T 18 2466.0469
785.4040 393.2056 7 E 17 2364.9992
8 F 16 2235.9566
1003.5095 9 A 15 2088.8882
10 K 14 2017.8511 1009.4292
11 T 13
1783.8605 12 C 12 699.2690
1882.9289 13 V 11 619.2537
1953.9660 14 A 10 569.7195
2068.9929 15 D 9 534.2009
2198.0355 16 E 8 476.6874
2285.0676 17 S 7 412.1661
2356.1047 18 A 6 368.6501
2485.1473 19 E 5 333.1316
2599.1902 20 N 4 268.6103
2759.2208 21 C 3 211.5888
2874.2477 22 D 2 262.1397 131.5735
  23 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [12, 21]
K: 391.177737 [10]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
LVNEVTEFAKTCVADESAENCDK, MH+ 2629.1755, m/z 877.0634
File: 20141212_25_75Percent_Labeled_3.15766.15766.3, Scan: 15766, Exp. m/z: 877.26, Charge: 3
b+ b2+ # Seq # y+ y2+
114.0913 57.5493 1 L 23   
213.1598 107.0835 2 V 22 2516.0915 1258.5494
327.2027 164.1050 3 N 21 2417.0230
228.6263 4 E 20 2302.9801 1151.9937
278.1605 5 V 19 2173.9375
656.3614 328.6843 6 T 18 2074.8691
393.2056 7 E 17 1973.8214
466.7398 8 F 16 1844.7788
502.2584 9 A 15 1697.7104
566.3059 10 K 14 1626.6733
11 T 13
12 C 12 699.2690
13 V 11
14 A 10
15 D 9
1806.8578 16 E 8 476.6874
1893.8898 17 S 7 412.1661
1964.9269 18 A 6 368.6501
2093.9695 19 E 5 333.1316
2208.0125 20 N 4 268.6103
2368.0431 21 C 3 211.5888
2483.0700 22 D 2 131.5735
  23 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [12, 21]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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304
Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
ADLA KYICENQDSISSK, MH+ 2333.0999, m/z 778.3715
File: 20141212_23_75Percent_Labeled_1.13862.13862.3, Scan: 13862, Exp. m/z: 778.67, Charge: 3
b+ b2+ # Seq # y+ y2+
72.0444 36.5258 1 A 17   
187.0713 94.0393 2 D 16 2262.0628 1131.5350
300.1554 150.5813 3 L 15 2147.0359 1074.0216
371.1925 186.0999 4 A 14 2033.9518
5 K 13 1962.9147
6 Y 12
7 I 11
1326.6432 8 C 10
9 E 9
1569.7287 785.3680 10 N 8
1697.7873 11 Q 7 382.6929
1812.8142 12 D 6 318.6636
1899.8463 13 S 5 261.1501
2012.9303 14 I 4 217.6341
2099.9624 15 S 3 161.0921
2186.9944 16 S 2 234.1448 117.5761
  17 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8]
K: 391.177737 [5]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
TYETTLEK C CAAADPHE CYAK, MH+ 2909.2459, m/z 970.4202
File: 20150202_22_75Percent_Beads_3.14981.14981.3, Scan: 14981, Exp. m/z: 970.8, Charge: 3
b+ b2+ # Seq # y+ y2+
102.0550 51.5311 1 T 21   
265.1183 133.0628 2 Y 20 2808.1982 1404.6028
394.1609 197.5841 3 E 19 2645.1349
495.2086 248.1079 4 T 18 2516.0923 1258.5498
298.6318 5 T 17 2415.0446
355.1738 6 L 16 2313.9970
419.6951 7 E 15 2200.9129
8 K 14 2071.8703
9 C 13
1677.7168 10 C 12 696.7871
1748.7539 874.8806 11 A 11 1232.5364 616.7718
12 A 10 581.2533
1890.8281 13 A 9 545.7347
2005.8551 14 D 8 510.2162
2102.9078 1051.9576 15 P 7
2239.9667 16 H 6 807.3454
2369.0093 17 E 5 335.6469
2529.0399 18 C 4 271.1256
2692.1033 19 Y 3 191.1103
2763.1404 20 A 2 218.1499 109.5786
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [9, 10, 18]
K: 391.177737 [8]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
TYETTLEKC CAAADPHE CYAK, MH+ 2518.0682, m/z 840.0276
File: 20150202_20_75Percent_Beads_1.13390.13390.3, Scan: 13390, Exp. m/z: 840.6, Charge: 3
b+ b2+ # Seq # y+ y2+
102.0550 51.5311 1 T 21   
133.0628 2 Y 20 2417.0205
197.5841 3 E 19 2253.9572
495.2086 248.1079 4 T 18 2124.9146
298.6318 5 T 17 2023.8669
355.1738 6 L 16 1922.8192
838.3829 419.6951 7 E 15 1809.7352
483.7426 8 K 14 1680.6926 840.8499
1126.5085 9 C 13 1552.5976 776.8024
643.7732 10 C 12 1392.5670
11 A 11
12 A 10
750.3288 13 A 9
14 D 8
1711.7301 856.3687 15 P 7
1848.7890 16 H 6
1977.8316 17 E 5 335.6469
2137.8622 1069.4347 18 C 4 271.1256
2300.9255 19 Y 3 191.1103
2371.9626 20 A 2 218.1499 109.5786
  21 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [9, 10, 18]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2436.2731, m/z 812.7626
File: 20150202_22_75Percent_Beads_3.24162.24162.3, Scan: 24162, Exp. m/z: 813.61, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 2337.2047
181.5892 3 D 15 2190.1363
246.1105 4 E 14 2075.1093
319.6447 5 F 13 1946.0667
6 K 12 1798.9983
1254.6075 627.8074 7 P 11
8 L 10 1182.6729 591.8401
9 V 9 535.2980
10 E 8 485.7638
1724.8452 11 E 7 421.2425
1821.8979 12 P 6
1949.9565 975.4819 13 Q 5 615.3824 308.1949
2063.9995 1032.5034 14 N 4 487.3239 244.1656
2177.0835 1089.0454 15 L 3 187.1441
2290.1676 16 I 2 260.1969 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 391.177737 [6]Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
VFDEFKPLVEEPQNLIK, MH+ 2045.0954, m/z 682.3700
File: 20150202_20_75Percent_Beads_1.23748.23748.3, Scan: 23748, Exp. m/z: 683, Charge: 3
b+ b2+ # Seq # y+ y2+
100.0757 50.5415 1 V 17   
124.0757 2 F 16 1946.0270
181.5892 3 D 15 1798.9585
246.1105 4 E 14 1683.9316
319.6447 5 F 13 1554.8890
383.6921 6 K 12 1407.8206
863.4298 432.2185 7 P 11
488.7606 8 L 10 1182.6729 591.8401
9 V 9
10 E 8
11 E 7
1430.7202 715.8637 12 P 6
1558.7788 779.8930 13 Q 5 308.1949
1672.8217 836.9145 14 N 4 244.1656
1785.9058 15 L 3 187.1441
1898.9898 16 I 2 130.6021
  17 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 2053.9027, m/z 685.3057
File: 20150124_22_75Percent_Beads_3.14185.14185.3, Scan: 14185, Exp. m/z: 685.54, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
683.3433 342.1753 2 K 13 1890.8394
3 A 12 686.2870
4 A 11 650.7684
5 F 10
6 T 9
7 E 8
1362.6068 681.8070 8 C 7
1522.6374 9 C 6
1650.6960 10 Q 5 266.6399
1721.7331 11 A 4 202.6106
1792.7702 12 A 3 167.0921
1907.7972 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
K: 391.177737 [2]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
YKAAFTEC CQAADK, MH+ 1662.7250, m/z 554.9132
File: 20150124_21_75Percent_Beads_2.12413.12413.3, Scan: 12413, Exp. m/z: 555.55, Charge: 3
b+ b2+ # Seq # y+ y2+
164.0706 82.5389 1 Y 14   
146.5864 2 K 13 1499.6616
363.2027 182.1050 3 A 12 1371.5667
217.6235 4 A 11 1300.5296 650.7684
291.1577 5 F 10 1229.4924
6 T 9 1082.4240
7 E 8
8 C 7
1131.4597 566.2335 9 C 6
1259.5183 10 Q 5 266.6399
1330.5554 11 A 4 202.6106
1401.5925 12 A 3 167.0921
1516.6194 13 D 2 131.5735
  14 K 1 147.1128 74.0600
[Click] to move table
Modifications:
C: 57.021415 [8, 9]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 2232.0927, m/z 744.7024
File: 20150124_20_75Percent_Beads_1.29621.29621.3, Scan: 29621, Exp. m/z: 745.05, Charge: 3
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
129.5579 2 Q 15 2103.0501 1052.0287
371.1925 186.0999 3 L 14 1974.9915
890.4652 445.7362 4 K 13 1861.9075
961.5023 5 A 12
6 V 11 636.3025
1191.6112 7 M 10
1306.6382 8 D 9
1421.6651 9 D 8 463.7345
1568.7335 10 F 7 406.2211
1639.7706 11 A 6 332.6869
1710.8078 12 A 5 297.1683
1857.8762 13 F 4 261.6498
1956.9446 14 V 3 188.1155
2085.9872 15 E 2 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 391.177737 [4]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 2232.0927, m/z 1116.5500
File: 20141212_24_75Percent_Labeled_2.21011.21011.2, Scan: 21011, Exp. m/z: 1117.26, Charge: 2
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
258.1084 129.5579 2 Q 15 2103.0501
371.1925 186.0999 3 L 14 1974.9915
890.4652 445.7362 4 K 13 1861.9075 931.4574
961.5023 481.2548 5 A 12 671.8210
530.7890 6 V 11 636.3025
1191.6112 596.3092 7 M 10
8 D 9
711.3362 9 D 8 463.7345
784.8704 10 F 7 406.2211
820.3890 11 A 6 332.6869
12 A 5 297.1683
1857.8762 929.4417 13 F 4 261.6498
1956.9446 978.9759 14 V 3 188.1155
2085.9872 15 E 2 276.1554 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Modifications:
K: 391.177737 [4]
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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Ions:
a 1+ 2+ 3+
b 1+ 2+ 3+
c 1+ 2+ 3+
x 1+ 2+ 3+
y 1+ 2+ 3+
z 1+ 2+ 3+
[Deselect All]
Neutral Loss:
 H2O (o)
 NH3 (*)
Mass Type:
Mono Avg
Mass Tol: 
Peak Assignment:
Most Intense
Nearest Match
Peak Detect
Peak Labels:
Ion m/z
None
Width: 650
Height: 400
EQLKAVMDDFAAFVEK, MH+ 1840.9150, m/z 920.9611
File: 20141212_24_75Percent_Labeled_2.20685.20685.2, Scan: 20685, Exp. m/z: 921.57, Charge: 2
b+ b2+ # Seq # y+ y2+
130.0499 65.5286 1 E 16   
129.5579 2 Q 15 1711.8724
371.1925 186.0999 3 L 14
499.2875 250.1474 4 K 13
570.3246 285.6659 5 A 12 671.8210
6 V 11 636.3025
800.4335 400.7204 7 M 10 586.7683
915.4604 458.2339 8 D 9 521.2480
515.7473 9 D 8 926.4618 463.7345
1177.5558 589.2815 10 F 7 406.2211
1248.5929 624.8001 11 A 6 332.6869
1319.6300 660.3186 12 A 5 297.1683
733.8529 13 F 4 261.6498
783.3871 14 V 3 188.1155
1694.8094 15 E 2 138.5813
  16 K 1 147.1128 74.0600
[Click] to move table
Click and drag in the plot to zoom X:   Y:         Enable tooltip
COMET/Lorikeet Spectrum Viewer
(TPP v4.6 OCCUPY rev 3, Build 201307241109 (MinGW))
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